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Magnetic Resonance Imaging (MRI) has been at the focus of medical research as its 
availability and fidelity has improved in the last thirty years. MRI offers both high spatial 
resolution and excellent soft tissue contrast compared to complimentary medical imaging 
techniques, without the need to expose patients to ionising radiation.  
Novel MRI methods that utilise the intrinsic body water signal are still being developed and 
refined. Arterial Spin Labelling (ASL) MRI provides a non-invasive method to measure tissue 
perfusion, which has been extensively applied in the brain, and demonstrated pre-clinically 
in the heart and kidneys. However, there is currently no literature reporting the 
development and use pre-clinical liver ASL – possibly due to complex methodology and 
quantification necessary in small animals.  
Clinical liver perfusion imaging is predominantly carried out using an injected Gadolinium-
based contrast agent; this technique can be challenging to quantify, cannot be immediately 
re-administered and may have complications for patients with renal impairment. A 
methodology to measure liver perfusion without the need for a contrast agent would find 
utility in a number of different hepatic diseases; monitoring pathophysiology and therapy 
efficacy. 
This research investigates the feasibility of a pre-clinical measure of liver perfusion using 
ASL and its potential application to a pre-clinical model of hepatic disease. We aim to apply 
the method to monitor novel therapy efficacy in pre-clinical disease models, to eventually 
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Context of Research 
The aims of this thesis research is explore the potential of magnetic resonance imaging 
(MRI) to measure liver perfusion in mice, for application to pre-clinical models of human 
disease. Perfusion measurements can potentially inform on tissue function, disease 
progression and therapy efficacy. 
This chapter reviews the existing literature on hepatic disease and dysfunction, covering the 
liver’s anatomy and subsequent pathophysiology. A review of the different available 
techniques to measure liver perfusion and function will then be followed by an overview of 
MRI techniques, highlighting the requirement and potential application for a non-invasive 
measurement of liver perfusion using arterial spin labelling (ASL) MRI. The research in this 
thesis will be performed on rodents, thus a strong emphasis of this chapter will include pre-




1.1 Liver Anatomy and Physiology 
1.1.1 Liver Dysfunction and Cirrhosis 
The liver has a significant role in blood filtration, biosynthesis, immunity and metabolism; 
thus the deterioration of hepatic homeostasis is associated with a high morbidity rate (1). 
Liver disease is the fifth most common cause of UK deaths (2), approximately 8000 new 
patients are diagnosed with cirrhosis in the UK each year (3). Fibrosis and subsequent 
cirrhosis pathophysiology is due to hepatic inflammation leading to fibrogenesis (4). As 
cirrhosis develops, an increased deposition of collagenous fibres within the liver sinusoids 
cause the liver to ‘stiffen’ and become more resistant to flow, resulting in portal 
hypertension (5). Currently, there are no available therapies for cirrhosis, and thus the 
clinical focus is on early prevention and lifestyle adjustments to minimise the need for a 
liver transplant.  
Anatomical ultrasound, X-ray computed tomography (CT) and magnetic resonance imaging 
(MRI) are insensitive to the initial stages of cirrhosis, however, there a number of blood 
serum markers that can stage fibrosis to cirrhosis (4). Palpation of the liver and invasive 
portal pressure measurements are commonplace to determine the onset of cirrhosis and 
portal hypertension (6); in addition to stiffness-sensitive techniques such as transient 
elastography using ultrasound (FibroScan) (7), and MR elastography (8). However, non-
invasive and spatially informative MRI measurements using perfusion has potential benefits 
to be used in tandem with multi-parametric assessments.  
1.1.2 Liver Cancer and Metastasis 
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the 6th 
most prevalent cancer worldwide (9). Cirrhosis patients are at the most risk to developing 
primary tumours, in addition to patients exposed to infection from hepatitis and 
carcinogens. Though a raised presence of the carcinoembryonic antigen blood serum 
marker occurs in many tumour types (10), it is not exclusive and sufficiently sensitive to 
diagnose the presence of tumours. Imaging has a large role in diagnosing tumours; 
anatomical CT and MRI are commonplace, as well as more invasive techniques of liver 
biopsy and laparoscopy.  
HCC is a well vascularised tumour and though anti-angiogenesis treatment has been trialled 
for treatment, resection of the affected lobe is the standard clinical procedure (9). Other 
successful clinical methods include percutaneous ablation, chemoembolization and liver 
transplantation. In order to guarantee a sufficient post-resection liver, techniques have 
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been developed which promote growth of non-cancerous lobes (11) which exploit the 
regenerative property of the liver.  
However, it is more common for cancers to develop in the liver as a secondary tumour site; 
metastasis of cancerous cells is an aggressive and late stage of tumour development (12). 
Approximately 6 in 10,000 people are diagnosed with colorectal cancer in Britain each year 
(13); approximately 40% of these will develop liver metastases, which results in a low 5 year 
survival rate (14). Additionally, for patients with other distal primary tumours, liver 
metastasis is a major cause of cancer-related deaths. Similarly to HCC, routine clinical 
practice is for patients to undergo hepatectomy of the affected lobe. However, such 
surgery is not without complications, is liable to remission (15), and is limited if the disease 
is widespread. A body of cancer research has thus focussed on developing tumour-targeted 
therapies (16), in order to minimise highly invasive surgery. Measurements of tumour 
perfusion have the potential to inform on tumour malignancy and therapy efficacy.  
1.1.3 Liver Anatomy 
The primary function of the liver is the clearance of toxins and foreign bodies from the 
blood stream, and consequently, the liver has a unique ‘dual’ arterial and venous blood 
supply (Figure 1.1A). Venous blood from the intestines, pancreas and spleen enter the liver 
via the portal vein (PV), which delivers approximately 75% of the blood to the liver (17). The 
remaining blood is derived from the hepatic artery (HA), originating from the descending 
aorta at the celiac trunk, which supplies hepatocytes with oxygen-rich blood. Though the 
portal vein conducts partly deoxygenated blood, it provides 50% of the liver’s oxygen, due 
to its relatively higher flow rate. This dual-supply works in tandem to produce a steady flow 
in healthy hepatic circulation: the hepatic artery will regulate changes in the portal flow. 
This process is known as the hepatic arterial buffer response (HABR)(18), there is no 
reciprocity of the portal vein however, as it cannot regulate the blood flow from other 
organs. The ratio of the arterial to total liver blood flow is known as the hepatic arterial 
perfusion index (HPI), which has been shown to increase in certain hepatic diseases (19).   
The hepatic arterial buffer response is impaired in cirrhosis and cannot account for the 
reduced portal venous flow, resulting in an overall reduction in perfusion (20). Reduced 
portal perfusion has been characterised by Doppler ultrasound (21), contrast CT 
measurements (22), as well as recent clinical liver MRI measurements (23, 24). The typical 
oxygen saturation of arterial blood and portal venous blood is 95% and 70% respectively 
(25), which will lead to a significant T2 and T2* difference between the two blood supplies, 
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arterial blood and venous blood T2 have been respectively measured at 40 and 5-7 ms at 
9.4T (26). This difference has potential to give information on the respective supplies to the 
liver; the signal changes under different gas challenges have been explored to give 
‘functional’ information (27). In addition, the disparity in relaxation times may potentially 
confound perfusion quantification, but may also lend to separating out the perfusion 
sources.   
 
Figure 1.1: A human liver schematic (A), supplied by the portal vein (short black arrow) and the 
hepatic artery (long black arrow). The blood is processed through the liver and collected into the 
inferior vena cava (short white arrow) [image adapted from Netter (28)]. Process of liver filtration 
through a liver lobule (B): the blood flows from the portal venule and hepatic arteriole along liver 
sinusoids, and finally the filtered blood is collected in to the central vein. The central veins coalesce 
into hepatic veins, which drain into the inferior vena cava [image adapted from Frevert et al. (29)]. 
Small mammals such as mice and rats are often used in research due to their similar 
physiology to man. In addition, the mouse and rat liver has the same function and similar 
relative PV and HA contributions to humans (30) making them suitable for pre-clinical 
models of hepatic disease. The main difference between the human and rodent liver is the 
arrangement of the lobes – the human liver is divided into four lobes: right, left, quadrate 
and caudate. In comparison, the mouse and rat liver is commonly split in to six lobes: 
upper- and lower right, upper- and lower caudate, left lateral and median. The liver’s 
microenvironment is comprised of lobules which pack together to form the lobes. The 
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lobules draw blood from the portal venules and hepatic arterioles (as well as bile from the 
bile ducts) and Kupfer cells break down and filter the blood within the liver sinusoids. The 
sinusoids are separated from the hepatocytes by the Space of Disse, which allows plasma 
and small molecular weight compounds to pass through. The filtered blood is collected in to 
the central vein which drains in to the inferior vena cava (IVC) via hepatic veins (Figure 
1.1B). This multiple input, multiple compartment tissue results in complicated 
pharmacokinetic models to describe the liver (5, 31). In addition, these models often need 
to be adapted in disease situations as the lobules physiology will change.   
1.1.4 Summary 
From understanding the progression of hepatic disease and therapeutic changes on the 
pathophysiology, it is apparent that blood flow imaging offers potential diagnostic 
information. Perfusion imaging may provide vital biomarkers of tissue functionality, inform 
on risk-affected areas and monitor disease progression: the next section reviews liver 
perfusion imaging techniques. A brief summary of the existing techniques will be explored, 
followed by a review of the MRI methods of estimating perfusion.  
1.2 Measurements of Liver Perfusion 
1.2.1 Clinical Techniques 
A large amount of clinical liver perfusion measurements have been undertaken using CT in 
combination with iodine-based contrast agents. From modelling of the uptake curves based 
on regions within the descending aorta and portal vein (32), the arterial and venous 
contributions to the liver parenchyma and disease nodules can be estimated. Hepatic CT 
has been successfully applied to measuring perfusion deficits in HCC, metastases, fibrosis 
and cirrhosis, and in addition detected changes in the HPI (32-34). However, the 
quantification of the contrast agent uptake is reliant on characterising the ‘arterial input 
function’, which requires high temporal resolution, and the imaging modality exposes 
patients to ionising radiation.  
Doppler ultrasound can be used to measure blood flow in the major vasculature, and has 
been demonstrated to image portal hypertension (35), and estimates of bulk liver flow can 
be derived from velocity measurements. However, though this technique is fast, non-
invasive and flow measurements showed a high sensitivity to the cirrhosis scores, there is 
an element of user-variability in this measurement.  Ultrasound has also been combined 
with a microbubble contrast agent to measure regional liver and malignant tumour 
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perfusion, though the quantification and pharmacokinetics of the contrast agent has not 
been extensively explored (36).  
1.2.2 Pre-clinical Techniques 
Pre-clinically, the majority of invasive perfusion measurements have been performed in rats 
rather than mice due to the larger anatomy facilitating intricate surgery. A body of 
literature reports the use of fluorescent or radioactively-labelled microspheres to 
systemically embed in the capillary bed, and the tissues can then be evaluated for their 
concentration relative to a blood sample. This ex vivo technique is often considered a gold 
standard, and has been applied in mice (37) and rats (38), though is not a trivial 
experiment, as there are a number of complications within the procedure and 
quantification (20).  
There are a number of in vivo techniques using clearance of a labelled contrast agents such 
as Indocyanine Green (ICG), galactose (39), 133Xe (40), 85Kr (41). These techniques are 
invasive, typically exposing the liver to a counter to then estimate a liver perfusion from the 
uptake of the contrast agent. These measurements, however, do not provide a regional 
measure of hepatic blood flow.  
1.2.3 Liver Perfusion MRI 
Anatomical liver imaging is a well-established method for MR; scans are commonly used to 
diagnose hepatocellular carcinoma (HCC), cirrhosis, metastases and hepatic lesions (42). 
Currently, dynamic contrast enhancement (DCE) MRI is the most common form of clinical 
liver perfusion imaging. DCE MRI utilises the T1 shortening caused by a paramagnetic 
contrast agent, typically a chelated form of Gadolinium. The post-bolus signal enhancement 
is modelled, based closely on the enhancement models from dynamic CT, to generate 
estimates of physiological parameters. DCE-MRI has been successfully applied to 
hepatocellular carcinoma (HCC) (43) and patients with liver metastases undergoing various 
therapies (44). It is commonplace for DCE-MRI to be used for qualitative diagnostic 
evaluation to determine tissue malignancy from arterial, portal and equilibrium phases 
(45). In addition, hepatocyte-targeting contrast agents can give liver-specific contrast, 
which describe the late phase enhancement as ‘hepatobiliary’ phase. Kinetic modelling 
developed for contrast-CT has been adopted by DCE-MRI such as single- and dual-input and 
single- and dual-compartment models which respectively address the vascular supply and 
contrast distribution (46). However the choice of modelling of DCE-MRI has not yet been 
standardised, and the modelled parameters yield a challenging interpretation – a 
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commonly reported parameter is Ktrans, which relates to the microvascular permeability, 
whereas a measurement of perfusion offers a more physiological assessment of the tissue.  
Tissue Approximate Perfusion Ranges (ml 100 g-1 min-1) 
Cortex 110 – 180 (47, 48) 
Myocardium 360 - 700 (49, 50) 
Renal Cortex 400 – 750 (51, 52) 
Total Hepatic 180 - 250 (53, 54) 
Skeletal Muscle 17 – 60 (55) 
Table 1.1: Typical ranges of mouse organ perfusion measured using ASL MRI and 
other invasive measurements.  
Pre-clinical applications of DCE-MRI have been applied to rat models of liver fibrosis (56) 
and HCC (57); both of these studies were carried out in a clinical 1.5T system, and utilised 
the imaging acceleration techniques available on human imaging system. Hartono et al 
carried out a feasibility study measuring liver blood flow in mice on a pre-clinical 7T system; 
across five mice, a mean liver perfusion of approximately 2.5 ml g-1 min-1 was estimated, 
when normalised to a typical mouse liver mass (2g) (58). The temporal resolution (2s) of the 
DCE acquisition however was insufficient to differentiate between arterial and venous 
supply to the liver parenchyma. The predominant issue with pre-clinical liver DCE MRI is 
defining the first bolus of contrast-agent due to the rapid circulation, which makes 
separating the arterial and portal venous blood supply difficult in addition to quantifying 
the perfusion signal.  
An alternative, non-contrast method of estimating bulk liver flow can be calculated from 
phase contrast (PC) angiography measurements in the portal vein. PC-MRI is well 
established on clinical scanners (59), and has been applied to rat liver dysfunction models 
(60), though pre-clinical development in this field is limited. Phase-contrast angiography is 
particularly useful for late stage liver dysfunction where reverse flow is possible. However 
bulk flow estimates based on input-vessel velocities do not provide localised measurements 
within the liver tissue and could not be directly applied to for example, metastases 
measurements, though velocity changes in the hepatic supply can be indicative of other 
gross hepatic dysfunction (61, 62).  
Barash et al. utilised a ‘functional-MRI’ approach to infer liver perfusion dynamics by 
measuring changes in T2*-weighted signal intensities in response to hyperoxia and 
hypercapnia (27). This technique reported a decrease in portal perfusion and increase in 
arterial perfusion following ligation of the portal vein, from the changes in signal intensities 
26 
 
under the two gas challenges relative to the normal liver. Edrei et al. also used this 
approach to measure a reduced perfusion within a model of colorectal liver metastases in 
mice (63). It was suggested that the signal intensity changes within the tumours were due 
to an increased arterial supply, as has been previously reported, though the interpretation 
of such signal changes is challenging, as this method does not a direct quantification of the 
tissue perfusion. 
Arterial spin labelling (ASL) is a contrast-free MRI method to measure perfusion, initially 
and predominantly applied in the brain (64). The technique has been applied to image 
other organs such as the heart, kidneys and pre-clinical tumour xenografts (49, 65, 66). To 
my knowledge, at the time of writing, no previous examples of pre-clinical hepatic arterial 
spin labelling (ASL) have been published, though a few recent examples exist of clinical liver 
arterial spin labelling: Katada et al (67) measured the portal perfusion in a HCC patient 
study, and these data were quantified using a single-input, single-compartment model and 
evaluated against CT portography. The limited amount of research may be due to the 
relatively low and unstructured signal across the liver compared to other researched organs 
(Table 1.1), in addition to complications due to respiratory motion and quantifying the dual-
blood supply. Bland-Altman analysis identified an overestimation in non HCC liver tissue, 
suggestive of a systematic error which was attributed to the blood/tissue T1 ratio which was 
not taken into account by the single compartment modelling. The inversion profile was 
planned to avoid the aorta, and so the application to liver tumours may be limited as 
cancerous deposits have a tendency to draw from the arterial supply (68). Hoad et al (69) 
used a free-breathing FAIR sequence to measure total liver blood flow in healthy 
volunteers, this sequence has been later applied to monitoring post-prandial changes in 
cirrhosis patients (70). This research used dual-input, single compartment model which 
showed improved reproducibility between imaging sessions over DCE-MRI. Recently, a 
‘pseudo-continuous’ ASL method to separate the arterial and venous contribution of the 
liver was demonstrated in normal volunteers and cirrhosis patients (71), which also 
measured post-prandial blood flow changes. This MRI technique is most promising, as a 
direct measure of arterial and venous perfusion in the liver can be achieved from separately 
labelling the vascular inputs, free of contrast agents and complex modelling of the 
perfusion quantification.  
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1.3 Arterial Spin Labelling 
1.3.1 Introduction 
This thesis focuses on perfusion imaging of the small animal liver; as there has been little 
published on hepatic arterial spin labelling (ASL), the following section introduces the 
technique and investigates developed pre-clinical and clinical ASL techniques. In addition, a 
focus will be made on previous kidney and cardiac perfusion imaging, as this may inform on 
the optimal methods of ASL preparation, perfusion quantification, and gated image 
acquisition, to counter respiratory motion of the liver. 
Arterial spin labelling ASL is a perfusion-measuring MR technique, originally developed for 
imaging cerebral blood flow (CBF) in rats (64). The principle of ASL is to use water in the 
blood as an ‘endogenous’ tracer – the spins within the arterial blood are inverted so that 
the perfusion signal will come from a difference in relaxation as these ‘tagged’ spins travel 
to and exchange with the tissue under investigation. The success of brain perfusion imaging 
led to the technique being adapted to good effect in cardiac (72) and kidney (73) perfusion 
imaging. However, application of ASL to the liver has not been extensively undertaken.  
The attractiveness of using ASL is that the technique can quantify blood flow without the 
need for invasive contrast agents or radio-chemicals, thus tissue perfusion can be utilised as 
a disease and regeneration biomarker. Though ASL suffers from a lower signal-to-noise 
ratio (SNR) than contrast-enhanced perfusion imaging, ASL will be better suited for 
longitudinal monitoring long term studies without potential discomfort from regular doses 
of contrast tracers or radiation exposure.  
ASL can be considered in two modes of operation; continuous arterial spin labelling (CASL) 
and pulsed arterial spin labelling (PASL). CASL was the first mode of perfusion MRI 
proposed by Williams, Detre and Leigh (74) – application of a long-duration (~ approx. 2 s) 
RF pulse and a magnetic field gradient centred on the carotid arteries resulted in the blood 
magnetisation undergoing adiabatic inversion during transit toward the brain (75). 
However, the long-duration, off-resonance RF pulse induced magnetisation transfer (MT) 
effects, due to saturation of large macromolecules in the tissue exchanging with the free 
water, leading to an over-estimation of the perfusion.  
However, due to the hardware demands and MT effects of CASL, the popularity of MR 
perfusion imaging moved to pulsed ASL. This format was first proposed around the same 
time by Kwong, Kim and Schwarzbauer (76) (77) (78), which uses a single inversion pulse to 
label the perfusing blood. This technique was far simpler to implement on standard MRI 
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scanners, and the single pulse removed the influence of MT saturation. Typical PASL 
sequences are “Flow-induced Alternating Inversion Recovery” (FAIR) and “Signal Targeting 
by Alternating Radiofrequency Pulses” (EPISTAR) (79) which orient the selective labelling 
pulse differently around the imaging slice to sensitise the images to perfusion. Though PASL 
has a reduced SNR relative to CASL, it is possible to tag closer to the imaging plane to 
optimise the perfusion signal, due to the reduced applied RF and gradients.  
1.3.2 Flow-induced Alternating Inversion Recovery (FAIR) ASL 
Arterial spin labelling estimates perfusion from signal subtraction, and the FAIR sequence 
achieves this by two signal preparations: a global and slice-selective inversion centred on 
the imaging slice. A T1 map will be generated from the global inversion experiment, and the 
perfusion-weighting will arise from the slice-selective inversion: an apparent faster 
recovery of the inversion recovery curve will be measured as a result of fresh magnetisation 
from the blood pool arriving in to the imaging slice and exchanging with the tissue water. 
FAIR methods have been used to obtain perfusion maps of the brain and kidneys, and such 
a labelling approach is predominantly applied to measurements of myocardium perfusion 
due to the difficulty of labelling the supply vessels to this tissue.  
1.3.3 Pseudo-Continuous ASL 
Continuous ASL resurfaced with the advent of ‘pseudo-continuous’ ASL (pCASL) (80), which 
replaces the long duration labelling pulse with a train of closely-spaced, short RF pulses to 
give an effectively continuous pulse. As a result of the discretisation of the RF pulse, a larger 
gradient can be applied and further off-resonance RF pulses can be used which reduces the 
influence of magnetisation transfer produced in CASL (81). The development of pseudo-
continuous ASL has facilitated vessel-selective labelling (81), (which can be achieved using 
intricate planning of the inversion slab in PASL (67)), which has been demonstrated to 
identify the cortical perfusion from the separate perfusing vessels (82).  
1.3.4 Renal ASL  
Both kidney and liver imaging employ similar gating strategies to overcome image artefacts 
from respiratory motion, thus renal ASL techniques offer useful information on the optimal 
approaches for perfusion measurements of the liver. Clinical examples of renal ASL have 
utilised EPI readouts for fast acquisition to overcome respiratory motion - however EPI may 
be difficult to implement within a mouse abdomen at high field due to susceptibility 
artefacts at air-tissue boundaries leading to image distortion. Clinical renal ASL have 
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employed controlled breathing strategies to acquire images (65), however, pre-clinical 
imaging is predominantly free breathing without invasive ventilating procedures.  
Pre-clinical kidney perfusion imaging has recently been applied in mice using FAIR with a 
respiratory triggered, single shot SE-EPI at 7T (83). This study optimised the inversion 
efficiency for the ASL tagging by including the mouse heart within the transmit coil, 
however the coronal imaging plane did result in some unwanted labelling in the slice-
selective inversion. Such unwanted labelling could be overcome by using a pseudo-
continuous ASL (pCASL), as demonstrated in mice at 11.75T by Duhamel et al (84). This 
study compared a FAIR and a pCASL preparation and also investigated between a two-shot 
SE-EPI and a single shot Rapid Acquisition with Relaxation Enhancement (RARE) readout. 
ASL preparation was respiratory triggered, and images were synchronised with respiration 
in order to acquire in the quiescent phase. The pCASL module demonstrated a 20% increase 
in sensitivity over the FAIR technique, and additionally the RARE readout was less liable 
than EPI to susceptibility variations and motion artefacts when imaging coronally rather 
than axially. The pCASL preparation module was found to be limited to around 65% the 
tagging efficiency of the FAIR technique (calculated as the ratio of the renal perfusion 
values), which could be attributed to loss of flow driven adiabatic inversion in the aorta due 
to respiratory motion and pulsatile flow.  
1.3.5 Myocardial ASL 
There has been a considerable body of pre-clinical cardiac ASL and the techniques here may 
be instructive for applications to the liver. Belle et al (72)  published one of the first 
quantitative in vivo measurements in rats, using an ECG gated, gradient echo sequence.  
The animals were ventilated and under sodium pentobarbital anaesthesia in this 
experiment, which is known to reduce heart and breathing rates – and the ventilation was 
paused during perfusion acquisition, which can be clinically translated as a voluntary 
breath-hold. Since this initial research, subsequent research has investigated the influence 
of isoflurane on myocardial perfusion and free–breathing strategies on myocardial 
perfusion imaging (85, 86). In 2012, Campbell-Washburn et al employed a free-breathing 
ECG gated FAIR Look-Locker sequence to study mouse myocardial perfusion at 9.4T (87). 
The Look-Locker technique shortened the acquisition time of multiple TIs post-inversion by 
regularly sampling the recovery curve with a small flip angle as to minimally perturb the 
magnetisation relaxation. As the inversion recovery period (approx. 6s) included a number 
of respirations, a retrospective algorithm was applied to discard corrupted images from 




From reviewing the literature, it becomes apparent that avoiding motion and susceptibility 
artefacts is key when performing ASL MRI in the abdomen and, in particular, the liver (88). 
The choice of either a CASL or PASL labelling method for the liver will determine whether 
portal venous and hepatic arterial or total hepatic blood flow will be measured. As the total 
liver blood flow is expected to be approximately half of that of the kidney (1.8 ml g-1 min-1 
to 5.1 ml g-1 min-1, from microsphere data in mice (37)), a method to measure the total in-
flow of blood to the liver, such as FAIR, in order to maximise the potential perfusion signal, 
will be ideal to initially assess the feasibility of liver ASL. In addition, this sequence is simple 
to implement whereas it may be technically difficult to implement a pCASL method in a pre-
clinical liver setting.  
Clinical liver ASL measurements have overcome breathing motion of the liver by timing the 
inversion and acquisition on free-breathing patient expiration (67, 69, 70), and also using 
breath-hold strategies (71). For pre-clinical measurements, a free-breathing approach will 
be implementable, though this will depend on stable physiology of the animal, which can 
vary and become more erratic over long experiment durations. Rajendran et al. imaged 
renal perfusion using a timing of the inversion and a single-shot EPI readout pulse, in a 
similar manner to the clinical liver examples above. Duhamel et al. acquired a single TI with 
a single-shot acquisition (EPI and RARE), by synchronising the readout with the respiration 
rate. This ‘timing’ method is reliant on rapid image acquisition, however, from initial 
experience, EPI of the mouse liver suffered from many artefacts. An alternative read-out 
method can employ retrospective gating of the data, in a manner demonstrated by 
Campbell-Washburn et al. in the mouse myocardium (87). Such a readout method offers 
promise in application to the liver, as the gradient-echo readout will not be as susceptible 
to distortions as EPI, and the efficient acquisition of multiple TIs will increase the accuracy 
of the perfusion estimate. 
1.5 Thesis Structure 
The aim of this thesis is to investigate the application of arterial spin labelling MRI to the 
mouse and rat liver. The remaining thesis is structured thus: 
Chapter 2 provides the relevant theory for the following chapters, covering some basic 
aspects of MRI, as well as functional imaging techniques to measure perfusion, blood 
velocity and the B0 field.  
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Chapters 3 to 5 report on the experimental results: Chapter 3 shows the development and 
optimisation of a T1-mapping based quantification of liver perfusion using a Look-Locker 
acquisition and a FAIR-ASL approach. Methods to prospectively and retrospectively gate 
acquisition were investigated, and this was followed by a repeatability study to 
demonstrate the robustness of the technique.  
Chapter 4 applies the optimised sequence to three pre-clinical liver models. First, the 
technique is used to measure perfusion differences between normal liver and two tumour 
cell lines in a mouse model of colorectal liver metastases. The perfusion changes within the 
tumours were then measured after administration of a vascular-disrupting therapy. Second, 
the sequence was applied to a rat model of cirrhosis, and compared to a phase-contrast 
MRI estimate of bulk liver flow. Finally, perfusion differences were measured between liver 
lobes in a rat model of selective portal ligation to stimulate rapid liver growth.  
Chapter 5 investigates the feasibility of pCASL in the mouse liver, to separate the flow 
contributions of the portal vein and the hepatic artery. Measurements of the blood vessel’s 
velocities and the B0 shifts during respiration were taken in order to optimise and simulate 
the efficiency of the pCASL tagging. Abdominal EPI was tested with a pCASL preparation in 
the kidneys, before being applied to the mouse liver.  
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Theory and Materials 
This chapter presents an overview of the relevant theory prerequisite for the following 
chapters. MRI theory, including image relaxation and image acquisition will be introduced. 
The origin and quantification of the MRI perfusion measurement using arterial spin 
labelling, used in Chapters 3 - 5, will be covered. In addition, the theory of phase-contrast 
velocity measurements and field mapping will be covered as these techniques are used in 




2.1 The Principles of Magnetic Resonance Imaging 
2.1.1 Origin of the MRI Signal  
A brief overview of magnetic resonance imaging (MRI) will be presented in this chapter, 
explaining the derivation of the signal and the acquisition of an image. However, more 
detailed explanations can be found in the literature of Haacke, Bernstein and McRobbie (1-
3).   
The origin of the nuclear magnetic resonance (NMR) and MRI signal is founded in the 
quantum mechanical description of nuclei with non-integer spin. Nuclear spin is an intrinsic 
property of protons and neutrons, and nuclei formed of an uneven number will exhibit a 
discrete angular momentum. The predominant non-integer spin isotope used in MRI is 1H – 
hydrogen, which is found in great abundance within organic tissue, in addition, MRI has 
been performed measuring 18F – Fluorine, 23Na Sodium 31P – Phosphorus signal. The spin 
property manifests as a nuclear magnetic moment, which in the presence of a magnetic 
field, cause these nuclei to precess from the resultant torque. This mechanism is similar to 
the classical example of a gyroscope precessing in the Earth’s gravitational field. Lamor 
described that the rate of precession will be proportional to the present magnetic field:  
       Equation 2.1 
The gyromagnetic ratio γ will vary depending on the nuclei – for Hydrogen, γH = 42 MHz/T. 
Characterisation of the Lamor frequency is fundamental to the ‘resonance’ principle of MRI, 
and it is possible to build up an image with the use of additional magnetic field gradients, as 
will be explained later.  
When present in a magnetic field (referred to as B0), nuclei will align parallel or anti-parallel 
to the external field. The two states of alignment have an energy difference ΔE = ℏω, where 
ℏ is the reduced Planck’s constant, which determines the detectable signal from the spins. 
From Equation 2.1, it is possible to observe that greater strength external fields will result 
in a larger energy difference. Most of the nuclei’s angular momentum will cancel out due to 
the parallel/anti-parallel alignment, however, a small number will remain unopposed in the 
lower energy state, as determined by the Maxwell-Boltzmann distribution: 




     Equation 2.2 
N+ represents the number of spins aligning parallel with B0, N- the number of anti-parallel 
spins, kB – the Boltzmann constant and T is the temperature. This ratio is very small at room 
temperature (approximately 7 N+ per million N-, at room temperature and at 1T), however 
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due the number of spins present within tissue, the small ratio manifests as a tangible 
macroscopic magnetisation.  The convention of MRI defines the B0 field in the z direction, 
thus the macroscopic magnetisation precesses around the z-axis at a frequency determined 
by Equation 2.1.   
2.1.2 MRI Principles: Excitation 
Common MRI field strengths between 1 – 9.4 T, equate to a resonant frequency 
approximately between 40 – 400 MHz for hydrogen nuclei, which is that of radiofrequency 
(RF). Using an electromagnetic pulse, the spins can be manipulated using the magnetic 
component of these waves.  
It is often easier to comprehend the interactions of the applied pulses by switching to a 
rotating reference frame, spinning around the z-axis at the Lamor frequency (Figure 2.2A). 
In this frame, the magnetisation is fixed, and pointing along the z-axis. Application of a 
circularly-polarised RF pulse at the Lamor frequency results in a relatively small 
magnetisation vector B1, in this example, along the y-axis (Figure 2.2B). The presence of this 
new external magnetic field will result in the magnetisation to precess around the y-axis.  
Changes in the magnetisation M(t) due to the magnetic field B(t) are described by the Bloch 
equations, which are derived from the Lamor relation. Ignoring any spin relaxation:  
   ⃑⃑    
  
  ⃑⃑       ⃑      Equation 2.3 
From this equation, in the rotating frame, it is predicted that the magnetisation will precess 
around the y-axis at a slower rate than the Lamor frequency. In the laboratory frame, the 
magnetisation rotates around the effective magnetic field Beff, which is the vector sum of 
applied fields (Equation 2.4). This results in the magnetisation to precess at an angle to the 
z-direction. The spins are described as being in an excited state, as the magnetisation will 
have a component in the transverse plane, which can be detected within receiver coils by 
Faraday induction. Applying the B1 field for ranges of durations and pulse powers will 
control the angle the magnetisation vector makes with the z-axis, known as the ‘flip-angle’ 
(Figure 2.2B). As the detectable signal within the receiver coils is determined by the 
transverse projection of the magnetisation vector, thus a maximal signal will follow a 90° 




Figure 2.2: (A) A spin precessing around the B0 field, applied in the z-direction. (B) A spin in the 
rotating frame during the application of an on-resonance RF pulse. In this example, the magnetic 
component of the circularly-polarised pulse is in the y-axis. Due to the presence of the new magnetic 
field B1, the spin begins to precess around y-axis. The angle (θ) the spin makes with the z-axis is 
known as the flip angle, which will depend on the strength and duration of B1. 
 
  ⃑        ̂     ̂  Equation 2.4 
2.1.3 MRI Principles: Relaxation 
Two signal decay mechanisms of the MRI signal have been empirically observed; 
longitudinal (T1) and transverse relaxation (T2 & T2*). T1 relaxation is propagated by thermal 
interaction between the spins and the “lattice” – the environment the spins are in. The 
spin-lattice relaxation determines the rate at which the longitudinal component of the 
magnetisation Mz returns to the B0 direction following excitation: 
    
  
  
     
  
  Equation 2.5 
Equation 2.5 describes that the rate of decay recedes as the spins approaches the 
equilibrium magnetisation M0. Methods to quantify tissue T1 properties are explored in 
Chapter 2.3.1. 
Transverse relaxation describes the loss of the detected MRI signal due to incoherent 
precession of the excited spins. When the macroscopic magnetisation is tipped into the 
transverse plane, the spins are in phase and a maximal transverse magnetisation can be 
detected. However, due to the magnetic field of each spin perturbing neighbouring spins, 
the spins will dephase as a result of the different Lamor frequencies each will be precessing 
at. In the rotating frame, this will appear as magnetisation vectors fanning away from the x-
axis, after a 90° flip angle excitation pulse. This results in the net transverse magnetisation 
Mx,y decaying to zero, as characterised by the transverse rate T2:  
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  Equation 2.6 
Spin-spin propagated decay as described by Equation 2.6 is the behaviour of spins in a 
perfect system. However, local inhomogeneities of the magnetic field, caused by the 
sample creating susceptibility variations, increase the rate of dephasing. This acceleration 
of dephasing is characterised by T2*. Introducing a factor T2’, which accounts for the field 









   Equation 2.7 
T2* decay behaves as T2 and is similarly described by Equation 2.6. It is generally observed 
that for the same tissue type, T2* < T2, and that transverse decay is much faster than the 
thermally-driven relaxation of T1. Methods to quantify tissue T2/ T2* properties are 
explored in Chapter 2.3.2. MRI acquires images using two techniques known as gradient 
echo and spin-echo imaging. The influence of the field inhomogeneities T2’ can be removed 
by the use of spin-echo MRI to characterise T2, and gradient-echo MRI will include T2* 
weighting; these sequences will be explained later in this chapter. 
2.1.4 MRI Principles: Slice Selection 
Consider a uniform sample in a uniform magnetic field; application of an on-resonance RF 
pulse will excite the entire volume, which obviously will not be medically relevant. 
However, applying a gradient Gz in the z-direction will facilitate a selective excitation:  
               Equation 2.8 
Using the Lamor relation, it is apparent that the sample’s resonant frequency is spatially 
dependent on z. Applying an RF pulse at one frequency will thus only excite a ‘slice’ of the 
sample (Figure 2.3). However, a radiofrequency emission will contain a finite bandwidth of 
frequencies (Δω). Thus, a slice thickness (Δz) is defined by the slice-selection gradient (Gz) 
and the excitation bandwidth:  
 
   
  
   
  Equation 2.9 
This relation assumes a uniform or ‘box-car’ excitation of the slice. The excitation profile is 
dependent on the Fourier Transform of the RF pulse shape, thus, for a box-car profile, a sinc 
RF pulse is required. As the ideal shape of a sinc pulse requires many ‘side lobes’, these 
pulses are often truncated, as a compromise between acquisition speed and idealised 
excitation profiles. Figure 2.3 also demonstrates how multiple slices can be excited using 
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the same slice-selection gradient: using successive RF pulses with resonant frequencies 
separated by their bandwidth; it is possible to excite contiguous slices for 2D MRI. 
 
Figure 2.3: Schematic showing the prinicple of spatial frequency encoding and slice-selection. A 
gradient Gz is applied along the z-axis, leading to a z-dependence on the Lamor frequency within the 
sample. Application of a RF pulse, with frequency ω0 and bandwidth Δω, will lead to a discrete slab 
with thickness Δz. Application of a separate RF pulse at another frequency will lead to a subsequent 
slice to be excited with the same gradient, facilitating multi-slice acquisition.   
2.1.5 MRI Principles: Frequency & Phase Encoding 
Once the slice has been excited, the sample information is extracted using frequency and 
phase encoding. Frequency encoding works in the same manner as the slice selection: a 
linear gradient is applied in the frequency-encoding direction (orthogonal to the slice-
selection), resulting in a spatial dependency of the frequencies. This gradient is also known 
as the read-out gradient (GRO), as this is applied during the image acquisition. Considering a 
1D example, with two samples at distinct positions – each sample will have a unique 
frequency during the application of GRO. The detected signal in the receivers will be two 
exponentially decreasing (due to transverse relaxation) sinusoidal frequencies mixed 
together. As the data has been frequency-encoded, a Fourier Transform (FT) is required to 
return the data in to real-space. Using a Fourier transform, it is possible to identify the two 
frequencies and respective amplitude, and knowing the magnitude and duration of the 
frequency-encoding gradient, the position of the signal sources can be identified.  
Phase-encoding extends this principle further by applying a phase-encoding gradient (GPE), 
perpendicular to the read-out gradient (and to the slice-selection). Phase-encoding 
gradients are applied incrementally to ‘comb’ the sample for spatial frequencies, and will 
build up a 2D image in Fourier-space or k-space.  
When acquiring the 2D k-space data, a single phase-encoding gradient is applied, alongside 
the read-out gradient (typically negative) to move the wave vector to the edge of the k-
space. During the data acquisition, the read-out gradient is turned on, resulting in the wave 
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vector (kRO) filling up this line of k-space. When the 2D k-space matrix is acquired, the 
largest signal is acquired when GPE = 0, and the lowest signal is when GPE is maximal (Figure 
2.4A). K-space is digitised in to a number of matrix points, (typically 64 or 128), and 
commonly a square matrix is built up by using the same number of phase-encoding steps as 
the frequency matrix. 
The receivers digitise the acquired signal using a demodulation process, which multiplies 
the acquired signal by a sine and cosine approximately at the B0 frequency. The resultant 
signals will be the sum of a low frequency and a high frequency signals – the high frequency 
component can be filtered out, and thus reduce required sampling frequency of the 
digitiser. The two resultant demodulated signals will then be digitised as the real and 
imaginary data, and recombined within the complex k-space.  
 
Figure 2.4: 2D image acquisition in k-space: (A) Schematic of k-space, application of phase-encoding 
and readout gradients move through k-space. The largest signal is acquired in the centre of k-space, 
the sustained readout gradient is applied alongside the receiver acquisition, so the signal is focussed in 
the middle of kro. The phase-encoding gradient is incremented per readout so that over the image 
acquisition, an analogous phase encode gradient is applied in the kpe direction. Increasing the number 
of phase-encoding steps and receiver digitisation will increase the image resolution. (B) From the 
fourier transform (FT) of the complex k-space data, the images can be separated in to the magnitude 
and phase images. The majority of MRI analyses the magnitude data, but useful information can be 
encoded within the phase image.  
 
A 2D Fourier transform of the k-space data will result in a complex, real-space dataset. The 
magnitude of this is the image form that is most prevalent in MRI, and the phase of the 
complex, real-space data can be used for velocity and field measurements (Figure 2.4B). 
The next sections look at the two forms of how the image is acquired: gradient- and spin-
echo imaging.  
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2.2 Pulse Sequences  
2.2.1 Gradient Echo Imaging 
The gradient-echo (GE) technique is designed to acquire the radiofrequency signal using a 
reversal of the read-out gradient in order to locate the maximal magnetisation signal in the 
centre of k-space; the steps have been described in Figure 2.5. Figure 2.5A shows a 
schematic of a sequence diagram: the applied RF, gradients and expected signal are 
represented with respect to time. Step 1 is the slice-selective excitation: the RF pulse shape 
represents a truncated sinc function. The slice selective gradient GSS, previously denoted as 
Gz, is applied and held on for the duration of the excitation pulse. A negative rephasing lobe 
is included to GSS to balance any additional phase accrual caused by the presence of the 
slice-selection gradient. The gradients have all been represented with a trapezoidal shape, 
to represent the real-world limitation of ramp-time for the gradients to be switched on.  
The signal refocusing is best understood in the rotating transverse plane, represented in 
Figure 2.5B: the magnetisation begins to dephase (step 2) following excitation, then the 
read-out gradient is applied negatively (step 3) which causes the spins to dephase faster. 
This negative lobe also moves the point in k-space to the edge of kRO, and the application of 
the phase-encoding gradient also moves the point in k-space in the kPE direction (red arrows 
Figure 2.5C). Two example trajectories have been shown for separate excitation and 
acquisitions; the application of different phase-encoding gradients will facilitate building up 
the k-space data. The time between successive excitation pulses is defined as the repetition 
time (TR).  
The read-out gradient is then reversed, and at the same time the receivers are turned on. 
The reversal of the read-out gradient causes the magnetisation to rephase (step 4), 
eventually forming a coherent echo (step 5). The time between excitation and rephasing is 
known as the “echo-time” or TE. The readout gradient is left on until the other edge of k-




Figure 2.5: Gradient Echo (GE) sequence. (a) Sequence diagram (RF – radiofrequency pulses, GSS – 
slice select gradient, GPE – phase encoding gradient, GRO – readout gradient, Signal – expected signal 
acquisition and receivers opened). (b) Schematic of the behaviour of four spins in the rotating 
transverse magnetisation frame. (c) K-space schematic showing the path traversed for two phase-
encoding steps. (d) Representaion of the acquired signal if the receivers were on for the steps.  Slice-
selective excitation (1) followed by immeditate dephasing in the transverse rotating frame (2). 
Spatial encoding by application of phase-encoding and a negative readout gradients (3), the readout 
gradient is then reversed (4) which will cause the transverse magnetisation to rephase.  A signal 
maximum occurs at the point the total readout gradient moment is equal to zero (5). The readout 
gradient is held on and the signal decreases as the magnetisation continues on to dephase (6).  
 
Considering the signal acquired in the receiver coils (Figure 2.5D), a maximal signal is 
present immediately following excitation, and the presence of the read-out gradient 
accelerates the signal decay, which is recovered following the reversal of the gradient. The 
signal at the echo will be reduced by the T2* decay present, due to field imperfections, thus, 
GE imaging is considered to be T2*-weighted. This effect of T2* decay can be removed by 
the use of spin-echo imaging, as will be explained in the next section.   
2.2.2 Spin Echo Imaging 
The spin-echo (SE) technique uses a second RF pulse to refocus the magnetisation in the 
transverse plane; the steps have been represented in Figure 2.6. The sequence diagram 
(Figure 2.6A) is similar to that of the gradient-echo technique, however, following excitation 
(step 1), a positive read-out gradient is applied alongside a phase-encoding gradient (step 
2). In the transverse plane (Figure 2.6B) the spins dephase as a result of the applied 
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gradient and local inhomogeneity, and the position in the k-space matrix (Figure 2.6C) is 
taken at the right-hand side. A slice-selective 180° RF pulse is then applied on the y-axis, 
which results in the magnetisations being flipped around the y-axis (step 3), also 
manifesting as a reflection in the x-y direction within k-space (grey arrow, Figure 2.6B). The 
spins will consequently begin to refocus (step 4), as each magnetisation will have the same 
angle to sweep at the frequency it was travelling before. The echo (step 5) will occur at 
twice the time period between the 90° and 180° pulse, thus the readout gradients are 
switched on before the echo time (TE) and the receivers are turned on, and the 
magnetisation will continue to dephase after (step 6). Due to the 180° pulse, the effects of 
the T2* are removed as the local dephasing is reversed to produce the signal echo, thus 
signal detected in the receivers is only reduced due to spin-spin interactions (Figure 2.6D).  
 
Figure 2.6: Spin Echo (SE) sequence. (a) Sequence diagram – the spin echo utilises an 180° pulse to 
refocus the spins. (b) Schematic of the behaviour of four spins in the rotating transverse 
magnetisation frame. (c) K-space schematic showing the path traversed for an example phase-
encoding step. (d) Representation of the acquired signal if the receivers were on for the steps.  Slice-
selective excitation (1) followed by spatial encoding by application of phase-encoding and a readout 
gradient (2). An 180° pulse is applied alongside a slice selection gradient (3), causing the spins to flip 
around the y-axis. The pulse is followed by the readout gradient (4) which will cause maximal 
rephasing when the readout gradient areas before and after the 180 are equal (5). The readout 




2.2.3 Echo Planar Imaging 
Echo planar imaging (EPI), was first presented in the early 1980s  by Mansfield et al. (4) as a 
rapid imaging technique in which multiple lines of k-space are acquired in every TR, 
resulting in short scan durations <100 ms. This segmented acquisition uses fast oscillations 
of the readout gradients to move in positive and negative trajectories along the frequency 
encoding direction. A brief phase-encoding gradient is ‘blipped’ in order for the data to fill 
k-space. EPI can be used as a gradient or spin-echo acquisition (Figure 2.7A & C), the 
sequence premise is as above, but with the rapidly oscillating gradients applied afterwards. 
Using such an acquisition method, the k-space matrix can be filled following a single 
excitation, (known as a ‘single-shot’). However, in many cases, a small number of 
interleaved ‘shots’ are used to systematically fill up k-space (Figure 2.7B). With its short 
acquisition time, EPI has found many applications in brain MRI, such as dynamically imaging 
functional MRI (fMRI), diffusion and perfusion imaging.  
However, the rapid gradients used in EPI can lead to image distortions as the technique is 
dependent on large, fast, and well-shielded gradient coils. Alternate echoes are time-
reversed before the Fourier Transform into the image domain, however residual 
differences between odd and even echoes due to eddy currents, gradient asymmetry and 
magnetic field inhomogeneity can lead to a reconstruction artefact known as a ‘Nyquist 
ghost’. The effect of this ghost can be corrected using an EPI reference scan with no phase-
encoding. In addition, the rapid bipolar gradients result in a small signal bandwidth in the 
phase-encoding direction, leading to large chemical shift artefacts, which can be minimised 
with suppression pulses. The small bandwidth means that perturbations in the magnetic 
field manifests as large image distortions in regions of high susceptibility, typically found at 
air-tissue boundaries.  Using a multi-shot EPI acquisition can decrease the image distortions 
by effectively increasing the phase-encoding bandwidth per shot.  
The techniques presented here and used in the remainder of this thesis use ‘Cartesian’ 
acquisition of k-space; the data is acquired along the frequency encoding direction. An 
alternative method to rapidly acquire images uses radial or spiral trajectories to cover k-
space. Such regimes can quickly acquire images and suppress motion artefacts, however, 





Figure 2.7: Echo Planar Imaging (EPI) sequence diagrams. (A) GE-EPI: The excitation steps (1-3) are 
the same as the GE technique. At the end of the readout gradient a phase-encoding gradient ‘blip’ is 
applied (4) to jump in up to the next phase-encoding step. The readout gradient is reversed, and the 
next echo is acquired (5) until the end of the readout gradient and the next blip (6). This process is 
continued until the end of the EPI acquisition; in this example, 7 lines of k-space are acquired per 
excitation, where usually this will much longer (up to 64 for a single-shot). (B) K-space trajectory for 
the GE-EPI example. (C) SE-EPI, which uses the same excitation as the standard SE-EPI, followed by 
the rapid gradient-switching.  
2.3 Quantification of MRI Relaxation 
2.3.1 Longitudinal Relaxation: T1 
The longitudinal relaxation times of tissues are quantified by inverting the magnetisation 
and characterising the signal evolution in a process known as ‘inversion recovery’. Solving 
Equation 2.5, and using a perfect inversion, the magnetisation will relax back to 
equilibrium, passing through zero (Figure 2.8A). As MRI signal is magnitude data, the signal 
will follow the magnitude of this equation: 
        (    
    ⁄ ) Equation 2.10 
  
Where S0 is the equilibrium signal, and S(t) is the measured time-dependent signal. The 
simplest MRI acquisition to characterise the signal recovery is shown in Figure 2.8B: an 
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inversion pulse is followed by an excitation and read-out (here shown as a gradient-echo). 
The time between inversion and excitation pulse is known as the inversion time or TI. The 
magnetisation is then left to recover back to equilibrium (typically around 5x the longest T1) 
before the next inversion pulse. Multiple TI measurements facilitate a better fitting of the 
signal recovery and improves the T1 estimation, and thus, this sequence is inefficient at 
characterising the signal recovery: one line of k-space of one TI is being acquired per 
inversion. Look and Locker (5) proposed a scheme to increase the efficiency of the 
sequence by including multiple, small flip-angle excitation pulses, separated by a regular 
inversion time (TILook-Locker) per inversion pulse (Figure 2.8C). This regime facilitates multi-TI 
acquisition per inversion, and the small flip-angle (<10°, (6)) sampling ensures that the 
inversion recovery is not disrupted.  
 
Figure 2.8: Quantification of T1:  (a) Schematic of magnetisation behaviour following a 180° pulse, 
this shape is known as inversion recovery (IR). (b) A IR-GE acquisition sequence diagram, the normal 
gradient echo acquisition is preceded by an inversion pulse. The inversion time (TI) is set to 
characterise the image signal along the IR curve, and the magnetisation is left to relax back to 
equilibrium before the subsequent 180° pulse set by the repitition time (TR). With this technique, a 
single line of a single TI is acquired per inversion pulse - increased TIs allow for better 
characterisation of the recovery curve. (c) Sequence diagram of a Look-Locker technique for efficient 
IR characterisation. The initial inversion is followed by  regularly spaced (interval TILook-Locker) 
small flip-angle (α < 10°) pulses, allowing for multiple TIs to be acquired per inversion pulse to 
increase the efficiency of the T1 characterisation. (d) The regular pulses in the Look-Locker 
acquisition each impart a small deflection in the magnetisation (black curve), and this acrues to an 
eventual signal saturation and the equilibrium magnetisation does not recover fully to M0 like the 




However, the Look-Locker train will partially saturate the tissue signal, resulting in an 
apparent longitudinal relaxation time, T1*, that is shorter than the true T1 time (Figure 
2.8D). If the sampling pulses with flip angle α is spaced at regular intervals TRLook-Locker, T1* 















T . Equation 2.11 
However, it is difficult to calculate the T1 from this equation because the exact value of α is 
impractical to estimate due to B0 inhomogeneity and imperfections in the selective pulse. 
T1* can then estimated by fitting data to a three parameter model (Equation 2.12) (7).   
             
     ⁄   Equation 2.12 
The true T1 can be estimated using Equation 2.13 (6), which factors the signal saturation, 
where β is the inversion efficiency from Equation 2.11, which assumes a perfect initial 
inversion.  
 )1(*11  TT  Equation 2.13 
    
2.3.2 Transverse Relaxation: T2 & T2*  
Transverse relaxation rates can be measured by repeating gradient and spin-echo 
acquisitions at a range of echo times, respectively for T2* and T2 quantification. Solving 
Equation 2.6 shows that the transverse signal decays exponentially with the increased 
incoherence of the spins (Figure 2.9A): 
         
      Equation 2.14 
The estimation of transverse relaxation will be improved with an increased number of 
echoes, thus the efficiency of the T2 and T2* measurements can be improved by using 
multiple echoes per excitation – an example pulse sequence of a multi-echo, GE acquisition 
has been shown in Figure 2.9B. Transverse relaxation times are often reported as the 
inverse rates: R2 and R2*. 
Spin echo measurements can be sped-up by using a fast spin echo (FSE) acquisition. The 
concept is similar to the multi-echo GE sequence; multiple 180° pulses and readouts follow 
the excitation pulse. As k-space is being filled following a single excitation, the image is 
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formed from a mix of echo times; therefore such a technique is not optimal for quantitative 
T2 mapping, though efficient for anatomical imaging.  
 
Figure 2.9: Quantification of the transverse relaxation: (A) Signal evolution of T2 (blue) and T2* 
(black) with echo time. Spin-echo experiments will give T2 weighting and gradient-echo will give T2* 
weighting. (B) Sequence diagram for a multi-echo gradient echo sequence for efficient T2* 
characterisation.  
2.4 Arterial Spin Labelling 
2.4.1 The Modified Bloch Equations 
Detre et al. first suggested using arterial blood to act as a endogenous tracer to measure 
tissue perfusion (8). The blood was labelled, via inversion, in transit within the carotid 
arteries. Following labelling, the blood will pass into the brain’s capillary bed and exchange 
magnetisation with the tissue. The tissue magnetisation will decrease, and with the use of a 
control image, the signal differences can be attributed to perfusion. The control image was 
performed by placing the tag equidistant from the image plane but outside the body such 
that any magnetisation transfer effects caused by a long duration RF pulse would be 
removed in the image subtraction. The Bloch equation of longitudinal tissue magnetisation 
(M) was modified to include a blood flow (P) term:  
      
  
 
       
  
  (
    
 
      ) Equation 2.15 
Where λ is the blood-tissue partition coefficient, which determines the freedom of 
exchange between the tissue and blood supply, which for most applications of arterial spin 
labelling is between 0.8 – 1 g ml-1 (9-11). Ma is the time-dependent magnetisation of 
arterial blood. This model assumes a fast exchange of labelled blood in to the tissue, a 
single compartment and a steady state such that the outflowing magnetisation is equal to 
M(t)/ λ. The solution to this modified Bloch equation, and thus the quantification of 
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perfusion is explored below. First, the two methods of blood labelling: continuous and 
pulsed ASL are explained.  
2.4.2 Continuous ASL and Flow-driven Inversion 
The technique of vessel-selective tagging introduced by Williams et al. used the flowing 
blood to promote the mechanism of adiabatic inversion. The method, known as adiabatic 
fast passage (12), applies a gradient in the direction of the blood flow (for example in the z-
direction) at the same time as an off resonance RF pulse, resulting in a position dependent 
frequency offset. Given a time-dependent position for the moving spins, this results in the 
effective magnetic field (Beff) in the rotating reference frame to have a time-dependence on 
the z-position. The polarity of Beff will then invert as the moving spins pass through the 
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  Equation 2.16 
At low velocities, the T2 relaxation of the blood will dominate, and at high velocities the 
change in Beff is too rapid for the spins to follow. Thus, spins moving at the optimal 
velocities to be inverted before they exchange with the tissue under investigation. By 
placing a tag location outside of the brain for the control experiment, no blood would be 
labelled. In addition, the control tag was positioned such that effects of magnetisation 
transfer saturation, from the off-resonance pulse, would be matched in order to not 
overestimate the perfusion.  
2.4.3 Pseudo-Continuous ASL 
2.4.3.1 Tagging Mechanism 
The hardware demands of long CASL pulse and gradient durations were circumvented by 
instead using a train of many short rectangular pulses (13), to create a ‘pseudo’ continuous 
labelling pulse. In addition, the short pulses dramatically reduce the effects of 
magnetisation transfer saturation. However, the Fourier transform of the rectangular pulse 
train creates a number of aliased tagging planes. This aliasing effect can be reduced by 
selecting an RF shape which has a smaller coefficient following the Fourier transformation, 
such as a Hanning pulse.  
The tag selectivity can be further improved by making the tag gradient time-dependent. An 
increased gradient (Gmax) is applied for the duration of the Hanning pulse, and the gradient 
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is reversed (Figure 2.10). Defining the average gradient (Gave) over the RF spacing, aliased 
labelling planes can be avoided in the following condition: 
     
    
 
    
   
  Equation 2.17 
Where ΔtRF is the spacing between the pCASL tagging pulses with duration δRF.  Thus, by 
maximising the ratio of Gmax/Gave, the spatial selectivity of the tagging pulse can be 
optimised. However, for this condition to produce an effective tag, Gave should be of the 
same order as a CASL tagging gradient. The control experiments are performed in two 
manners; i) balanced, where the tag gradient waveform is repeated, and ii) unbalanced, 
where by alternating the gradient polarity, Gave = 0. The control tag is applied in the same 
location, unlike the extra-corporeal location used in the original CASL experiment. In both 
control schemes, the phase between successive tagging pulses is shifted 180° (14), thus the 
Beff is maintained parallel to the main field and the spins do not invert.  
 
Figure 2.10: Pseudo-continuous arterial spin labelling (pCASL) sequence diagram. The tag is formed 
from many closely spaced Hanning-shaped RF pulses; these are applied at the same time as the tag 
gradient with amplitude Gmax, applied in the blood vessel direction. In this balanced sequence, the 
tag gradient is rewound to maximise the ratio of the maximum gradient to the average gradient 
between pulses. This pulse block repeats for the tag duration, followed by a post labelling delay to 
allow the tagged spins to perfuse the organ. An image readout, for example EPI, follows this delay; 
the post labelling delay can be varied to assess perfusion dynamics.  
2.4.3.2 Multi-phase pCASL Tag Optimisation 
Though the pCASL method offers ease of implementation over CASL and an increased SNR 
over PASL techniques, the method is reliant on the phase evolution of the successive RF 
pulses following that of the moving spins. The tagging will experience a reduced efficiency 
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due to a number of factors including B0 inhomogeneity and gradient and B1 imperfections, 
leading to a potential underestimation of perfusion. 
Jung et al. proposed a system to optimise the control and labelling in situ, which varies the 
phase offset between successive RF pulses (15). It was proposed that the generalised phase 
of the moving spins will be generated from the sum of two phases; the track and offset 
phases. The track phase is contributed by the tagging gradient Gave, the pulse spacing Δt and 
the distance between the tag plane and the iso-centre z0: this phase will increment for each 
pulse. An additional offset phase describes the tag and control RF trains; tagging is achieved 
by having a zero phase offset between successive pulses, therefore m = 0. A control pulse 
train will have a 180° phase shift between successive pulses, thus m = 1. However, as a 
result of field inhomogenities and hardware imperfections, the phase increment may be 
affected by a ‘phase tracking error’ ε, between successive pulses. The effect of the phase 
tracking error can be observed in Figure 2.11. The idealised case with no alias phases is 
represented with a circle; the tag pulse has a phase offset of 0°, the spins follow Beff and an 
optimal inversion is achieved (Figure 2.11A). The control experiment has a phase offset of 
180°, and the magnetisation remains at equilibrium. The case with a -45° tracking error is 
presented with a cross, the adiabatic condition is not fully met and the magnetisation is not 
maximally inverted – in this model the tracking error on the control tag does not 
significantly alter the magnetisation. The phase tracking error thus results in a reduced 
tagging efficiency (Figure 2.11B), calculated from the difference between the tag and 
control magnetisation normalised by the equilibrium magnetisation.  
In order to negate the inefficiency of the intrinsic phase error, Jung et al. proposed to 
increment the tag/control offset phase across a 2π range: 
                 
 
 
                 Equation 2.18 
For example m is stepped 45° from 0° to 315°. Jung et al. proposed a method of perfusion 
quantification which models the shape of the tagging efficiency, an additional advantage 
being that different supply vessels may have variant levels of phase errors. The multi-phase 
technique can also be used to calibrate single vessel labelling in a more traditional tag-
control pair experiment; the tag and control phases will be selected from the maximal 




Figure 2.11: Phase tracking errors induced by system faults and field inhomogeneities will result in 
unwanted phase evolution between successive tagging pulses and thus the magnetisation will not be 
optimally inverted (a), equivalently this will reduce the tag efficiency (b). An ideal case with zero 
phase errors is marked with a circle, and a phase error of -45° has been marked with a cross [images 
taken from Jung et al.(15)].  
  
2.4.4 FAIR ASL 
Kwong, Kim, Schwarzbauer et al. proposed flow-sensitive alternating inversion recovery 
(FAIR) pulsed ASL around the same time (16-18). Rather than using a long continuous 
labelling module, FAIR employs two adiabatic inversion pulses to perfusion-sensitise 
images. The pulsed technique reduced the effects of magnetisation transfer and avoided 
complex labelling for organs such as the heart. The tag condition is created by a ‘global’ 
inversion pulse over the tissue, thus the blood arriving within the imaging slice is recovering 
longitudinally. The control condition is created by a narrow, ‘slice-selective’ inversion 
around the imaging slice; unlabelled blood then immediately flows into the slice, and as this 
magnetisation exchanges with the tissue, causes an apparent acceleration in the 
longitudinal tissue magnetisation (Figure 2.12).  Pulsed ASL sequences typically employ 





Figure 2.12: Schematic of the Flow-induced Alternating Inversion Recovery (FAIR) sequence: A global 
inversion of all the spins (a) provides a T1 measurement (blue curve, c) and a selective inversion 
around the read-out slice (b) will yield an accelerated T1 recovery (red curve, c) as un-inverted 
arterial magnetisation exchange with the tissue within the read-out slice. Perfusion can be estimated 
from the difference between the two T1 experiments.  
 
2.4.5 Perfusion Quantification 
2.4.5.1 General Model 
A general model of perfusion was constructed by Buxton, et al. (20) which considers the 
magnetisation within a voxel after arterial blood tagging and incorporates transit delays 
from the tag plane to the imaging slice. Three functions are defined to explain the signal 
evolution of the magnetisation difference between tag and control ΔM(t): the delivery 
function c(t), the residue function r(t,t’), the relaxation function m(t). The delivery function 
describes the normalised concentration of arterial magnetisation arriving in the voxel. The 
residue function describes the fraction of tagged water molecules which arrived at time t’ 
but within the voxel at time t. The magnetisation relaxation function describes the fraction 
of the original longitudinal tag carried by the water molecules that arrived at time t’ and 
remains at time t. 
The signal difference is constructed as a sum over of the delivery of tagged magnetisation 
to the tissue weighted by the fraction of the remaining magnetisation in the voxel. The 
amount delivered to a voxel between t’ and dt’ is 2αM0Pc(t’), where α represents the 
inversion efficiency, and P is the blood flow. The fraction of the delivered magnetisation 
which remains at time t is then r(t-t’)m(t-t’):  
 
          ∫    
                   
 
 
 Equation 2.19 
This model is based on three assumptions of ‘plug flow’, single-compartment kinetics and 
complete extraction from the arterial blood and tissue. The plug flow assumption 
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essentially models that no labelled blood arrives until the arterial transit time δ, followed 
by uniform labelling for the tag duration τ, followed by no labelling: this describes the 
delivery function. The arterial transit time, or transit delay, is due to the gap between the 
labelling plane and imaging plane – for pulsed ASL techniques, this is generally shorter due 
to the narrow slice-selective profile around the imaging slice. The single-compartment 
kinetic assumption describes that potential sub-compartments within the tissue maintain 
the same concentration ratios due to a rapid exchange of water. In addition, a steady state 
is assumed that the ratio of the total tissue magnetisation to the venous magnetisation is 
equal to the blood/tissue partition coefficient: this assumption describes the residue 
function. The complete extraction assumption means that the labelled water is completely 
extracted from the vasculature as soon as it arrives within the tissue voxel. The 
magnetisation first relaxes at the rate of the arterial blood T1a, and once it exchanges with 
the tissue, continues to relax at the tissue rate T1: this assumption hence describes the 
relaxation function. These assumptions can be described mathematically: 
              
Equation 2.20 
                   (continuous)         
                          (pulsed)         
              
              
 
      
 
 
    
 
These equations can then be solved for both the pulsed and continuous labelling schemes. 
The equations are separated in to piecewise functions, separated by the arterial transit 
delay and tag duration.  
2.4.5.2 Pulsed ASL Solution 
The signal difference following pulsed labelling is as follows: 
              
Equation 2.21 
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With the following substitutions: 
 
       
              
      





       
                  
  





















The signal difference is thus directly proportional to the level of perfusion, as well as a 
number of other factors. The substitution qp(t) allows for a number of factors to be 
collected in to a single, dimensionless term, which typically has a value close to 1. For FAIR 
the tag duration τ, is given by the volume coverage of the RF coil. 
2.4.5.3 Continuous ASL Solution 
Solving for the continuous labelling case: 
              
Equation 2.22 
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With the substitution: 
           
                    
 






       
Similarly to PASL , the qc(t) term simplifies the equations and collect the terms which relate 
to the steady state of the continuous labelling; if t or τ are much longer than T1’, then qc 
approaches 1. In this condition the theoretical advantage of CASL to PASL is derived; the 
CASL signal reaches a peak steady-state dependent on the flow, apparent relaxation and 
arterial transit time which is approximately a factor of e larger than PASL.  
2.4.5.4 Belle Model 
Belle et al. (21) suggested a two-compartment model in order to quantitatively study 
myocardial perfusion measured using FAIR. The two compartments under consideration 
were the intravascular capillary blood and the extra-vascular tissue; the arterial and venous 
magnetisation signals are neglected due to their small contribution in the heart. Each 
compartment has a characteristic longitudinal relaxation time, i.e. labelled blood relaxes 
with the longitudinal relaxation time of arterial blood, until it reaches and exchanges with 
the tissue. This implies a fast exchange condition that labelled spins are instantaneously 
pass from the intravascular volume to the tissue (22). This model, though not designed for 
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liver parenchyma, was chosen as a simple perfusion model to initially estimate liver 
perfusion with; the quantification of liver perfusion will be later explored Chapter 3.5.  
Quantification of FAIR using the Belle model characterises the apparent acceleration of the 
longitudinal decay as un-inverted spins flow in to the imaging slice. The apparent T1 decay 
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  Equation 2.24 
T1.cap is the intravascular capillary blood longitudinal relaxation time which can be measured 






















Equation 2.25 demonstrates that the perfusion may be estimated from the ratio of the 
slice-selective to the global T1 values, thus this technique benefits from an optimised T1 
mapping sequence.  
2.5 Phase Contrast 
Phase contrast MRI (PC-MRI) uses a gradient-echo sequence with velocity-encoding 
gradients, applied in the direction of the flow, to proportion phase data to the rate of flow. 
Velocity encoding gradients take a bipolar form (Figure 2.13): stationary spins will accrue 
and lose phase so that at the end of the gradient module they will have a zero net phase, 
whereas moving spins will experience a changing gradient strength, and thus accumulate a 
non-zero net phase at the end of the velocity-encoding module. The sequence is repeated 
with the polarity of the bipolar gradients reversed in order to estimate the velocities from 




Figure 2.13: Pulse sequence diagram for a cardiac gated phase contrast sequence with flow encoding 
only in the slice-selective direction. This sequence was based from a cardiac cine sequence, in order 
to map flow variations in the cardiac cycle. The sequence continues to pulse during respiration, but 
does not acquire in order to maintain a steady state. The inclusion of bipolar gradients with 
amplitude G and duration τ will impart a phase to moving spins, and no phase to stationary spins. 
 
The phase difference between two complex datasets Z1 and Z2 can be calculated using 
Equation 2.26, where the ‘*’ represents the complex conjugate (2):  
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)  Equation 2.26 
Application of a gradient will give rise to a series of gradient moments mn. The bipolar 
nature of the gradients will remove the m0 component for static spins, and the relatively 
small contributions of higher moments (i.e. accelerating spins) are ignored. A phase φ will 
be imparted due to the gradient moment m1 on spins moving with velocity v, where γ 
represents the gyromagnetic ratio:  
          Equation 2.27 
With a consecutive, rectangular, bipolar gradient with strength G, and lobe duration τ, this 
yields a gradient moment m1 given by Equation 2.28: 
      
   Equation 2.28 
Due to periodic nature of phase, the maximal encodable velocity (venc) will be limited by a 
final phase difference of π:  
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  Equation 2.29 




     
  Equation 2.30 
The voxel-wise velocity measurements (cm s-1) can be subsequently used to estimate bulk 
flow to the tissue, by summing up the velocities over the  cross-sectional area (cm2) of the 
blood vessel, and normalising this to the total mass of the tissue (mtissue). The factor of 60 is 
included to convert the bulk flow estimate to physiologically relevant units of ml g-1 min-1: 
 
      
  
       
∫     Equation 2.31 
Generally, in pre-clinical measurements perfusion units of ml g-1 min-1 are used for mice 
(typical weight around 30g). For larger animals and humans, a scaled perfusion measure of 
ml 100 g-1 min-1 is more typical. 
2.6 B0 Mapping 
Field mapping is performed using a GE acquisition over multiple echoes. The phase of the 
spins will evolve in the presence of the external magnetic field, and thus the differences in 
B0 can be estimated from the evolution of the phase signal over different echo times (TE) 
(23):  
    γ      Equation 2.32 
The B0 field can be estimated from a single echo, though the accuracy of the map is 
improved with including a number echoes. In the ideal case the longest TE will not have 
exceeded a phase of π, however unwrapping algorithms can be applied to overcome this. A 
requirement of the TE spacing is that the water-fat phase is kept constant; this increment 
can be determined using the Larmor equation (3):  
 
     
 
   
  Equation 2.33 
Where σ is the chemical shift, which for water-fat is approximately 3.5 ppm. For 9.4T, using 
a gyromagnetic ratio of 42.56 MHz T-1, the echo spacing ΔTE is equal to 0.71ms.  
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2.7 Pre-Clinical MRI Equipment 
2.7.1 Mouse set-up 
All in vivo experiments were performed in accordance with the UK Home Office Animals 
Scientific Procedures Act, 1986. Mice scans were performed in a 9.4T Agilent VNMRS 20 cm 
horizontal-bore system (Figure 2.14A) with 1000 mT/m gradient inserts with an inner 
diameter of 60 mm (Agilent Technologies, Santa Clara, US). Chapters 3 & 4 used a 39 mm 
transmit/receive birdcage coil (Rapid Biomedical, Rimpar, Germany) (Figure 2.14B), and 
Chapter 5 used a 35 mm transmit/receive birdcage coil (Rapid Biomedical, Rimpar, 
Germany).  
Both mice and rats were anaesthetised using 4% isoflurane (Abbot Laboratories, Illinois, 
USA) in 1 L O2/min, and generally maintained between 1-2 % isoflurane in 1 L O2/min within 
the MRI scanner, so that the breathing rates would be between 40 – 80 breaths per minute. 
Mice temperatures were monitored and maintained using heated water pipes and a 
temperature probe, and respiratory bellows were placed below the sternum for 
physiological monitoring (SA Instruments Inc., Stony Brook, NY) (Figure 2.14C). An example 
respiratory trace can be seen in Figure 2.14D, the white and red blocks (arrow) indicate 
where the gate has been set to. The starting point and the width of the respiratory gate can 
be adjusted by the user. For example, the trigger point can be set at inspiration or 
exhalation, and the gate can be further delayed after these triggers. However, the success 
of these blocks is dependent on the strength and consistency of the breathing. The majority 
of the experiments were performed without ECG probes, except for cardiac gating phase-
contrast MRI measurements which used a three-lead ECG system (SA Instruments Inc., 
Stony Brook, NY). 
The physiology recordings can be sent to a Power1401 data-logger and recorded in Spike2 
v5 software (Cambridge Electronic Design, Cambridge, UK) (Figure 2.14E). In addition, a 
marker can be programmed in to the pulse sequence, typically placed to signal a RF 
emission. Thus, these markers can be compared against the physiology within the Spike2 
software to check the timing of the data acquisition with the status of the respiration. 
These recordings are later used for retrospective analysis in Chapter 3.4. A gating simulator 
(SA instruments, NY, USA) (Figure 2.14F), which can generate cardiac traces, including 
respiration induced spikes to the waveform, was used to test triggering in phantom 





Figure 2.14: Photographs of the equipment used for the majority of the mice experiments. (A) The 
9.4T MRI scanner, with the 60 mm gradient inserts. The mouse bed, including the monitoring 
system, anaesthetic and water pipes are fed in to this side of the scanner. (B) The 39 mm 
transmit/receive birdcage coil used for imaging; the coil is fed in to the rear of the magnet. (C) 
Mouse cradle: (1) heated water pipes, (2) nose cone for anaesthesia administration, (3) respiratory 
bellows (4) rectal temperature probe. (D) Screenshot of the animal monitoring software, reporting 
on the animal temperature and respiratory rate. The digital gating has been marked by an arrow, 
corresponding to the red and white block in the software, the position and duration of which is 
determined by the user. (E) Digital data-logger with inputs set up for recording RF pulse markers, 
ECG pulses, and digital respiratory gating (as seen in D). (F) Respiration and cardiac simulator box 
with adjustable amplitude and rate. 
 
2.7.2 Rat set-up 
Scans were performed on the 9.4T magnet, with 400 mT/m gradient inserts and an inner 
diameter of 120 mm (Agilent Technologies, Santa Clara, US), using a 72 mm 
transmit/receive birdcage coil (Rapid Biomedical, Rimpar, Germany). The rat bed is a larger 
analogue to the mouse set-up, with heated water pipes keeping the animal warm and the 
respiratory bellows and temperature probe used for monitoring the animal’s physiology. In 
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Feasibility of Pre-Clinical Liver 
Perfusion Measures using Arterial Spin 
Labelling 
This chapter shows the progression and optimisation of hepatic perfusion estimates 
obtained using a Flow-sensitive Alternating Inversion Recovery (FAIR) ASL with a Look-
Locker read-out. The sequence was initially applied to a mouse liver, and then optimised in 
a T1-matched agarose phantom. Prospective and retrospective-gating techniques to remove 
image artefacts from respiration were implemented and compared. Once an imaging 
acquisition and analysis pipeline was established, the repeatability and reproducibility of 
this technique was tested in a cohort of mice. The Look-Locker read-out was further 
adapted to improve the acquisition efficiency, with additional testing in phantoms and in-
vivo for possible sources of systematic errors. 
The FAIR Look-Locker sequence was initially developed by Dr Adrienne E. Campbell-
Washburn; its application has been previously published in the mouse heart. The 
prospective gating sequence was developed alongside Dr Simon Walker-Samuel. The 
retrospective data-logger based rejection was initially implemented by Dr A. E. Campbell-
Washburn, though my own variant of the algorithm was applied to the data. 
The work in this chapter has been published in NMR in Biomedicine; R. Ramasawmy, A. E. 
Campbell-Washburn, J.A. Wells, S.P. Johnson, R. B. Pedley, M. F Lythgoe and S. Walker-




3.1 Initial Application to a Mouse Liver 
An evaluation of liver perfusion measured by a FAIR ASL technique with a Look-Locker 
readout (FAIR-LL) was carried out in a wild-type mouse. This sequence was chosen as it had 
been previously established and tested in the mouse myocardium, thus would be an ideal 
platform to explore imaging and gating strategies in the liver. The mouse was anaesthetised 
and maintained using 1.5% isoflurane in 1L/min O2. An initial pilot test applied a cardiac-
gated cine sequence, typically used to capture the heart’s movement through the cardiac 
cycle, to image any resultant liver motion due to the heart’s adjacent location (data not 
shown). From these data, it was apparent that the superior liver was affected by cardiac 
motion, however the majority of the liver remained relatively static, so it was decided for 
initial testing a respiratory triggering would be sufficient.  
3.1.1 Pulse Sequence 
The scan parameters were as follows: an axial, single 2 mm slice, 128 x 128 matrix, FOV 30 x 
30 mm2, with 50 Look-Locker readouts spaced at TILook-Locker 110 ms, and  a sampling flip 
angle α of 10°. Inversions were interleaved between a slice selective inversion pulse (6 mm 
thick) and a global inversion (1), total acquisition time was around 15 minutes. Each 
inversion pulse was triggered post exhalation, followed by 50 segmented readout blocks 




Figure 3.15: Pulse sequence diagram of the T1-mapping acquisition using a Look-Locker technique. 
An adiabatic inversion is triggered post-exhalation followed by 50 sampling blocks, each separated 
by TILook-Locker. Each sampling block contains four closely-spaced sampling pulses given by TRRF, which 
acquires four lines of k-space of each TI per inversion, which reduces the sequence duration. For a 
128 phase-encode lines, 32 inversions are needed to acquire the image. 
  
3.1.2 Perfusion Quantification 
Total liver perfusion (P) maps were initially quantified using the Belle model (Section 
2.4.6.4), which has been developed and previously demonstrated for measurements in the 
mouse myocardium (2). Liver perfusion estimates using the FAIR method will include both 
arterial and portal contributions, given by the difference in slice-selective (T1, selective) and 
global (T1, global) longitudinal relaxation measurements.  
Prior to pixel-wise T1-fitting, an edge-preserving filter (3) was applied to all data. Slice-
selective and global T1 maps were generated in MATLAB (MathWorks, Natick, MA, USA) 
using a non-linear least-squares parameter fit. The effects of the Look-Locker readout on 
the inversion recovery was corrected for by using the formula stated in Chapter 2.2.2. A 
blood-tissue partition coefficient λ = 0.95 mlg-1 was taken from previously reported 
85Krypton gas clearance measurements (4). T1,cap is the intravascular capillary blood 
longitudinal relaxation time which has been measured in the ventricular blood pool in the 
mouse heart to have a value of 1.9 s at 9.4T (1).  
3.1.3 Initial Evaluation: Results 
As the first measure of liver perfusion in a mouse using arterial spin labelling (to our 
knowledge), this pilot experiment proved to be very encouraging. Figure 3.16A is an axial 
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fast-spin echo (FSE) image that acts as a structural reference: the liver has been indicated 
with the dashed ROI. Blood vessels, such as the inferior vena cava (IVC), appear hypo-
intense.  A homogeneous global T1 map (mean T1 = 1.46 s) can be seen across the liver 
parenchyma (Figure 3.16B); blood vessels are demarcated to their longer T1. Figure 3.2C 
shows the resultant perfusion map across the liver. An area of perfusion signal loss is 
observable (star) which may be due to motion corruption-induced T1 fitting errors. A high 
“perfusion” signal can be observed at the loci of the major vasculature, such as the IVC 
(arrow), though this does not represent classical perfusion (i.e. the delivery of blood to the 
capillary bed). A heterogeneous perfusion signal can be seen across the liver parenchyma, 
with the mean perfusion of the liver tissue (removing the blood vessels) estimated to be 0.8 
mlg-1min-1. This is much lower than expected (5), and likely to be due to the large region of 
perfusion signal dropout. However, visual assessment of the large vessel-liver parenchyma 
contrast provided some encouragement that accurate mapping of mouse liver may be 
feasible with further methodological optimisation. Looking at the raw ASL data, it was 
possible to observe many images with motion-induced ghosting artefacts (Figure 3.16D). 
 
Figure 3.16: Initial mouse liver perfusion measurement using a Look-Locker FAIR protocol: (A) fast 
spin echo reference image, the liver has been outlined (dashed ROI). (B) Estimated global T1 map 
(mean T1 = 1.46 s) from the FAIR experiment. (C) Perfusion map – high, non-physiological perfusion 
can be seen at the location of the major vasculature, such as the inferior vena cava (arrow). The 
perfusion map shows area of low signal (star) – which could be a result of no strategy being applied 
to account for mouse respiration. (D) Example TI which has been corrupted by respiratory motion, as 
observed by ghosting artefacts (arrow). 
From these initial measurements, it was decided to include a gated, high-resolution fast-
spin echo sequence to the imaging protocol, in order to delineate tissue and vessel 
structures to aid understanding of the perfusion maps.  
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In addition several key iterative improvements to the pulse sequence were applied to 
optimise the T1 mapping for liver perfusion estimates, including methods to remove the 
influence of respiratory motion from free-breathing acquisition strategies.  
3.2 Sequence Optimisation 
3.2.1 Phantom Experiments 
A 1.5% agarose phantom doped with copper sulphate was created to approximately match 
the T1 measured in a few mice livers (approximately 1200 ms). This phantom would be used 
to develop and optimise pulse sequences to minimise animal usage.  
When reconstructing the Look-Locker phantom images, an artefact became apparent; a 
hypo-intense vertical line could be seen in the second TI, which then was visible for the next 
few images (Figure 3.17). Investigating the corresponding k-space images, a zipper-like 
artefact could be seen to one side of the central few lines (phase-encoding was in the left-
right orientation). In addition, simulating the Fourier transform of a solid line at the location 
of the artefact in MATLAB showed that such a localised signal increase would correspond to 
the observed vertical line. Closely inspecting the in-vivo images showed that this artefact 
was also present, though not as apparent possibly due to physiological noise. This artefact 
is sub-optimal, as this will lead to localised errors in the T1 measurement.  
 
Figure 3.17: Observation of a line artefact (arrow) present from in the second image in both the 
global and slice-selective inversions. The line can be seen as a result of a zipper-like artefact present 
in the central lines of k-space (arrow). This artefact was present in the in-vivo images, but was 
obscured by physiological noise. 
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3.2.2 Spoiler Optimisation 
It was hypothesized that this artefact was caused by stimulated echoes (6) as a result of the 
fast sampling, that were more apparent during  low amplitude phase-encoding gradients as 
these would not effectively crush out the signal. These stimulated echoes were likely to be 
more apparent in the water-based phantom due to its T2 of 94 ms being much longer than 
the mouse liver T2 of 18 ms (data not shown).  
To investigate this, an experiment was carried out incrementing the sampling flip angle (α) 
from 3 – 10°, which is the upper limit of the small angle approximation in the Look-Locker 
sampling technique (7). In addition sampling angles of 20° and 30° were used to emphasise 
any echo stimulation.  
Selecting only the second TI, where the artefact is most prominent, flip angles less than 5° 
showed no evidence of the line artefact (Figure 3.18A). The line becomes more apparent at 
higher flip angles, and at the extreme higher sampling angles the artefact becomes hyper-
intense and wider, most likely due to stimulated echoes producing measurable signal at 





Figure 3.18: Investigating the line-artefact by increasing the sampling flip angle (A). Each image is the 
second TI from the slice-selective datasets. The artefact is not apparent at low flip angles (<5°) and 
becomes more pronounced at larger flip angles (arrow). Increased application of spoiler gradients (B) 
shows a successful removal of the artefact at a spoiler gradient strength of 20 G cm
-1
. The source of 
the artefact can be understood from the Fourier image where a zipper-like artefact can be seen in 
the right hand side of k-space (arrow). 
In order to null these echoes, spoiler gradients were added after each segmented read-out. 
A 1 ms duration spoiler, with increasing strengths of 0, 10, 20 and 30 G cm-1 were applied 
(Figure 3.18B) with the sampling angle set to the maximal 10°. It is apparent from these 
data that a spoiler of 20 G cm-1 is sufficient to remove the line artefact. Assessing the T1 of 
the phantoms in a ROI not including the line artefact, there was no significant difference (p 
> 0.05, one-way ANOVA) between the spoiler strengths, and thus a spoiler of 20 G cm-1 was 
used in the following experiments.  
3.2.3 Flip Angle Optimisation 
The sampling angle of the Look-Locker readout will determine the SNR of the ASL data. 
Previous literature has stated the limitation of using a Look-Locker sampling technique is 
that the quantification is reliant on a small sampling angles (<10°) to not overly perturb the 
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inversion recovery (7). Incrementally increasing the flip angle in an agar phantom from 3 – 








 Equation 3.34 
Where S  is the mean magnitude within the sample and N  is the mean magnitude of a 
noise region. This equation accounts for low-signal Rician distribution of the noise (8). The 
SNR estimation was taken from the last TI of each data set.  
It is possible to observe the benefit of using a higher flip angle in Figure 3.19A; the mean 
estimated global T1 measurements do not display any dependence on flip angle, but the 
standard deviation of the T1 values within an ROI reduces at increased sampling angles. 
However, as the background noise increases as well as a function of flip angle, the SNR 
estimates decreases with flip angle (Figure 3.19B).  
 
Figure 3.19: Increasing the sampling flip angle does not affect the measured T1 in an agar phantom 
(A), but the standard deviation within a ROI decreases, as shown by the error bars. However, the 
signal-to-noise decreases slightly with increased flip angle (B). Testing the flip angle dependency in-
vivo (C), the standard deviation of the T1 estimate of a homogenous tissue region again decreases at 
higher flip angles. 
The experiment was repeated in-vivo, increasing the sampling flip angle from 5 – 10°. A ROI 
was drawn in a uniform region of liver parenchyma; Figure 3.19C shows the sampling flip-
angle dependency of mean T1 and standard deviation within that ROI. There are no 
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significant differences between the measurements (p > 0.05, one-way ANOVA). From this 
data, a sampling flip angle of 8° was chosen, as a compromise of SNR and standard 
deviation of the estimated T1 which will determine the uncertainty of the perfusion as 
estimated by the Belle model.  
3.2.4 Inversion Ratio Optimisation 
The width of the slice selective inversion is an important experimental parameter in pulsed 
ASL studies. Too narrow a width can lead to non-perfusion related signal differences 
between the images acquired following slice selective and global inversions due to slice 
profile effects (6). Too broad a width can lead to long arterial transit times which may 
violate assumptions of the perfusion quantification model. In this section I performed 
experiments to optimise the width of the slice selective inversion pulse within the FAIR-LL 
sequence applied to the mouse liver. The global inversion pulse was chosen to be 15-20 cm, 
larger than the typical length of a mouse. 
The slice-selective inversion thickness was optimised in-vivo by increasing the inversion 
thickness around a 1 mm slice from 3 – 10 mm in vivo. The mean signal was measured from 
a ROI drawn in the portal vein to monitor the inflow of blood in to the slice. The assumption 
of the FAIR quantification is that the spins originally outside the slice-selective inversion 
immediately replenish the blood magnetisation and exchange with the tissue. Thus, the 
mean signal within a perfusing blood vessel following inversion would be time-independent 
as the inflowing spins are all at equilibrium magnetisation.  
However, signal relaxation back to equilibrium was observed across all inversion 
thicknesses (Figure 3.20A). Regular ‘dips’ within the mean signal are due to respiration-
induced signal loss. Assessing the early phase recovery (zoomed box), the larger inversion 
thicknesses (see key) have lower signal: the blood has not completely washed in due to the 
slow portal flow. This may produce an underestimation of the liver perfusion; this will be 
further discussed in section 3.7.1. Similar signal recovery was observed between 
thicknesses of 3 to 6 mm.  
Quantifying the T1 and ROI standard deviation of a uniform area of liver parenchyma (Figure 
3.20B), there appears to be a slight trend up to 6 mm after which, it appears to plateau. 
From combining these results, a 6 mm slice-selective inversion thickness was chosen for 




Figure 3.20: (A) Analysing the mean magnitude of a ROI within the portal vein following an increasing 
slice-selective inversion thickness from 3 to 10 mm (see key). Time in this plot is measured at the 
inversion times of the Look-Locker sequence (separated by 74 ms). The signal should stay constantly 
at the equilibrium magnetisation, however there is a slight recovery observable - the slow moving 
portal blood is not replenishing the blood in the slice immediately. The dips within the signal (arrow) 
represent where respiration has occurred and the ROI signal has been obscured by motion artefacts. 
Zooming in to the early phase of this measurement, there is a trend at larger thicknesses to have a 
reduced initial magnitude as the blood has further to travel in to the slice at the thicker inversions. 
(B) The mean T1 and standard deviation of a uniform liver parenchyma ROI as a dependency on the 
slice-selective inversion. 
These results formed an optimised protocol of the FAIR ASL technique for mice livers, as 
well as refinement of the Look-Locker readout for efficient T1 mapping. The next section 
investigates gating strategies to remove the influence of respiratory motion artefacts in a 




3.3 Prospective respiratory gating 
3.3.1 Respiratory-gated Look-Locker sampling 
To characterise the T1 recovery, a sampling period of approximately 6 seconds is used; this 
will contain a number of inhalations when imaging anaesthetised rodents (typical breathing 
rates are from 40 – 90 breaths per minute). The current quantification uses a ‘brute-force’ 
method; utilising the high number of sampling points along the recovery curve and 
assuming that this will allow a reasonably estimate of T1. However, as the Belle model of 
perfusion quantification is reliant on T1 differences, this approach may produce large errors 
in the perfusion estimates. In addition, alternative models of perfusion which rely on image 
subtraction, the influence of motion artefacts will greatly distort the model fitting.  
A prospective gating strategy was proposed that would pause the Look-Locker sampling 
during inhalation Figure 3.21. This ‘pausing’ was chosen rather than a technique which 
would pulse continuously and acquire when appropriate, as natural variety in the breathing 
rate will lead to a number of images having an incomplete k-space due to the segmentation 
of the acquisition. The TIs with incomplete Fourier data could then be omitted 
retrospectively, but this does not present a distinct alternative to using the normal Look-
Locker acquisition with retrospective gating. The advantage of prospective gating is that the 
all the images acquired can be used, which may improve the T1 estimate.  
The sequence was designed to ’check’ the gating status, as set up on the physiological 
monitoring software (SA Instruments, NY, USA) and pause the sampling until the next 
quiescent respiratory phase, to ensure no image was corrupted by breathing motion.  
 
 
Figure 3.21: Pulse sequence schematic of the prospective respiratory-gated, Look-Locker acquisition. 
The black blocks represent the segmented sampling modules (see Figure 3.15), which are paused in 
this sequence as a result of the digital respiratory gate (white blocks) set up on the physiological 
monitoring.   
However, ‘pausing’ the sequence will cause some complications for analysis: as stated in 
Chapter 2.2.2, Look-Locker quantification of T1 is dependent on a regular spacing of the 
79 
 
small sampling pulses due to the steady magnetisation during the inversion recovery. 
However, the proposed ‘pausing’ would violate this clause. In addition, the second problem 
is the segmented structure of the sequence; if the animal is breathing irregularly, then 
neighbouring k-space lines of one image can potentially have a mixture of TIs; this will 
result in image reconstruction artefacts as well as T1 quantification difficulties. The ‘real-
world’ effects of these were explored in the next section. 
Normal and gated sequences were carried out, with the sampling pulses and respiratory 
gates recorded using a digital data-logger (Cambridge Electronics, UK). An initial method of 
T1 estimation using an average TI from all the gated timings was tested. Simulations were 
then created to estimate the discrepancies in quantification, and finally the sequence was 
repeated in phantoms using a gating simulator (SA instruments, NY, USA). 
3.3.2 Assessment of Respiratory Gating 
Figure 3.22A is an example image at a TI during a respiration using the standard Look-
Locker readout and the same TI using the prospectively-gated sequence is shown in Figure 
3.22B; it is clear that the gated sequence improves the quality of the raw image. In this 
dataset, no distinct image reconstruction artefacts were present in the prospectively-gated 
acquisition. 
 
Figure 3.22: An image acquired during respiration with the Look-Locker sequence (A), 
and the same TI acquired using the gated technique (B); the gated sequence clearly 
improves the raw data with no obvious image artefacts. 
For the prospective breathing method, the quantification of the T1 recovery required each 
inversion and sampling timings recorded, as the animal’s breathing may be inconsistent 
between the separate inversions.  Such breathing irregularity has been visualised in Figure 
3.23.  
Figure 3.23A shows a normal, un-gated Look-Locker timing; in this sequence, with 4 lines 
acquired in one segment and 50 TIs per inversion, each 180° pulse will be followed by 200 
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sampling pulses. Time is along the x-axis, and the Look-Locker RF pulse number (LL RF 
index) is along the y-axis. A normal-mode Look-Locker sampling acquisition is observable: 
four pulses separated by TRRF are then followed by the TILook-Locker, the TIs are regularly 
spaced.   
An example timing graph of a gated Look-Locker acquisition after a single inversion can be 
seen in Figure 3.23B; the flat regions correspond to where the sequence is paused during 
respiration. Overlaying all the sampling timings from an entire FAIR experiment (i.e. 64 
inversions, Figure 3.23C), it is possible to visually assess how varied the breathing was, by 
the ‘band thickness’. For example, choosing a particular LL RF index, the band thickness is 
the spread of the timings for that TI; the bands become wider with time due to 
physiological drift in the respiratory rate. Two different examples of prospective gating are 
shown: a relatively consistent breathing (Figure 3.23C) over the duration of the Look-Locker 
sequence, and inconsistent breathing (Figure 3.23D) with a clear outlier. We can produce a 
simplified estimation of T1 by averaging the sampling timings for each Look-Locker RF index. 
 
 
Figure 3.23: The Look-Locker acquisition was designed to partially sample 50 Tis per inversion, with 4 
lines of each image acquired in quick succession; this will result in 200 RF pulses post-inversion. 
These graphs demonstrate the differences and difficulties in using a gated acquisition. A normal, un-
gated acquisition (A); the pulses are regularly timed. An example gated acquisition following a single 
inversion (B); flat regions can be seen where the sequence is waiting for the breathing motion to 
stop. A whole experiment with all the recorded sequence timings overlaid, with a relatively 
consistent breathing rate (C) and more erratic breathing (D). 
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The potential benefits of gating can be seen in the T1 maps (Figure 3.24A); the free-
breathing map exhibits areas of where the T1 fitting failed (arrow). A visual assessment 
between the two sequences shows a reasonable correspondence of T1 values. Across both 
slice-selective and global T1 maps, the prospective-gating sequence produced a mean 2.4% 
underestimate of T1 values in a homogenous region of liver tissue. The differences in signal 
recovery from a ROI of liver tissue can be seen in (Figure 3.24B); the free-breathing signal 
(red) has signal deviations as a result of the respirations artefacts, which can result in an 
over-estimation of T1. The gated signal (blue) doesn’t display such reductions in signal, 
though the relaxation of the magnetisation during the sampling pauses causes some step 
increases in the signal. The perfusion map calculated from the free-breathing acquisition 
exhibits high perfusion and signal drop out (arrow, Figure 3.24C), whereas the liver 
parenchymal perfusion was much more even with the prospective gating- showing the 
necessity for strategies to overcome the influence of respiratory motion on the perfusion 
signal.  
This experiment has demonstrated a method of perfusion acquisition which improves on 
the free-breathing technique, demonstrating the importance of removing the influence of 
respiratory motion. However, the quantification of the T1 was carried out using a simplistic 
averaging of the LL RF indices. Though this performed well relative to free-breathing, the 
possible errors in this method were then investigated by using a gated Look-Locker 




Figure 3.24: (A) Demonstration of T1 mapping using a Look-Locker acquisition that has been 
triggered (normal) and the respiration gated (gated) sequence. In the normal slice selective data, 
signal dropout can be seen (arrow) where the inversion recovery was not successfully fitted; this 
problem was not present in the gated data. A band of increased T1 (arrow) can be seen in the 
normal global inversion data, most likely due to a respiratory artefact present in the images; the 
gated sequence produces a much more homogenous T1 map. The gated T1 mapping was 
calculated using the mean inversion times from the segmented acquisition. (B) Assessing the 
normal signal (red) in a small ROI, the inversion recovery is disrupted as a result of the respirations 
artefacts, which can result in an over-estimation of T1. The gated signal (green) doesn’t display 
such large fluctuations, but sampling saturation and recovery is visible. (C) The resultant perfusion 
map from the free-breathing analysis (calculated using the Belle model) shows regions of spurious 
high perfusion, and signal dropout (arrow), whereas the gated acquisition produces a much more 
homogenous perfusion signal within the liver parenchyma. 
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3.3.3 Gated Look-Locker Simulation and Phantom Experiment 
A simulation of the signal with a gated Look-Locker acquisition was carried out to compare 
potential estimation errors in the quantification. An algorithm was established that could 
model the magnetisation saturation caused by the progressive small angle sampling pulses. 
The model assumed a perfect inversion, and would subsequently calculate the deflection of 
the magnetisation after each pulse using a T1 of 1.2s. Inputting the sequence timings 
recorded during the in vivo gated acquisition, the effects of disrupting the Look-Locker train 
could then be visualized.  
The modelling was performed using two sampling flip angles of 5 and 10° (Figure 3.25A). 
The magnitude of the modelled magnetisation has been plotted to reflect the acquired MR 
signal (points), and a three parameter fit shows the simple approach to quantify the signal 
(line). The magnetisation can be seen to recover during the sampling pauses, followed by a 
signal saturation decrease due to the applied pulses, which is much more apparent at the 
larger flip angle. The three-parameter fit works reasonably well with the 5° flip angle, but is 
obviously inadequate to truly model the magnetisation, particularly at the larger flip angle. 
However, the percentage T1 under-estimate was less than 1% for both a 5 and 10° flip angle 
in the simulation.  
The gated sequence was then applied in a phantom using a physiology simulator. The 
advantage of using a phantom study to investigate the quantification effects of averaging 
the TIs is that a ground truth measurement can be made in the agarose without gating.  
The physiological simulation box has modules for both respiration and cardiac traces. In 
order to simulate respiration, the ECG signal amplitude was minimised and the respiratory 
rate was set to approximately 60 breaths per minute. It was observed that the software did 
occasionally miss gates, though is not ideal, will add an element of variation in to the 
acquisition to potentially mimics the in vivo scenario.  
The signal recovery of the gated sequence applied to the phantom using the physiology 
simulator, taken from the mean signal in a uniform ROI, can be seen in Figure 3.25B. The 
signal of the 10° flip angle is expectedly higher, though wasn’t accounted for in the 
simulation. It is possible to observe that the 5° signal (points) and it’s fitted (line) follows 
closer than the 10°, which exhibits large recovery and saturation periods, in accordance 
with the simulation. The fitting averages through these signal ‘oscillations’, which leads to a 
T1 underestimation: the 5° and 10° estimated T1s were respectively reduced to 93% and 





Figure 3.25: (A) Simulations of inversion recovery with a disrupted Look-Locker sampling train. 
Two different sampling flip angles have been used; 5° (blue) and 10° (red); the three-parameter fit 
of the data has been added. The effect of the sampling saturation and recovery during the pauses 
can be visualised in the 10° simulation – however, both flip angles estimated the simulated T1 
well. Prospectively-gated inversion recovery signal and fitting following a global inversion in an 
agar phantom for a 5° (blue) and 10° (red) sampling regimes, using a physiology simulator box. 
3.3.4 Conclusion 
Though the respiratory gated sequence performs well to eradicate motion artefacts from 
the raw data, the analysis is complex and introduces a systematic T1 underestimation. The 
reconstruction of the images and quantification are overly reliant on stable physiology. The 
dataset shown in Figure 3.24 is from a more consistent breathing dataset – however large 
fluctuations in the pulse timings can have adverse effects on the ‘averaged’ TI based 
inversion recovery fitting.  
To shorten the scan time to ideally minimise the amount physiological drift, fewer TIs could 
be captured: the last TI in the normal acquisition is around 6s, and approximately 10s for 
the gated scan. The pausing of the sequence causes the final image to be acquired later 
than the necessary 5 x T1,liver (approx. 6 s) allowed for magnetisation recovery. The phantom 
experiments showed that the gated sequence will produce underestimations of the 
longitudinal relaxation, though these measurements may be worsened by the variations in 
acquisition caused by the occasional missed gates, even from using a physiology simulator. 
Though the in vivo signal recovery did not seem as dramatically affected as the phantom, 
the T1 underestimation and mixed sources of timings per data set mean that such a 
prospective gating strategy will have difficulties to estimate perfusion.  
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As cardiac imaging has successfully applied retrospective methods to analyse data and 
remove motion artefacts, three retrospective methods were then investigated to improve 
perfusion estimates.  
3.4 Retrospective respiratory gating 
3.4.1 Recorded Data-based rejection 
This method has been previously reported in a Look-Locker acquisition in the mouse 
myocardium (1). The acquisition pulse timing and the respiration status are recorded, and 
the images can then be automatically rejected afterwards based on two criteria:  
 Image rejection if at least 50% of k-space has been acquired during a respiration. 
 Image rejection if one of the three central lines of k-space were acquired during 
respiration.  
The threshold of 50% was chosen as a limit to the number of corrupted k-space lines in a TI, 
however the most apparent image artefacts occur when the any of the central three lines 
of k-space have been affected. The digital respiration gate was set using SA Instruments 
software, and this trace and the timing of the RF pulses were acquired in Spike2 (Cambridge 
Electronics, UK). The retrospective data conditioning programs were written in MATLAB. 
3.4.2 Phase Encoded Noise-Based Image Rejection (PENIR) 
The PENIR scheme was initially developed for retrospective gating where respiratory trace 
recordings for FAIR-LL perfusion imaging were not available. PENIR exploits the presence of 
“ghost” artefacts in the phase-encoded direction due to subject motion. PENIR highlights 
corrupted images by observing spikes in a user-determined ROI from the extra-corporeal 
space (Figure 3.26A). From this area the mean signal (Figure 3.26B, blue dotted line) will be 
expected to spike due to respiratory motion-induced ghosting. A threshold is generated 
from the mean noise signal plus one standard deviation in the remaining extra-corporeal 
field and is calculated every ten TIs. When the spikes significantly exceed the data-
generated threshold (red solid line), images acquired at those inversion times will be then 
be attributed to respiratory induced artefacts and rejected from T1-fitting. Typically, 
without the PENIR correction scheme, the signal within a liver parenchyma ROI will be 
reduced due to the motion artefact (solid diamonds, Figure 3.26C), which will result in an 




Figure 3.26: The Phase Encoded Noise-based Image Rejection (PENIR) scheme for retrospectively 
removing motion-corrupted data: Axial image of a mouse liver with an example user-determined ROI 
(dashed) in the phase-direction, extra-corporeal space (A). Significant increases in the mean noise 
signal (B) (point-line) above a signal-generated threshold (solid line) will result in image omission 
(greyed areas). Inversion recovery fitting (C) in a liver region will typically over-estimate T1 without 
correction (dashed line) compared to with rejection (solid line) due to reduced tissue signal from 
corrupted images (solid diamonds). 
3.4.3 Assessment of Retrospective Gating Strategies 
Ten mice underwent a series of perfusion measurements over two imaging sessions 
(Section 3.6) and four retrospective data conditioning modes were compared:  
 No conditioning; 
 Image rejection due to acquisition of any of the central three k-space lines during a 
breath as recorded by a digital data logger (1);  
 Image rejection due to 50% or more of the lines in k-space being acquired during 
respiration as recorded by a digital data logger;  
 Image rejection using the Phase Encoded Noise-based Image Rejection (PENIR) 
algorithm. 
The differences in retrospective gating on T1 mapping can be visualised in Figure 3.27: the 
dataset with no conditioning (mode i) exhibits areas of signal dropout (arrow) which 
corresponds to data that cannot successfully be fitted to the inversion profile due to 
motion artefact-induced signal deviations. The T1 maps following gating using the data-
logger (mode ii & mode iii) and PENIR (mode iv) successfully recover these areas. 
For comparison across all the rejection modes, data from 19 of 20 data sets were evaluated 
as one session was untenable due to a data-logger malfunction. From the implemented 
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Look-Locker protocol, a total of 50 TIs are acquired and it is optimal to maximise the 
inversion recovery sampling points in order to minimise the uncertainty in the T1 estimate. 
Conditioning with mode (ii) (data-logger rejection based on the central three k-space lines 
being corrupted) 34.2 ± 10.3% of the readout images remained post rejection, mode (iii) 
(data-logger rejection based on 50% of the k-space lines being acquired during respiration) 
62.8 ± 4.9% and mode (iv) (PENIR) 54.3 ± 13.4%. Mode (ii) may be rejecting the data too 
harshly and mode (iii) may not be sufficiently rejecting the data; the PENIR scheme 
produced the smallest uncertainty in the T1 fitting.  
Perfusion estimates were calculated for each conditioning mode, using the Belle model as 
above. No rejection, mode (i), gave perfusion estimates that were non-significantly higher 
(p > 0.2, Tukey ANOVA) than the respiratory-corrected estimates (2.8 ± 0.4 mlg-1min-1 
compared to the rejected average 2.3 ± 0.5 mlg-1min-1), which is consistent with the 
Campbell-Washburn’s results (1). Averaged over the animals there was not a significant 
perfusion difference between data conditioning modes (p = 0.21, ANOVA with Tukey test) 
though there were 10 cases out of 18 (55%) where the Tukey analysis returned a significant 
difference (p < 0.05) between mode (i) and mode (ii), 9 cases (50%) between mode (i) and 
mode (iii), 8 cases (44%) between mode (i) and mode (iv). No significant difference in 
perfusion was measured between modes (ii), (iii) and (iv). This is suggestive of an error in 
the perfusion estimate without any conditioning, which is perhaps not surprising given the 
marked signal instability that is introduced by motion as previously demonstrated (e.g. 





Figure 3.27: Comparison of T1 maps following the different retrospective gating strategies: mode(i) 
no correction; mode(ii) data-logger based correction based on the central three lines of k-space; 
mode(iii) data-logger based correction based on the percentage of corrupted lines within an image; 
mode (iv) PENIR corrected. Without any gating, the T1 map suffers from areas of poor fitting (arrow), 
this region is successfully recovered by all three conditioning modes. Representative data from a 
single mouse is shown.  
3.4.4 Conclusion 
Both prospective and retrospective respiratory gating of the Look-Locker readout have 
been explored. Where the prospective gating has the advantage of reduced respiratory 
motion in the raw data, the subsequent quantification of the T1 is complex. Four 
retrospective conditioning modes were explored, and these showed a marked 
improvement on the uncertainty of the T1 fitting.  
The data logger-based and PENIR retrospective respirator gating algorithms can both be 
used to improve the T1 and perfusion quantification when using the Look-Locker sequence: 
the advantage of acquiring many TIs allows images to be discarded whilst maintaining 
adequate sampling of the inversion recovery. Previous analysis of the data logger-based 
rejection favoured the rejection criteria if any of the central three lines of k-space were 
acquired during respiration (data not shown). The PENIR mode gave the smallest 
uncertainty in the T1 measurements, showing the most promise for application to the liver. 
No significant differences were measured between the different retrospective approaches, 
thus the PENIR system does not seem to suffer from any apparent loss of accuracy.  In 
addition the PENIR system does not require additional hardware to record the data, thus it 
is possible to retrospectively apply it to datasets that had not acquired the respiration and 
pulse timings.  
For both image rejection schemes, both require steady animal physiology – variation in 
breathing rates will result in many TIs having been acquired during respiration, which will 
result in a large block of image rejection by all conditioning modes. A slower breathing rate 
will also result in fewer images being thrown away, though it has been suggested that slow 
rates of free-breathing can produce larger fluctuations in breathing (9).  Generally, a larger 
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amount of ghosting can often be seen towards the later TIs (data not shown), as slight 
changes in breathing rates will be most apparent later, and the rejection of this late 
‘equilibrium’ point can affect the T1 quantification.  
In the scenario of inconsistent breathing rates, the automated data-logger based rejection 
can throw away too many images to allow robust quantification, although it is possible to 
vary the 50% threshold. The PENIR system included a check of a minimum number of TIs 
(chosen to be 15 from visual analysis of fitting), where the noise threshold could be 
increased to allow more images to be included. A more iterative version of this thresholding 
may provide a better retrospective-gating strategy in the future. 
A combination of the data-logger and PENIR conditioning modes could be an optimal 
method of image rejection; the PENIR system fails to reject images when the magnetisation 
passes through zero due to the low SNR, and the data logger system could assist this region.  
From these data, PENIR was chosen to retrospectively respiratory gate the FAIR-LL data 
prior to T1 quantification. Finally, to complete the perfusion imaging pipeline, two 
approaches to quantify liver perfusion were assessed.  
3.5 Perfusion Quantification Model 
With the FAIR preparation and gating strategy optimised, the quantification model was 
reassessed to determine the suitability of the Belle model. A large body of perfusion 
quantification uses the general kinetic models to fit the magnetisation post ASL preparation 
(10), however, the quantification for the mouse liver has not been explored: two cases of 
clinical liver perfusion estimates employed a general model (11, 12). Gunther et al. further 
developed the FAIR quantification model to account for the Look-Locker saturation of the 
magnetisation (13): 
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 Equation 3.34 
Where R1 is 1/T1, δR = R1a – R1,app, R1a is the relaxation rate of arterial blood. R1,app is defined 
by R1,app = R1 + P/λ - ln(cos α)/TI2, where α is the flip angle, and TI2 is the time between the 
Look-Locker pulses. This dependency on flip angle requires Look-Locker acquisitions to have 
a robust B1 spatial characterisation, however, the exact flip angle isn’t required for 
calculating the perfusion as this can be extracted from fitting Equation 3.1. M0 was taken 
from the last successful TI of the Look-Locker readout, as a parameter-matched equilibrium 
90 
 
image wasn’t acquired for the preliminary tests, this saturated M0 will cause the perfusion 
to be overestimated. M(TI) was the pixel-wise PENIR retrospectively-gated signal. A two 
parameter fit was used to estimate perfusion, f, and arterial transit time.  
FAIR datasets were analysed from three mice, and the PENIR scheme was applied to 
remove the motion-corrupted TIs. The perfusion map as estimated using the Gunther 
adaptation of the general kinetic model can be seen Figure 3.28A; a lower level of perfusion 
can observed across the liver parenchyma, PGunther = 0.90 ± 0.26 ml g
-1 min-1 (mean ± 
standard deviation), compared to Belle model estimate (Figure 3.28C), PBelle = 2.09 ± 0.58 ml 
g-1 min-1. The arterial transit time (ATT) map estimated from the fitting can be seen in Figure 
3.28B – reduced transit times can be seen in the blood, and a homogenous ATT can be seen 
across the liver parenchyma (mean ATT 0.27 ± 0.01 s).  
From these measurements, the perfusion estimated by the Belle model is closer to previous 
invasive microsphere measurements in mice livers,  which measured a mean perfusion of 
1.8 ± 0.3 ml g-1min-1 (14). In addition, the fitting success of the general model can be seen in 
Figure 3.28D. The blue points represent the difference in tissue signal post slice-selective 
and global inversion, and the red line shows the expected behaviour of the model. It is clear 
that the general kinetic model does not fit the data suitably, and further work is necessary 
to develop this. However, owing to the concordance of the Belle model to literature values, 
the following research will use this quantification approach. The Belle model is susceptible 
to producing high flow from fast inflowing blood, so care will have to be taken to remove 
the influence on non-liver perfusion levels – values over 10 ml g-1 min-1 were chosen to be 
excluded from the mean perfusion measurements.  
The optimised FAIR-LL in combination with the PENIR algorithm now offers an imaging 
pipeline to estimate mouse liver perfusion, the repeatability and reproducibility of the 





Figure 3.28: (A) Perfusion quantification using general kinetic model with Look-Locker correction. (B) 
Corresponding arterial transit time (ATT) map, reduced transit times can be seen at the location of 
the large vessels. (C) Perfusion map from the same dataset following Belle quantification, the 
perfusion is markedly increased. (D) – quantification fitting from general k model shows poor model 
fitting (red line) success to the data (blue points). 
3.6 Repeatability and Reproducibility of Hepatic FAIR-LL ASL  
3.6.1 Materials & Methods 
3.6.1.1 Animal models 
10 female BALB/C mice aged 6-8 weeks were anesthetised with isoflurane (3% in 1L O2/min 
for induction) and placed in a supine position within the scanner bore, as this was found to 
be optimal for placing the respiratory bellows. Animals were maintained at a steady level of 
isoflurane (approx. 1.9% isoflurane in 1L O2/min) during scanning. Animals had access to 
food and water ad libitum and were weighed immediately before being placed in the 
scanner.  
3.6.1.2 Imaging Procedure 
An axial, respiratory-triggered, high-resolution, T2-weighted, multi-slice Fast Spin Echo 
sequence was used to determine a suitable and consistent slice for ASL measurements. 
Image parameters included: FOV = 30 x 30 mm2, matrix size= 192 x 192, TR = 1500 ms, 
effective TE = 19 ms, three averages, whole liver coverage with 0.5 mm thick slices. 
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A single-slice, respiratory-triggered, segmented Look-Locker FAIR sequence with a spoiled 
gradient-echo readout was used to acquire the ASL data. Sequence parameters included: 1 
mm thick slice, FOV = 25 x 25 mm, matrix size = 128 x 128, TE = 1.18 ms, inversion time 
spacing TILook-Locker = 110 ms, repetition time between Look-Locker sampling pulses TRRF = 2.3 
ms, sampling flip angle αRF = 8°. TRI: 13 s, 50 inversion recovery readouts, 4 lines per 
segmented acquisition with 50 sampling points. A 6 mm localised selective inversion was 
followed by a global inversion, with the scan taking around 15 minutes. An adiabatic fast-
passage inversion pulse with a length of 2 ms and bandwidth of 20 kHz was used for slice-
selective and global preparations (15), and 500 µs Gaussian radiofrequency pulses were 
used for Look-Locker excitation. Datasets were retrospectively corrected for respiratory 
motion using the PENIR algorithm, prior to T1 mapping and perfusion quantification.  
3.6.1.3 Repeatability and Reproducibility Assessment 
For the repeatability and reproducibility study, ten female Balb/C mice were scanned under 
the same protocol, one week apart. Each protocol contained a high-resolution, respiratory 
gated fast spin echo sequence which was used to determine the location of the porta 
hepatis, where both the hepatic artery and portal vein are visible. Four consecutive ASL 
scans were then performed, with the animal maintained at a constant level of anaesthesia 
and temperature.  
3.6.1.4 Quantification 
Mean perfusion was obtained by drawing an ROI within the liver parenchyma, avoiding the 
major blood vessels as they will contribute high (non-physiological) perfusion. In addition, 
spurious estimates of perfusion were removed by automatically thresholding the values 
above 20ml g-1 min-1 (2, 14), and noise-induced negative perfusion values were set to zero. 
3.6.1.5 Statistical Analysis 
The coefficient of variation (CV) (Eq. 4), a normalised measure of the data variability given 
by the ratio of the standard deviation σ to the mean µ, was used to compare 





CV  Equation 3.35 
Three modes of variation were calculated: repeated measurements within an imaging 
session were used to assess the within-session CV (CVWS ± standard error). The between-
session CV was estimated from comparing index-matched scans between week 1 and week 
2 for each mouse (i.e. week 1-scan 1 with week 2-scan 1). The between-animal variation, 
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CVA, reflects the variability between perfusion estimates in different animals, was 
calculated from all ASL scans. Each coefficient was calculated from a region encompassing 
all the liver parenchyma within the slice. The inter-animal precision was obtained from the 
standard deviation of perfusion estimates between animals.  
To determine the minimum detectable change in perfusion given by hepatic ASL, Bland-
Altman repeatability coefficients (RC) (Eq. 5) were calculated. Bland-Altman RCs correspond 
to the 95% confidence interval given by two perfusion estimates; ΔP is the difference in 














RC  Equation 3.36 
Repeatability coefficients were calculated from the first two scans within each session, for 
each week and averaged to produce RCWS. The between session repeatability coefficient 
RCBS was generated from averaging the RCs of number-matched scans between the weeks 
for all the animals.  
3.6.2 Results 
3.6.2.1 Hepatic Arterial Spin Labelling 
The quantification of perfusion using the optimised T1-difference method can be visualised 
in Figure 3.29. Taking the mean signal within a ROI of liver tissue, the different tissue 
relaxation can be observed following slice-selective (red) and global (blue) inversion (Figure 
3.29A) – respiration-corrupted images have been omitted from the data. Applying the 
fitting pixel-wise, T1 maps following slice-selective (Figure 3.29B) and global (Figure 3.29C) 
inversions can be generated; the mean global T1 measured in the liver was 1.36 ± 0.06 s 
(mean ± standard deviation). An example fast spin echo image with the perfusion map 
overlaid on the liver parenchyma (Figure 3.29D); high non-physiological perfusion values 
are present within the major vasculature and there is a heterogeneous signal across the 
liver parenchyma. Mean perfusion measured across liver ROIs, inclusive of both repeat 
scans and including all animals, was 2.2 ± 0.3 mlg-1min-1 (mean ± standard deviation).  
Again, this value agrees well with previous microsphere measurements in similar-weight 
mice measured a mean total hepatic perfusion of 1.8 ± 0.3 ml g-1min-1 (14). This paper also 
measured a reference perfusion in the kidneys 5.1 ± 0.8 ml g-1min-1, which agrees well with 
a kidney ROI within the ASL data 5.3 ± 0.6 ml g-1min-1. Additionally, previous liver blood flow 
measurements in mice using DCE-MRI obtained 4.96 ± 1.87 ml min-1 (5) and a bulk 
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perfusion can be estimated as 2.48 ml g-1min-1 to match the ASL-estimated values, assuming 
an approximate mouse liver mass of 2g (16). In addition, the measured perfusion values 
agree well with previous literature measuring rat liver perfusion using 85Krypton clearance 
(2.41 ± 0.50 ml g-1 min-1)(4), microspheres (1.9 ± 0.1 ml g-1 min-1)(17), and two clearance 
techniques using Indocyanine Green (2.03 ± 0.13 ml g-1 min-1) and galactose (2.28 ± 0.49 ml 
g-1 min-1)(18). Although the majority of invasive liver blood flow measurements have been 
performed in rats, from analysis of renal ASL applied to the two species(19), we expect the 
physiology to be comparable to mice. 
   
 
Figure 3.29: Quantifying perfusion from a hepatic FAIR-LL ASL dataset: The perfusion signal comes 
from the difference in longitudinal recovery (A) following slice selective (red) and global (blue) 
inversion. The inversion recovery plots were generated from the mean signal within a small ROI 
within liver tissue, and dataset had been retrospectively gated.  Example T1 map acquired after a 
slice selective inversion (B) and global inversion (C), T1 values have been clipped at 2 seconds (mean 
liver T1: 1.36 ± 0.06 s). The resultant perfusion map of liver parenchyma overlaid on high-resolution 
T2-weighted Fast Spin Echo (FSE) image (D). Non-physiologically high perfusion values can be seen 





3.6.2.2 Repeatability and Reproducibility of Liver Perfusion Estimates 
A significant increase in animal mass was measured from week 1 (18.5 ± 0.6 g) and week 2 
(18.9 ± 0.4 g) (P < 0.05, paired t-test). No significant difference in respiratory rate during 
scanning was observed between weeks 1 and 2 (49 ± 8 breaths/min in week 1 and 49 ± 9 
breaths/min in week 2, P > 0.3). Furthermore, no significant correlation was measured 
between estimated liver perfusion and animal weight, breathing rate or isoflurane 
concentration, which was individually constant but varied from 1.7 to 2.2 % in 1L/min O2 
across the subjects. No influence of anaesthesia was expected as previous measurements 
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did not find a significant change in total liver blood flow over these relatively small 
differences in isoflurane concentration (20).  
The variation within each perfusion imaging session across the cohort can be visualised in 
Figure 3.30A. From fitting each perfusion imaging session, a significant trend in perfusion 
was measured (p < 0.01, t-test) – though the mean perfusion change per scan (-0.05 mlg-
1min-1) is within the uncertainty of the technique; this is also reflected in a non-significant 
paired t-test using the first and last perfusion estimate across the all the imaging sessions (p 
> 0.2). Additionally, there was no between-session perfusion trends observed when 
comparing scan-index matched perfusion estimates between week 1 and 2 estimates (p > 




Figure 3.30: Repeatability and variability in mean liver perfusion, across all animals (shown in 





 per scan) within each session across the cohort, though this is within the uncertainty of 
the technique. No trends were observed between the imaging sessions. Bland-Altman plots showing 
the within-session variation in mean estimated liver perfusion from the first and second scan (B) and 
between-session mean perfusion repeatability plots (C) .The central, thick solid line represents the 
mean difference, and the two outer lines show the ± 1.96 x standard deviation. For all the plots, the 
mean difference measured was within the error of the technique, and no trends can be 
distinguished. 
3.6.2.3 Coefficient of Variation 
The within-session coefficient of variation CVWS, was 7 ± 1%, the between-session 
coefficient of variation CVBS was 9 ± 1%. The between-animal CVA was 15 ± 1%, The CVs 
between three data conditioning modes varied within 1%. The inter-animal precision was 
calculated to be ± 0.3 mlg-1min-1 across the whole liver.  
3.6.2.4 Repeatability Coefficients 
Figure 3.30B shows Bland-Altman plots to visualise the within-session differences by 
comparing perfusion estimates from repeated measurements. The plot is not suggestive of 
a magnitude dependence in perfusion estimates and has a mean difference of +0.01 ± 0.34 
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mlg-1min-1. Between-session Bland-Altman analysis is also free from any magnitude 
dependence and measured a mean difference of +0.01 ± 0.46 mlg-1min-1.  The Bland-Altman 
repeatability coefficient provides an estimate of the percentage change required to 
measure a significant variation in a particular parameter estimate: the within session Bland-
Altman repeatability coefficient RCWS was 18% and the between session repeatability 
coefficient RCBS was calculated to be 29%. 
3.6.3 Discussion & Conclusion 
This study tested the repeatability of the optimised liver ASL imaging pipeline. The 
variability in the within-session and between-session measurements were relatively small 
and comparable to previous myocardial perfusion variability using a similar technique (1). 
The repeatability coefficients give a measure of the required percentage change to observe 
a significant difference in perfusion measurements. The between session repeatability was 
larger than the within session changes, this was within expectations due to week-to-week 
changes. The minimum sensitivity for between session changes was 29%, which shows 
promise for application to disease and therapy monitoring: previously reported differences 
in perfusion between cirrhotic and normal patients have been approximately 30% (21) and 
DCE-MRI estimates of the perfusion related transfer constant Ktrans have shown change a 
40% change post vascular targeting therapy (22).  
From the repeatability and reproducibility analysis, the largest variability was between 
animals, suggestive that subject variability was greater than that of the technique. 
However, it is difficult to isolate the precise source of variation, as the variability of the 
technique will contribute to the between animal variability measure. A slight downward 
trend was observed in the perfusion estimates over the imaging session, this may be due to 
dehydration during the experiment – the effects of this may have to be accounted for long 
duration scanning sessions, perhaps by using a saline infusion.  
Between-session and between-animal perfusion variability has been previously attributed 
to variations in the level of administered anaesthesia. Isoflurane level has been previously 
reported to have a significant influence on myocardial perfusion measurements (23), 
although no such association was found in this study, which is agreement with previous 
liver studies (20). The influence of anaesthesia on perfusion can be seen from a FAIR-LL ASL 
experiment incrementing the level of administered isoflurane in two mice (Figure 3.31). No 




A further potential source of variability was the feeding status between animals, as animals 
were allowed to feed ad libitum. The portal vein draws blood from the intestines, and so 
the between animal variability observed may be exacerbated by differing dietary habits 
between the mice. Previous behavioural studies in mice reported a cyclic consumption of 
food approximately every 24 hours (24), though no trend in perfusion was correlated with 
the time of the day to suggest that an ad libitum diet may not be an influential factor to the 
variability in liver perfusion. Future studies may investigate the FAIR-LL technique’s 
sensitivity to post-prandial liver perfusion changes following a controlled diet (25).  
 
' 
Figure 3.31: Physiological influence of anaesthesia on myocardial and hepatic perfusion in two 
subjects (diamond and triangle) with a liver (blue) and myocardial (red) ROI in a single slice. In this 
experiment the isoflurane was incrementally increased from 1.25 to 2.25% in 1L/min of Oxygen; a 
marked increase can be seen in the myocardial tissue (red) over the administrated range; where the 
liver perfusion values (blue) aren’t affected. In addition, no trend was observed between liver 
perfusion and isoflurane. 
This chapter has shown the development of a hepatic ASL technique, the repeatability 
analysis shows that it has promise in application to pre-clinical models of liver disease. 
Before such applications are explored, a few investigations were carried out to further 
explore the Look-Locker acquisition.  
3.7 Further Optimisation of the Look-Locker Acquisition 
3.7.1 Multi-slice FAIR-LL ASL  
The FAIR-LL acquisition has thus far been single-slice; however by including more sampling 
pulses to the Look-Locker train, it is possible to acquire additional slices without increasing 
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the total acquisition time (Figure 3.32). This will allow for greater efficiency in coverage of 
the liver, which would be of particular use in application to pathology. 
3.7.1.1 Methods: Pulse Sequence  
 
Figure 3.32: Multi-slice adaption to the Look-Locker sequence. This schematic shows a three slice 
acquisition; each single-slice readout block (black) has an additional two slices (red and blue) added 
in – each slice is acquired directly after the other at TRRF (3.1 ms). Using the method, it is possible to 
increase liver coverage and maintain the same scan duration. 
Figure 3.32 demonstrates a three-slice example multi-slice adaptation of the Look-Locker 
acquisition; the new slices have been added in red and blue. By designing the sequence in 
such a manner and maintaining the TILook-Locker, the total acquisition time will not be altered. 
With no gap between the three slices and each slice being 1 mm thick, the slice-selective 
thickness of 6 mm will be suitably wide enough to perfusion-weight all the slices. The 
effective slice-selective inversion thicknesses for each slice will be 4, 6 and 8 mm; from the 
optimisation of the inversion thickness (Figure 3.20), it possible to see that the slice furthest 
from the direction of flow may have some reduced perfusion as a result of the slow inflow 
of portal blood.  
This inflow effect can be addressed using a blood-pool reference to inform a more complex 
model of perfusion developed by Campbell-Washburn et al. (26). The perfusion-modified 
Bloch equations are altered to factor in a time-dependent blood magnetisation, and thus 
the quantification requires a more complex numerical integration to estimate perfusion. 
Though this has been successfully implemented in the mouse myocardium, initial attempts 
to quantify the perfusion with this method was computationally expensive and returned 
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falsely high estimates of perfusion (Figure 3.33). This will need further work to refine this 
model for the liver, thus for the remainder of this chapter, the original Belle model will be 
used for perfusion quantification as before.  
 
Figure 3.33: Preliminary investigations in to a blood-pool correction to the perfusion quantification: 
(A) slice-selective T1 map (mean T1 = 1.16 s), (B) global T1 map (mean T1 = 1.23 s), (C) tissue T1 map 
(mean T1 = 0.91 s) – derived from accounting for the blood relaxation taken from an ROI within the 
portal vein. The single-slice quantification method shows a perfusion map within physiological 
values (D) where the corrected quantification (E), exhibits high perfusion (mean standard perfusion 









3.7.1.2 Results: Comparison with Single Slice Measurement 
The sequence was run in an agar phantom to measure if the increased pulses in the multi-
slice sampling train affected the T1 estimation compared to the single slice acquisition. No 
significant difference or bias (t-test, p > 0.05) was measured between the multi-slice and 
the single-slice measurements (Figure 3.34A). In addition, no significant differences were 
found in the T1 measurements when using a gap of 0 or 0.2 mm between the slices, so 




Figure 3.34: (A) Comparison of T1,Selective in three different slices as acquired by multi-slice (MS, red) 
and single-slice (SS, blue) FAIR-LL acquisition in an agar phantom – no significant differences were 
measured between the techniques. (B) Three T2-weighted, fast spin echo images of a liver (ROI 
outlined) at the different slice positions (Row FSE) and the corresponding single-slice perfusion maps 
(Row Single-Slice ASL) and multi-slice perfusion maps (Row Multi-Slice ASL). Visual inspection 
indicates good correlation between the two techniques; high flow can be seen at major blood 
vessels and a ring of high perfusion can be observed in the renal cortex (arrow).  
The multi- and single-slice sequences were then performed in-vivo in three mice to assess 
any perfusion differences. Visual assessment of the example perfusion maps in Figure 3.34B 
shows good correspondence between the multi- and single-slice FAIR-LL. The high regions 
of flow correspond to the locations of blood vessels which appear hypo-intense in the FSE 
anatomical images. The kidney has been included within the analysis ROI, which appears 
hyper-intense relative to the liver parenchyma on the FSE (arrow). In both sets of perfusion 
maps a ‘ring‘ of raised perfusion can be seen within the renal cortex relative to the medulla 
(27). Across all three slices, the multi-slice under-estimates the perfusion 97.2 ± 16.3%, 
though this is non-significant (t-test; p >0.5) – the global T1 was non-significantly 
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overestimated 107 ± 11% (t-test; p>0.05). By each slice; slice 1, which is closer to the portal 
vein, over-estimates perfusion: 118 ±  10%, slice 2 agrees well  99.7 ±  9.6 %, and slice 3 
underestimates perfusion 74 ± 29%, though none of these were measured as significantly 
different (t-test, smallest p > 0.2), this is likely to be due to the slice positioning relative to 
the label plane as discussed above. This may be additionally related to the slice ordering 
during readout: due to the slice-selective inversion being centred about the first readout 
slice, the readout order is arranged such that the central slice was acquired first.  
The quantification used for the multi-slice perfusion estimates has been the regular Belle 
model as used in the previous section. Figure 3.20 demonstrated the inflow of blood in the 
portal system isn’t fast enough for the quantification assumptions to hold. However, this 
simplified approach to the multi-slice quantification visually compares well, but is likely to 
induce a systematic error. Further work will be required to investigate Campbell-Washburn 
modified Belle model: this method accounts for perfusion underestimation per slice by 
drawing a ROI within a blood vessel – however, this is difficult in more superior parts of the 
liver where the portal vein has branched in to small venules. In addition, this proposed 
method doesn’t factor in the arterial contribution to the liver, as the hepatic artery is so 
small and its contribution to the total liver flow is much smaller than that of the portal vein.  
Thus, due to the added complexities with multi-slice imaging, single-slice analysis will be 
used for the remainder of this thesis, though a multi-slice acquisition will be acquired so 
future development may retrospectively increase the available data. 
3.7.2 Look-Locker Resolution & Segmentation 
3.7.2.1 Pulse Sequences & Methods 
Two adaptations to the Look-Locker acquisition were explored in this section: the 
acceleration of the sequence by increasing the segmentation of the sequence, and varying 
the number of TIs within the Look-Locker train.  
The FAIR-LL sequence and retrospective gating is reliant on steady breathing in order to not 
induce too much physiological noise within the raw data. In order to improve this, an 
investigation was carried out in speeding-up the acquisition time in order to minimise 
possible physiological drift. The segmentation of each TI was increased from 4 to 8 samples, 
the additional sampling pulses can be seen in the schematic in red in Figure 3.35A.  
Secondly, in order to possibly facilitate an alternative method of quantification using the 
subtraction of the magnetisation, the TILook-Locker was decreased and thus more TIs could be 
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included. The original hypothesis was to improve the temporal resolution to improve 
alternative perfusion modelling and also enable the implementation a DCE-like dual-
compartment analysis to be able to split the venous and arterial blood supply. DCE fitting is 
highly reliant on a high-temporal resolution to partition the blood contributions, and so the 
temporal resolution of the sequence was increased to 100 TIs with a TILook-Locker 50 ms 
(Figure 3.35B). Alternatively, two normal acquisitions could be interleaved, however that 
would be less efficient than increasing the number of TIs.  
 
Figure 3.35: (A) Increasing the segmentation or speed-up factor (SF) of the Look-Locker acquisition. 
Each sampling block has four more sampling pulses added (red) to halve the acquisition time. (B) 
High temporal resolution adjustment to the Look-Locker sequence. Extra sampling blocks (red) have 
been added in to create a smaller TILook-Locker, and thus increase the temporal resolution of the 
sequence. 
Four different Look-Locker sampling trains were then compared: acquiring 50 TIs with a 
speed-up factor (SF) of 4, acquiring 100 TIs with a SF of 4, acquiring 50 TIs with a SF of 8, 
and acquiring 100 TIs with a SF of 8. These acquisitions were first tested in an agar phantom 
to compare the T1 estimations and then applied in-vivo.  
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Finally, Monte-Carlo (MC) simulations were carried out testing the influence of increasing 
the number of TIs to best characterise the T1 value. A normally-distributed noise profile was 
added to the inversion simulation, with an SNR of 10, as measured from the in-vivo 
experiments in this section. The number of TIs were increased from 5 to 100, with the TIs 
evenly distributed across 7 seconds, and a simulated T1 of 1.2 seconds. 100 repeats were 
carried out, and the error in the T1 estimation as produced from MATLAB’s nlparci 95% 
confidence interval was calculated for each number of TIs. 
3.7.2.2 Results: Comparison of LL Acquisition Strategies 
From ANOVA analysis in phantoms, no significant differences were measured across the 
read-out strategies (ANOVA; p>0.8). The in-vivo results can be seen in Figure 3.36A; no 
significant differences can be visualised between the different speed-up factors and TIs for 
both the T1,global and perfusion maps. Taking a liver parenchyma ROI, the effects of 
saturation can be visualised in the signal evolution plots (Figure 3.36B). The increased 
number of TIs (blue and green) causes a greater amount of signal saturation; however the 
T1 maps still agree well due to the Look-Locker quantification accounting for the saturation.  
There are no obvious saturation differences for increasing the speed-up factor, which will 
allow faster acquisition. 
The overlay of the MC simulations can be seen in Figure 3.36C, the error in the T1 
estimation can be seen to decrease with increased TIs – however there isn’t such a large 
improvement between 50 and 100 TIs (Δ T1,TI = 50 = 0.17s, Δ T1,TI = 100 = 0.12s).  
3.7.3 Conclusion 
The sequence can be easily manipulated to acquire more slices, more images and in a 
shorter frame of time with no deterioration of image quality. The multi-slice acquisition, 
though visually looks promising when compared to a single-slice acquisition, will require 
further development to implement the blood pool correction factor to best estimate the T1 
and perfusion maps with the modified Belle model (28).  
The high temporal resolution sequence will need further investigation with the general 
kinetic and dual compartment modelling. If the perfusion contributions from the arterial 
and venous supplies can be separated using a DCE-MRI type model, this will have potential 
application to liver disease models, where the ratio of the perfusion can vary. The increased 
segmentation does not seem to affect the T1 and perfusion estimates, which halves the 
acquisition time and thus reduce the image sensitivity to breathing variation.  
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As no changes were observed by increasing segmentation and temporal resolution, it is 
recommended to use to help improve the liver ASL imaging using a Look-Locker readout, 
with a single-slice analysis. However, as the repeatability analysis was carried out using a 
speed-up factor of 4 with 50 TIs, Chapter 4 applies this single slice acquisition to pre-clinical 
models in response to therapy. AS Chapter 5 uses the FAIR-LL as a reference scan and T1 





Figure 3.36: (A) Comparison of T1 and perfusion maps using a combination of segmentation speed-up 
factors (SF) and number of TIs in the Look-Locker sampling train; the increased RF duty does not 
affect the longitudinal relaxation or perfusion maps. (B) Comparison of global inversions from the 
mean signal in a uniform region of liver tissue. The higher segmentation has an observable saturation 
difference, though from the T1 values are recovered due to the inversion efficiency correction 
(Chapter 2, Eq 13).  (C) Overlaid Monte-Carlo simulation of the error in the T1 estimation (from 95% 
confidence interval) as a function of the number of TIs. The plots show that the larger number of TIs 





3.8.1 Discussion and Conclusion 
In this chapter, we have applied a Look-Locker FAIR arterial spin labelling MRI for the first 
time to measure liver perfusion in a pre-clinical setting. We have optimised the technique 
and investigated the technique’s reproducibility and repeatability within and across imaging 
sessions. In addition, a method of retrospective gating (PENIR) was introduced that is 
wholly data-generated and was applied to reduce the perfusion estimate error.  
The implemented FAIR-ASL preparation and T1-based quantification is attractive due to its 
estimation of the total liver blood flow (i.e. both portal venous and arterial) independent 
from modelled parameters. The Belle model proved to be a more accurate measure of liver 
flow than the generalised perfusion model, when compared to previous invasive 
microsphere measurements.  
A measurement of global liver perfusion changes may be a useful quantity when applied to 
models of cirrhosis and liver dysfunction (21). In addition, the parenchymal T1 value has 
been reported to increase as a result of inflammation and fibrosis development (29) and 
cirrhosis onset (30) – a quantitative MRI parameter which is generated by the Look-Locker 
FAIR ASL acquisition. 
The signal exhibited recovery in the portal vein following slice-selective inversion, even at 
the smallest inversion thickness. This means that the FAIR assumption isn’t entirely valid, 
however the blood-pool quantification could be used here to account for any potential 
underestimation in perfusion.    
The intrinsic low perfusion SNR of ASL experiments leads to the majority of methods 
employing the efficient EPI readout, however such a technique is particularly challenging in 
the rodent liver; the surrounding abdominal fat and air cavities in the stomach and lungs 
can make imaging prone to distortion and signal dropout. Hence a gradient echo acquisition 
was used, and to increase the efficiency of the ASL data set, a Look-Locker method was 
applied – however this employs a low sampling flip angle which can result in low SNR 
images leading to some noise in the perfusion maps. In an alternative set-up, this may be 
improved using a surface receiver coil, though we found a sub-optimal coverage of the liver 
using such an arrangement.  
FAIR-LL ASL has been demonstrated in this chapter as a repeatable measure within the 
mouse liver. In the next chapter the technique will be applied to a number of hepatic 
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diseases. First, in tandem with a vascular targeting therapy of liver metastasis, then applied 
to rat model of cirrhosis. Finally, the perfusion of liver lobes will be measured in an 
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Application of Hepatic Arterial Spin 
Labelling to Pre-Clinical Liver Models  
This chapter applies the developed FAIR-LL ASL pipeline to animal models of hepatic 
diseases. Initially we investigated the feasibility of ASL perfusion measurements in 
subcutaneous xenograft tumour models and subsequently applied it to an orthotopic 
model of colorectal liver metastasis. A vascular disruption agent therapy was then applied 
in situ to two lines of liver tumours, and the pre- and post-therapy perfusion was measured 
and compared to R2*, a biomarker which has been trialled clinically. The FAIR-LL technique 
was then applied to a rat model of cirrhosis, to measure changes in perfusion with the 
onset of liver dysfunction. Finally perfusion changes were measured within a model of 
hepatic hyperplasia stimulation to image the lobe function in combination with high-
resolution imaging of lobe growth.  
The subcutaneous tumour and liver metastases research in this chapter was undertaken in 
collaboration with Dr Sean Peter Johnson, who cultivated the cells and implanted the 
mouse models. The histology and immunohistochemistry was performed by Uzma Qureshi 
and Professor Barbara Pedley. The vascular disrupting agent OXi4503 was developed by 
Oxigene, and procured by Professor Barbara Pedley. The acute, in-situ therapy monitoring 
with MRI was designed in collaboration with Dr Simon Walker-Samuel and Dr Sean Peter 
Johnson. The cardiac-gated phase contrast MRI sequence was developed by Thomas 
Roberts and Dr Simon Walker-Samuel. The subtractive phase-contrast MRI estimate of total 
liver blood flow was developed and validated by Dr Manil Chouhan. The liver cirrhosis 
research was led by Dr Manil Chouhan who designed the study, set up the model, and 
carried out the MRI- which was further assisted by Dr Alan Bainbridge. Details of the PC-
MRI technique and validation can be found in his thesis. The liver ligation model was 
developed and performed by Dr Dipok Dhar, and the MRI and segmentation was performed 
in collaboration with Dr Manil Chouhan.  
The application of a vascular disrupting agent to a mouse model of colorectal liver 
metastasis is currently in submission. The perfusion measurements in subcutaneous 
tumours contributed to Walker-Samuel, S., et al., In vivo imaging of glucose uptake and 




4.1.1 Translational Research of Hepatic Disease and Therapy 
Measurements of liver perfusion can have diagnostic value, and this chapter applies the 
previously optimised arterial spin labelling method to pre-clinical models of liver 
metastases, cirrhosis and lobe regeneration. As these diseases present differing flow 
dynamics to homeostasis, these will offer a validation of the sensitivity of the optimised ASL 
sequence.  
Approximately 35,000 people are diagnosed with colorectal cancer in Britain per year (1), 
and about 40% of these will metastasise to the liver, in addition to a number of other 
primary tumour sites. Curative intervention is most critical at this stage, and a number of 
therapy options are available. Anti-cancer treatments such as vascular disrupting agents 
(VDAs) have shown promise to cause acute cessation of blood flow, and thus a method to 
directly measure perfusion changes following therapy would be of great utility. 
Furthermore, acute imaging following a VDA therapy can test the within-session sensitivity 
of the optimised liver FAIR ASL sequence.  
In the UK, approximately 8000 new patients are diagnosed with cirrhosis each year (2). As 
cirrhosis develops, the liver becomes ‘stiffer’ and more resistant to flow due to deposition 
of collagenous fibres (3). Currently, there is no therapy available for cirrhosis, though 
surgical techniques such as hepatic resection and portal shunting have been used to 
assuage patient comfort (4). As there is an increased risk to patients associated to the Child-
Pugh scoring of cirrhosis (5), accurate stratification of patient severity is key. A battery of 
blood tests are performed to diagnose cirrhosis, however, MRI offers the potential to 
localise any complications due to the disease. In addition to increases in tissue stiffness, 
perfusion has been shown to decrease as a result of cirrhosis, thus arterial spin labelling will 
have potential as a contrast-free method to characterise the level of liver dysfunction.   
In patient cases of primary and widespread metastatic liver tumours, hepatic resection 
presents the best long term patient outcomes (6). Healthy livers are estimated to be 
functional with only 25% remaining; however for patients with hepatic dysfunction or 
damage due to chemotherapy, the advised future liver remnant (FLR) is around 40% (7). In 
some cases, such target liver volumes are difficult to achieve, thus there exist surgical 
techniques which promote lobe growth via selective portal occlusion or embolization. In 
particular, one recent procedure has shown a lot of promise which promotes the FLR to 
increase by 10-46% within 6-8 weeks (8). The insult due following selective ligation causes 
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neighbouring lobes to enlarge, and a further dissection along the falciform ligament can 
cause a rapid growth of the left lateral lobe. However, so far in this experimental 
procedure, little has been done to characterise the functionality of the enlarged liver lobes, 
asides from histological assessment from post-surgery biopsies. Arterial spin labelling may 
offer an assessment of liver function via liver perfusion, and in addition, contribute to the 
questions concerning the mechanism of the liver regeneration (9).  
4.2 Methods: Cancer models 
4.2.1 Cell lines: LS174T & SW1222 
Two human colorectal cancer cell lines were used for the cancer research in this thesis, 
which exhibit different cellular and vascular structures. SW1222 tumours are well 
differentiated and have a well perfused vascular network, whereas LS174T tumours show 
poor differentiation and are comparatively less well vascularised and perfused, generally 
with larger hypoxic and necrotic regions (Figure 4.39F) (10, 11).  
4.2.2 Subcutaneous Tumour Model  
All in vivo tumour experiments were performed in accordance with the local regulations 
and the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines 
(12). 
The majority of cancer research has been performed in subcutaneous xenografts; the 
model is very reliable to establish and the tumour volume can be easily determined by 
callipers. The FAIR-LL sequence was first applied to a subcutaneous model to establish 
levels of perfusion within the solid tumours.  
All cancer models were performed on immunocompromised mice (MF1 nu/nu, female, 6-8 
weeks old, 25-30 g). Subcutaneous models were set-up using an established protocol: 5x106 
SW1222 cells were injected subcutaneously into the right flank of three mice using a 27G 
needle. Tumours were inspected visually and allowed to grow over 10–16 days. 
4.2.3 Orthotopic Model of Liver Metastasis 
Orthotopic models of cancer investigate tumours within a more clinically-relevant location 
compared to subcutaneous models. Metastasis models allow for tissue-specific 
environments and tumour heterogeneity, which has potential for translation to clinical 
patients.   
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Models were established using a previously published protocol. Mice were anaesthetised 
with isoflurane in O2 at a concentration of 4% for induction, followed by 1.5% for 
maintenance. A subcutaneous injection of 0.1mg/kg buprenorphine (Vetergesic, Reckitt 
Benckiser, UK) was administered and the flank of the animal sterilised with clorhexidine 
solution. A laparotic incision of approximately 1cm was then made above the location of 
the spleen and the organ exteriorised for injection. Tumour cells were injected 
intrasplenically at a concentration of 1x106 cells in 100µl in serum free media and allowed 
to wash through to the liver for 1 minute, followed by splenectomy to avoid the 
development of tumours at the site of injection (13). The laparotic incision was sutured 
(Ethicon, Johnson & Johnson, USA) and closed with wound clips (Autoclip system, Harvard 
Apparatus, UK).  
For the models of colorectal liver metastases, SW1222 (n = 6) and LS174T (n = 6) cells were 
implanted using the protocol above. Tumour cells were transfected with luciferase so 
bioluminescent imaging could be used for early screening of model success. Solid tumour 
deposits which formed within the liver were monitored for cell engraftment using 
bioluminescent imaging (Photon Imager Optima, Biospace Lab, France) 1-3 weeks post-
surgery. Mice that presented bioluminescent signal from the liver region were then 
promoted to T2-weighted anatomical MRI at weeks 3-5 to observe tumour growth; 
perfusion MRI was performed in week 5.  
4.2.4 Histology Methods 
At the end of the MRI experiments, mice were intravenously injected (15 mg/kg) with the 
perfusion marker Hoechst 33342 (Cambridge Bioscience, UK) one minute before culling. 
Haematoxylin and eosin (H&E) staining for basic cell morphology was performed on 10µm 
thick slices on an AxioSkop bright-field microscope (Carl Zeiss, Germany). For 
Immunohistochemical (IHC) histology, livers were excised and snap frozen in 
isopentane/liquid nitrogen, before sectioning on a cryostat at 10µm thickness. Blood 
vessels were stained using the vascular endothelial marker CD31 (Abcam, UK), and dual 
biomarker images of blood vessels combined with the perfusion marker were taken on an 
AxioImager microscope (Carl Zeiss, Germany). 
H&E and IHC histology was performed on untreated SW1222 and LS174T liver tumours, and 
further H&E staining was performed on the VDA-treated SW1222 metastases.  
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4.3 Application of FAIR-LL ASL to subcutaneous models 
4.3.1 Subcutaneous MRI Protocol 
Mice were anesthetised and then placed in the scanner so that the implanted tumour was 
upwards to facilitate maximising the tumour within a coronal field of view (FOV 20 x 20 
mm2). Dental paste (FlexiSil, Prevest DenPro, Germany) was applied to the tumour and 
flank region to restrict any movements due to respiratory motion.  Thus, the FAIR 
acquisition and analysis was as before but without triggering or retrospective gating.  
4.3.2 Results & Discussion 
 
Figure 4.37: Application of FAIR-LL ASL to a SW1222 subcutaneous tumour model. (A) Axial GE image 
shows the tumour implantation marked by an arrow. (B) Slice-selective T1 map shows a relatively 
homogenous structure within the tumour. (C) Resultant perfusion map within the tumour, the cell 
line presents low flow in the centre of the tumour and relatively higher flow around the tumour 
edge.   
Subcutaneous tumours developed in all three mice, an example FAIR-LL dataset can be seen 
in Figure 4.37. An axial, GE image demonstrates the orientation of the tumour (arrow), the 
applied dental paste does not present any MR signal. The tumours are generally 
homogenous structures, though can exhibit necrotic regions, particularly in larger tumours. 
The T1 maps reflected this unstructured phenotype (Figure 4.37B), with mean T1,selective 2.13 
± 0.07 s (mean ± std, n = 3). The perfusion maps presented very low levels of blood flow 
across the tumours (Figure 4.37C), mean perfusion was 0.19 ± 0.08 ml g-1 min-1. A raised 
level of perfusion was measured at the periphery of the tumours, corresponding with 
vascular cast data (not shown) of these cell lines presenting large vessels chaotically 
networked around the tumour edge. Previous subcutaneous tumour FAIR measurements in 
three renal cancer cell lines measured similarly low perfusion levels, relative to other 
tissues: 0.801 ± 0.233 ml g-1 min-1 (A498), 0.751 ± 0.286 ml g-1 min-1 (786-0), and 0.102 ± 
0.090 ml g-1 min-1 (Caki-1) (14) and 0.926 ± 0.429 ml g-1 min-1 (A498) (15).  
Previous measurements have used twenty-four and forty averages to facilitate measuring 
the low perfusion. As the perfusion measurements presented low levels of tumour blood 
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flow, this will yield a low perfusion SNR, it is recommended that multiple averages of the 
FAIR-LL sequence are used to minimise quantification error from the T1 differences. The 
hepatic ASL sequence was then applied to a mouse model of liver metastases to investigate 
any measurable level of perfusion within the tumours and differences between neoplasms 
to hepatic parenchyma. 
4.4 Perfusion Measurements of Colorectal Liver Metastases  
4.4.1 Liver Metastases MRI Protocol 
Liver metastases successfully developed in 3 out of 6 LS174T models and 6 out of 6 SW1222 
models. The hepatic ASL imaging pipeline used in Chapter 3.6 was applied to these two 
models of liver metastases.  
Bioluminescent and high-resolution, T2-weighted fast spin echo MRI (parameters as before 
in Chapter 3.4) were used to assess the success of tumour implantation over weeks 2 – 5 
(Figure 4.38). The doubling time of liver metastases, estimated from volume estimations 
from manual segmentation, was 3.9 ± 0.6 days and 2.4 ± 0.6 days (mean ± standard error), 
for SW1222 and LS174T cells respectively. This is consistent with the range of doubling 
times observed in studies with other tumour cell lines: between 1.2 and approximate 4 
days (16, 17). In addition, Kalber et al. measured a growth rate of approximately 2-3 days in 
LS174T liver metastases (18), which is in good agreement. These values reflect the variable 
growth rate in orthotopic tumours than traditional subcutaneous models, A similar rate of 
growth has been reported in subcutaneous models of SW1222 tumours; between 3 and 5 






Figure 4.38: Monitoring the growth rate of a mouse model of liver metastases. (A) Bioluminescent 
images show light signal emitted from the site of the liver within a week of cell implantation. The 
signal intensity increases as the number of cells multiply over the weeks. (B) After three weeks, the 
tumours form solid tumours that can be visualised with a high-resolution T2-weighted imaging. In 
this series of manually segmented 3D visualisations, the liver appears semi-transparent red and the 
tumours as yellow. These tumours can be seen to increase in volume over three weeks.  
The liver metastases appear hyper-intense (Figure 4.39, arrow) relative to the liver 
parenchyma (outlined) for both cell lines The FAIR-LL data was planned according to the 
anatomical images for a slice that contained a maximal number of tumours with a 
sufficiently large thickness and cross sectional area (0.7 mm2, approximately 50 voxels), in 
order to avoid partial volume effects and to increase the number of tumour voxels for 
analysis. ROIs were drawn in the normal-appearing liver and tumours from the T1,selective 
map, and comparisons were assessed using Kruskal-Wallis ANOVAs. 
4.4.2 Results 
An example mapping from the SW1222 cohort has been shown in Figure 4.39B & C. The 
T1,selective maps (Figure 4.39B) were used to segment the metastases (arrow) as the tumour 
T1,selective was significantly raised (p < 0.0001, Kruskal-Wallis ANOVA) from the liver and 
vasculature for both cell lines: T1,liver 1.34 ± 0.07 s (mean ± std, both cell lines), T1,Portal Vein 
0.29 ± 0.21 s (both cell lines), T1,SW122 2.15 ± 0.11 s (n = 6), T1,LS174T 2.49 ± 0.13 s (n = 3).  
Observing the perfusion map in Figure 4.39C, low levels of perfusion are presented at the 
tumour locations relative to the liver parenchyma, and three metastases have been 
outlined which were sufficiently thick to avoid partial volume overestimation of perfusion. 
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A significant difference (p < 0.05, Kruskal Wallis ANOVA) was measured between the 
perfusion levels within the liver, SW1222 and LS174T metastases: Pliver 2.32 ± 0.34 ml g
-1 
min-1 (mean ± std), PSW1222 1.03 ± 0.72 ml g
-1 min-1, PLS174T 0.28 ± 0.16 ml g
-1 min-1 (Figure 
4.39D). This reduced level of perfusion is consistent with histology imaging (Figure 4.39E & 
F) of perfusion, as reported by the presence of Hoechst (blue), and blood vessel endothelial 
cells as marked by CD31 (red). The liver regions are marked by an arrow, which presents a 
well vascularised and perfused tissue. A marked reduction in perfusion and blood vessels 
can be seen in the SW1222 metastases region, (Figure 4.39E, star) and an even sparser 
tumour vascular environment is observed in the LS174T tumours (Figure 4.39F, star). 
 
Figure 4.39: Application of FAIR-LL to a mouse model of colorectal liver metastasis. (A) Anatomical 
high-resolution T2-weighted fast spin echo image shows an example liver with SW1222 tumour 
deposits (arrow) to be relatively brighter than the normal liver (red outline). (B) Corresponding T1 
map following slice-selective inversion; these maps were used to segment the tumours in the 
perfusion data as the tumour T1 (arrow) was significantly higher than the liver, and additionally 
distinct from the vasculature. (C) In the perfusion map, the tumour regions (outlined) exhibit a 
reduced level of perfusion relative to the liver parenchyma. Flow estimates with non-physiologically 
high values can be seen at the location of the blood vessels. (D) A significant difference in perfusion 
was measured between the liver, SW1222 and LS174T liver metastases. This is concurrent with 
histological evaluation, which shows a marked reduction in perfusion (Hoechst, blue) and blood 
vessels (anti-CD31, red) between liver (arrow) and tumour (star) in the SW1222 metastases (E) and is 
even further reduced in the LS174T line (F).  
These data demonstrate the FAIR-LL method’s sensitivity to different levels of perfusion, 
and is a novel measurement of blood flow in mice liver metastases using an ASL method. 
The reduced perfusion of the metastases relative to the normal liver agrees with a number 
of previous invasive techniques; such as Hoechst measures of perfusion IHC in LS174T liver 
metastases (18) , 133Xe clearance imaging in rat a model of Walker-256 carcinoma 
metastases measured a perfusion within the liver as 0.84 ml g-1 min-1 and the tumours as 
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0.36 ml g-1 min-1 (21), microsphere measurements in a sarcoma rat model measured the 
tumour flow to be approximately 70%  that of the liver (22). From these encouraging 
results, the hepatic ASL technique was then applied to monitor tumour perfusion following 
a vascular targeting therapy. 
4.5 Monitoring Perfusion changes of Colorectal Liver Metastases following 
Vascular Disrupting Agent Therapy 
4.5.1 Introduction: Vascular Disrupting Agents 
Tumour vasculature is an attractive target for anti-cancer therapy, as the delivery of oxygen 
and nutrients from recruited blood vessels promote growth and malignant progression 
(23). The two main classes of chemotherapeutics to emerge from research targeting the 
tumour vasculature are anti-angiogenic compounds, that aim to stop any further vessel 
recruitment, and vascular disrupting agents (VDAs), that aim to destroy the existing tumour 
vascular network.  
Anti-angiogenic compounds have been effectively applied to primary liver tumours in phase 
I & II clinical trials, however such therapy would be predominantly applied for early stage 
prevention of metastasis, rather than acute treatment (24). Little has been reported 
beyond phase I trials of vascular disrupting agents, due to toxicity or inefficacy (24). 
Vascular disrupting agents have an acute effect (typically within 24 hours of administration) 
(25), and do not cause a decrease in tumour volume due to a remnant surviving rim.  
Therapeutic efficacy is commonly evaluated using the ‘response evaluation criteria in solid 
tumours’ (RECIST 1.1) (26), where response to therapy is assessed according to the  
apparent change in tumour size. This has been more recently amended with the modified-
RECIST (mRECIST) (27) which accounts for the potential of derived parameters to assess 
tumours. However, as neo-adjuvant therapy was initiated for reducing tumour burden prior 
to resection, a strong emphasis of the mRECIST criteria remains on volumetric decrease. As 
VDAs have been shown to be effective at destroying the tumour vasculature, they have 
been used in combination with other therapies (28). 
Changes in tumour pathophysiology have been assessed using MRI techniques such as 
dynamic contrast enhancement (DCE-MRI), intrinsic susceptibility (IS-MRI), and diffusion 
MRI (29). Though VDA treatment is succeeded by tumour regrowth from a surviving rim, 
there is still potential for use in combination therapy (30). However, due to the mechanism 
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and the acute nature of the drug action, there is potential for it to be used in conjunction 
with perfusion measurements from arterial spin labelling to inform on therapy efficacy. 
4.5.2 Study Design 
A study was performed in the two cell lines of colorectal liver metastases following 
administration of the vascular disrupting agent (VDA) OXi4503. This VDA has been trialled 
clinically (24), and though the therapy trials have recently subsided, the drug is known to be 
acutely effective (31), and hence will be a good candidate to mediate within-session, post-
therapy perfusion changes. In addition to the perfusion measurements, the intrinsic 
susceptibility, given by R2*, was measured to reflect a clinically-trialled biomarker following 
VDA treatment (29). The susceptibility is expected to rise following treatment, due to the 
increased presence of paramagnetic deoxyhaemoglobin within the tumour following 
vascular shut down. 
As the perfusion within the LS174T tumours was low at baseline, and there was more 
uncertainty in the success of this tumour model, a control cohort was only established with 
SW1222 tumours (5 successful engraftments out of 6). The response to dosing study was 
performed 5 weeks following surgery in three groups: SW1222 with VDA treatment (n = 6), 
SW1222 with saline (n = 5) and LS174T with VDA treatment (n = 3). The main focus of this 
study was to assess the acute changes, however, in addition, a few mice were imaged over 
five days following the OXi4503 treatment.  
4.5.3 In-situ VDA Response MRI Protocol 
A primed intra-venous (i.v.) line was set up in the tail vein of the mouse, and secured in 
place for an in-situ administration of the vascular disrupting agent OXi4503. Baseline 
perfusion and previously optimised R2* measurements were performed before 
administering 40mg/kg OXi4503 or saline via the i.v. line. R2* imaging followed immediately 
up to 90 min post-dose, followed by an ASL acquisition at 90 minutes; this scan time had 
been determined due to the local limitations of small-animal imaging, so the animals may 
recover for potential longitudinal measurements. In addition, previous literature has 
reported a 50% reduction in blood flow within an hour following OXi4503 (31).   
4.5.4 MRI Methods & Analysis 
Values of the MRI transverse relaxation rate (R2*) were estimated from a respiratory-gated 
multi-echo, multi-slice gradient echo sequence. Sequence parameters included: 8 echoes, 




slices, and slice thickness 1mm. R2* was estimated using a maximum likelihood approach 
that took into account the Rician distribution of the data (32). 
Paired t-tests (Wilcoxon) were performed on metastases and internal controls of normal-
appearing liver, before and after in-situ dose for both perfusion and R2* measurements. 
Longitudinal changes were analysed by normalising each tumour to its baseline value and 
differences between the days were assessed using Kruskal-Wallis analysis. 
Liver and metastasis volumes were manually segmented using Amira 5.4 (FEI, Oregon, 
USA). Tumour locations were manually assessed on the high-resolution T2 weighted images 
and divided into three categories: a) peripheral, b) near small, and c) near large vessels. The 
limit to the tumour’s proximity to major vasculature was defined as 3-4 voxels (0.5 mm) for 
both small and large vessels. Venous and arterial blood vessels appear hypo-intense on the 
T2-weighted image and small vessels were categorized by a cross sectional area less than 
0.1 mm2 (around 7-8 voxels). The perfusion and R2* differences between the location 
categories were analysed using Kruskal-Wallis ANOVA comparisons. 
Across the cohort of animals, for the SW1222 + VDA 18 metastases were evaluated from 
the single-slice ASL data and 34 metastases were assessed by IS-MRI data, 12 metastases 
were assessed for the LS174T + VDA by ASL and IS-MRI, and 10 metastases were assessed 
for the SW1222 + saline for both ASL and IS-MRI.  
4.5.5 Results: Acute R2* and Perfusion Changes 
4.5.5.1 Response to OXi4503 
Pre-treatment tumours showed variable baseline measurements of perfusion and R2*; a 
heterogeneous response to OXi4503 was observed in both ASL and IS-MRI techniques as 
can be seen in an example SW1222 model in Figure 4.40. Baseline measurements for 
perfusion (top) and R2* (bottom) have been overlaid on the T2-weighted anatomical image. 
The highlighted tumour demonstrates the expected response post-treatment; the perfusion 




Figure 4.40: Image data showing the acute response at 90 minutes to 40 mg/kg of OXi4503, assessed 
using perfusion measured by hepatic arterial spin labelling (A) and intrinsic susceptibility MRI (via the 
R2* parameter) (B). Images are overlaid on high resolution T2-weighted axial anatomical data, in 
which tumour deposits appear hyperintense relative to liver parenchyma. A heterogenous response 
to OXi4503 therapy was observed across the metastases. One tumour has been highlighted to show 
the regional response.  
The changes within the different groups as detected by ASL and IS-MRI can be seen in Table 
4.2; the percentage changes for the liver have been included as an internal control. The 
results show that a significant decrease in perfusion was detected in SW1222 metastases 
for both treated and control groups, and a non-significant increase was measured in the 
treated LS174T tumours. In general, the liver perfusion decreased following the systemic 
administration, though non-significantly. A varied response was seen with the R2* across all 
the groups, a significant change was measured with the VDA-treated LS174T tumours, and 








Table 4.2: Absolute (perfusion in ml g-1 min-1, R2* in ms-1) and percentage change (mean ± std) of 
SW1222 metastases treated with OXi4503 (n = 6), LS174T metastases treated with OXi4503 (n = 3) 
and SW1222 metastases given a saline control (n = 5). The internal control of the liver has been 
included for each group. Stars denote the significance determined by paired Wilcoxon t-tests (* p < 
0.05, ** p < 0.01, *** p < 0.001).  
4.5.5.2 Correlation of Perfusion and R2* Changes with Baseline Measurements 
Figure 4.41 shows the potential predictive nature of baseline perfusion measurements by 
ASL; acute changes for perfusion and R2* taken 90 minutes post i.v. injection of OXi4503 
can be observed relative to the baseline measurement for both SW1222 and LS174T 
tumours. A significant linear correlation (R2 = 0.76, p<0.001 Pearson’s R) for SW1222, 
though non-significant (R2 = 0.18, p >0.1) for the LS174T was found between the baseline 
and the change in tumour perfusion after administration of the vascular disrupting agent 
(Figure 4.41, top row). However, no corresponding correlation was observed between 
baseline R2* and subsequent change in intrinsic susceptibility after OXi4503 (Figure 4.41, 
row R2*). No significant correlation (p > 0.1) was measured between the changes in 
perfusion and the change in R2* at 90 minutes following OXi4503 administration. 
SW1222 + OXi4503 LS174T + OXi4503 SW1222 + Saline
Tumours -0.49 ± 0.44 0.04  ± 0.23 -0.17  ± 0.31
% -43 ± 33 % *** 61 ± 152 % -16 ± 39 % *
Liver -0.35  ± 0.28 -0.14  ± 0.45 -0.54  ± 0.28
% -12 ± 12 % -10 ± 27 % -26 ± 15 %
Tumours 0.005 ± 0.028 0.013 ± 0.012 0.011 ± 0.016
% 0 ± 26 % 28 ± 25 % *** 6 ± 10 %
Liver 0.012 ± 0.010 0.016 ± 0.010 0.008 ± 0.012







Figure 4.41: Graphs showing the relationship between pre-therapy perfusion and R2* in SW1222 and 
LS174T liver metastases, and the subsequent change in each parameter at 90 minutes following 
administration of 40 mg/kg OXi4503. A significant, negative correlation was found between pre-
therapy and post-therapy vascular perfusion (SW1222: R
2
 = 0.76, p<0.001 Spearman’s rho, LS174T: 
R
2
 = 0.78, p<0.001 Spearman’s rho), although no such correlation was found for R2*. A graph of the 
change in R2* against the change in perfusion (C) showed no significant correlation (p=0.19, 
Spearman’s rho), however a suggestion of a negative trend can be discerned, in conjunction with the 
expected behaviour. 
4.5.5.3 Relationship between response and tumour location 
In Figure 4.42A, three example tumours have been outlined as classified by their proximity 
to large vessels (>8 voxels, red), small vessels (<8 voxels, green) and distal (>4 voxels, blue) 
to vasculature - typically located at the periphery of the liver lobe. Figure 4.42B shows a 
manually-segmented 3D rendering of an example mouse liver from T2-weighted FSE MRI 
data, in which the liver parenchyma can be seen in transparent red, the major vasculature 
in purple, metastases in yellow and the tumours have been coloured according to their 
classification.  
Figure 4.42C shows the percentage changes in SW1222 tumour perfusion (red, green and 
blue outline) and R2* (solid red, green and blue) at 90 minutes post OXi4503 when liver 
metastases were grouped according to their location. This analysis was not performed in 
the LS174T tumours due to the low number of tumours.  
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Tumours close to major vasculature were better perfused at baseline (p < 0.05, Kruskal-
Wallis ANOVA): 1.5 ± 0.8 mlg-1min-1 (mean ± standard deviation), 1.3 ± 0.7 mlg-1min-1, 0.6 ± 
0.3 mlg-1min-1 for locations 1), 2) and 3) respectively. No significant differences in perfusion 
reduction were measured between the groups (p > 0.1, Kruskal-Wallis ANOVA), though the 
data suggests that the largest perfusion decreases can be observed in metastases proximal 
to vasculature. The most consistent mean decrease in perfusion was observed in 
metastases proximal to large vessels (-62% ± 19%, mean ± standard deviation), whereas a 
more varied decrease in blood flow was seen in tumours near smaller vessels (-36% ± 51%). 
Tumours in the periphery of the liver lobe displayed a smaller but largely variable response 
in perfusion (-32% ± 25%).  
No significant differences (p > 0.05, Kruskal Wallis ANOVA) were measured between 
baseline R2* measurements: 0.11 ± 0.05 ms
-1, 0.27 ± 0.14 ms-1, 0.21 ± 0.11 ms-1 for locations 
1), 2) and 3) respectively. No significant differences were measured in R2* response post-
OXi3403 as grouped by location (p > 0.15, Kruskal Wallis). Metastases in all locations 
behaved inconsistently for R2* (large vessel 16% ± 26% (mean ± standard deviation), small 
vessels -13% ± 29%, and periphery -4% ± 20%).  
This heterogeneous response to therapy has been observed in H&E histology (Figure 
4.42D): a necrotic centre is observable in some tumours (arrows) where other metastases 
in the same lobe have seemingly not responded (stars).  However, histology was not 
directly paired to the MRI data as it is difficult to follow single tumours from the MRI to the 
histology due to the malleable and lobular nature of the liver. As all animals were followed 
longitudinally, the results of which are reported below, the earliest histology was taken at 




Figure 4.42: (A) Example determination of tumour location into three categories: proximal (< 0.5mm) 
to large vessels (> 0.1mm
2
) (red), small vessel (green), and peripheral to vasculature (blue). 
Vasculature appears hypo-intense on T2-weighted images, and example vessels have been 
highlighted with an arrow. (B) A 3D visualisation of a manually-segmented mouse liver at week 5 
post-implantation, showing liver parenchyma (transparent red), major vasculature (purple) and 
metastases have been coloured as classified by their location. (C) Percentage change in perfusion 
and R2* at 90 minutes following administration of 40 mg/kg of OXi4503, categorised according to 
proximity to vessels and location within the liver (see colour bar). Large perfusion decreases were 
observed in metastases close to large and small blood vessels though tumours near smaller vessels 
demonstrated a more variable response. Peripheral metastases did not display a significant change 
in perfusion. No significant changes were measured in R2* across the defined liver locations. (D) H&E 
histology at 24 hours shows a varied response of OXi4503 to a model of liver metastases – successful 
administration in tumours exhibit a necrotic core (arrows) and unaffected deposits have viable cells 
(stars). 
4.5.6 Longitudinal Monitoring 
The OXi4503-treated mice with metastases were monitored at 24 hours (n = 5 SW1222, n = 
3 LS174T), 72 hours (n = 3 SW1222, n = 2 LS174T) and at 120 hours (n = 2 SW1222, n = 2 
LS174T) post administration; the saline-SW1222 mice were not followed longitudinally. 
However, due to the single slice hepatic ASL acquisition and the flexible nature of the 
arrangement of the liver lobes, it was difficult to capture consistent tumours within a single 
acquisition. As a result, in combination with animals being taken for longitudinal 
assessment by histology, it was difficult to maintain the number of tumours for analysis for 
longitudinal monitoring. The changes in mean tumour perfusion and R2* (with standard 
error), normalised to baseline, over 5 days can be seen for both SW1222 (Figure 4.43A) and 
LS174T (Figure 4.43B) cell lines. Visual inspection of the graphs suggest that both cell lines 
exhibit the expected decrease in tumour perfusion and increase in R2* at 24 hours post 
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treatment, however, no significant differences were found between days in either cell line 
or either MRI derived quantity (SW1222 perfusion p > 0.15, SW1222 R2*p > 0.9, LS174T 
perfusion p > 0.5, LS174T R2* p > 0.4, Kruskal Wallis ANOVA). In addition, analysis of the 
SW1222 tumour cells and corresponding normal-appearing liver T1 (Figure 4.43C) showed 
no significant changes over time in the liver (Kruskal-Wallis ANOVA p > 0.1), however, a 
significant reduction in tumour T1 was found at 120 hours (Kruskal-Wallis ANOVA p < 0.01). 
This result is in accordance with previous pre-clinical research which observed a reduction 
in T1 following therapy, hypothesised to reflect the number of remaining viable tumour cells 
(33).  
 
Figure 4.43: Normalised longitudinal changes of perfusion (blue) and R2* (red) for SW1222 (A) 
LS174T (B) cells following OXi4503. No significant differences were found between baseline, 24 
hours, 72 hours and 120 hours following therapy with either MRI-derived parameter. (C) A significant 
reduction was measured in SW1222 tumour longitudinal relaxation following OXi4503 treatment, 
though no changes were measured in the liver.  
4.6 Discussion: Application of FAIR ASL to Liver Tumour Models 
This was a novel measurement of perfusion within a model liver metastases using ASL MRI; 
blood flow differences between tumour and liver parenchyma were measured that 
reflected the histology. The correlation between baseline SW1222 perfusion measurements 
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and post-VDA response provides evidence towards the accuracy of the ASL measurement, 
in addition to the acute efficacy of the treatment. Thus FAIR-LL may offer a robust measure 
for clinical assessment of VDA therapy, furthermore, the correlation found suggests that a 
diagnostic perfusion measurement may inform on the therapy approach.  
The FAIR sequence was first applied to a model of subcutaneous tumours, and a low level 
of perfusion was measured, as previous reports have shown, though in different cell lines 1 
(21, 22). The low perfusion signal may be improved by increasing the averaging, by using a 
faster imaging readout such EPI (14). As the subcutaneous tumours are stationary, and are 
fixed in place by use of a dental fixative, the advantages of image rejection using a Look-
Locker readout are potentially superfluous. 
The significant decrease in saline-administrated SW1222 tumours and large, though non-
significant, percentage increase VDA-treated LS174T perfusion is most likely due to 
variability in the low baseline perfusion measurements: 0.3 ± 0.2 ml g-1 min-1 (LS174T), 0.6 ± 
0.5 ml g-1 min-1 (SW1222 + saline) and 1.0 ± 0.7 ml g-1 min-1 (SW1222 + VDA). From Chapter 
3.5, the variability in perfusion was measured to be ± 0.3 ml g-1 min-1, so the treated LS174T 
and saline SW1222 perfusion values are approaching the lower limit of the sensitivity of the 
technique, and percentage variations can be amplified. Excluding LS174T metastases which 
exhibit a perfusion less than this threshold, the percentage change is still non-significant, 
but reduced to 13 ± 89 %.  
The measurement perfusion decrease of treated-SW1222 tumours did not correspond to 
an increase in R2*, which has been previously reported, though not in SW1222 cell line (34). 
The LS174T tumours exhibited a slower baseline R2* (0.047 ± 0.004 ms
-1) compared to VDA-
treated SW1222 (0.132 ± 0.062 ms-1) and saline-administrated SW1222 tumours (0.144 ± 
0.017 ms-1). A faster R2* can be due to a number of factors, but suggests that there is a 
native raised susceptibility, possibly due to the content of deoxyhaemoglobin (34). 
However, as a hypoxic environment has been previously reported within the LS174T 
tumours, this result will need further investigation.  
Bland Altman repeatability coefficients (35) calculated in the previous chapter for hepatic 
FAIR-LL determined the minimum percentage change for significance within the same 
session as 18% for the ASL technique. A separate test-retest dataset was carried out (data 
not shown) for the IS-MRI sequence, which estimated the within-session repeatability 
coefficient to be 17%. Using these values, a significant change in perfusion was detected in 
the OXi4503-treated SW1222 and LS174T tumours. However, the repeatability analysis may 
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have to be repeated in tumours, as they exhibit a reduced perfusion. The between-session 
repeatability measurement will be of particular interest for longitudinal monitoring 
following therapy.  
A limitation of the tumour blood flow quantification is that it assumed the liver’s blood-
tissue partition coefficient – however previous ASL methods assumed a λT of 1 (14), and 
other invasive measurements vary from 0.46 – 0.96 (21, 22) which may induce a difference 
to the perfusion estimate. However measurements of the partition coefficients are highly 
invasive and not trivial.  
The multi-parametric imaging approach used in this study showed that these 
complimentary measures can aid understanding of the tumour micro-environment: the R2* 
values did not change where the perfusion decreased in the treated SW1222 tumours, and 
the R2* did increase in the originally low-perfused LS174T tumours. The induced changes in 
perfusion and R2* were not significantly correlated. This lack of correlation may be due to a 
complex pathophysiological relationship between changes in perfusion and changes in 
blood oxygen saturation following VDA therapy. 
Further histological evaluation is necessary to determine the role of tumour and vessel 
proximity, according to our classifications. Previous anti-CEA targeted therapy reported a 
better uptake in large peripheral tumours rather than centrally located tumours, which are 
likely to be nearer large vessels (10). However this contrasting conclusion may be due to 
the larger tumours generally showing an increased uptake and the mechanism of targeting 
being different. A previous clinical trial of a combretastatin-based VDA reported 
heterogeneity in the treatment response but did not group the response by location in the 
liver (29). 
This study showed a lot of promise of FAIR-LL ASL being applied to mice models of liver 
cancer, and the technique has the potential to be included in to future studies to assess the 
tumour viability though perfusion. The FAIR-LL sequence was then applied to a rat model of 
cirrhosis in order to detect the expected decreases in perfusion.   
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4.7 Application of FAIR-LL to a Rat Model of Liver Cirrhosis 
4.7.1 Introduction 
Reduced liver perfusion in patients with cirrhosis has been characterised by contrast CT 
measurements (36), as well as recent clinical liver ASL techniques (37, 38). These 
measurements of liver perfusion using ASL-MRI were additionally performed alongside 
portal flow measurements using phase-contrast (PC) MRI which characterised post-prandial 
blood-flow differences between cirrhotic and healthy livers. This next section investigates 
the application of the FAIR-LL sequence alongside phase-contrast MRI to a rat model of 
liver cirrhosis – pre-clinical liver perfusion measurements of cirrhosis using ASL has not 
been previously reported, and there are limited examples of flow quantification using DCE-
MRI. First, the two techniques estimates of liver perfusion will be compared in healthy rat 
livers, following this, their sensitivity to reduced blood flow in liver dysfunction will be 
investigated.  
4.7.2 Methods 
4.7.2.1 Cirrhosis Model 
Male Sprague-Dawley rats, weighing 250-300g, were randomised to bile-duct ligation (BDL) 
procedure (n = 12) or sham laparotomy (n = 13).  BDL and sham surgery was conducted as 
described previously (39): a midline abdominal incision was made under 2% isoflurane and 
intraperitoneal levobupivacaine in both groups.  For animals undergoing BDL procedure, 
the common bile duct was isolated, triply ligated with 3-0 silk and sectioned between the 
ligatures.  After closure and recovery, BDL animals were maintained for 5 weeks to allow 
the development of portal hypertension and features of cirrhosis. 
4.7.2.2 FAIR-LL ASL MRI 
Rats were positioned prone within the bore of the scanner with physiological monitoring of 
the ECG, respiratory rate and temperature. A respiratory-gated, 2D, GE sequence was used 
to plan ASL and phase-contrast imaging. Perfusion was measured by the respiratory-
triggered, segmented FAIR Look-Locker ASL sequence with the same Look-Locker readout 
parameters as in Chapter 3.6. Images were acquired with a 2 mm slice thickness, matrix 128 
x 128, and FOV 65 x 65 mm2. A 9 mm slice selective inversion was interleaved with global 
inversions to acquire the FAIR data. The PENIR algorithm was used to correct for motion 
artefacts and the Belle model was applied for quantification.  
Mean perfusion of each subject was calculated from two users, blinded to the group, 
placing three circular ROIs on separate areas of the liver devoid of any blood vessels.  
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4.7.2.3 Phase Contrast MRI 
A subtractive methodology had been previously validated in-house to estimate total liver 
bulk flow, and hepatic arterial fraction. Respiratory-gated 2D PC-cine sequence (Chapter 
2.5) was carried out using the following methodology. Within the imaging software, three 
markers were positioned in the vessel lumen of axial images for automated planning of 
scanning slices to ensure slice othorgonality to the blood vessels (VnmrJ 3.2, Agilent, 
Oxford, UK).  Two separate positions were imaged in order to estimate total liver perfusion; 
the inferior liver with both the portal vein (PV) and inferior vena cava (IVC) within the slice, 
and imaging the IVC at the superior liver, before it returns to the heart. The total liver blood 
flow (TLBF) was extracted from the difference in the IVC flows before and after the 
contributions of the liver outflow, assuming a steady state of flow within the liver. The 
portal venous contributions can be directly measured from the portal vein, and this value 
can be subtracted from the TLBF to estimate the contribution of the hepatic artery (HA) - as 
this vessel is generally too small for the applied resolution. The hepatic perfusion index 
(HPI) was estimated as the hepatic arterial flow normalised to the TLBF. 
Phase contrast cine parameters: 2 mm slice thickness, TR 10 ms, TE 1.2 ms, 20° flip angle 
and a 128 x 128 acquisition matrix, minimum of ten frames throughout the cardiac cycle, 2 
averages; one PC-MRI dataset took 10-15 minutes to acquire. Data were acquired using a 
venc settings of 33 cm/s for PV and inferior IVC flows, 66 cm/s for superior IVC flows. Bulk 
flow of each vessel was quantified integrating the velocities over the cardiac cycle, and 
estimations of PV, TLBF and HA bulk perfusion were normalised to explanted liver weight. 
Data were analysed using in-house developed MATLAB code. For comparison with the bulk 
flow estimates, ASL perfusion was calculated in units of ml 100 g-1 min-1. 
4.7.3 Results 
4.7.3.1 Comparison of HASL to PCMRI estimates of liver perfusion 
An example, mid-liver phase contrast MRI dataset can be seen in Figure 4.44A & B. From 
the gradient echo readout (Figure 4.44A), the major vasculature appears hyper-intense and 
has been labelled on the image. From the resultant phase-contrast data (Figure 4.44B), 
coherent signal can be seen at the location of the blood vessels – the descending aorta has 
a negative polarity due to the flow running anti-parallel to the IVC, PV and HA. An example 
hepatic ASL dataset is shown in Figure 4.44C & D; bright regions corresponding to the 
vasculature in the gradient-echo anatomical scan (Figure 4.44C) align with high, non-
physiological regions of flow in the perfusion map (Figure 4.44D). A relatively homogeneous 
perfusion signal can be seen across the liver parenchyma.  
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Mean perfusion measured in the sham-operated rat with FAIR ASL was 317 ± 84 ml 100g-1 
min-1 and total bulk flow estimated by the PC-MRI measured 444 ± 119 ml 100g-1 min-1. 
Bland-Altman analysis (Figure 4.44E) comparing the bulk perfusion estimated by PC-MRI 
and the mean perfusion from the ASL exhibit no magnitude dependence, though a 
significant mean difference  was measured of 127 ± 71 ml 100g-1 min-1; p < 0.01 (paired t-
test). Previous literature using invasive techniques has shown rat liver perfusion to be 
between 190 – 240 ml 100g-1 min-1 (40-42), suggestive that the PC-MRI is overestimating 
the total bulk flow. However, the limited optimisation of the FAIR technique in the rats may 
be influencing this discrepancy; this will be further discussed later. In addition, an outlier 
can be seen in Figure 4.44E, which can be caused by low perfusion measurements due to 




Figure 4.44: Comparison of phase contrast MRI and FAIR-LL ASL measurements applied to liver 
perfusion. (A) Example GE magnitude image of the PC-MRI. The vasculature appears bright, and the 
descending aorta (DA), inferior vena cava (IVC), portal vein (PV) and hepatic artery (HA) have been 
labelled. (B) In the corresponding phase contrast image coherent signal can be seen at the vessel 
loci; the HA is much more apparent as a smaller vessel next to the PV, and the DA is flowing in the 
opposite direction. (C) Reference GE image, the vasculature appears hyper-intense relative to the 
liver (outlined) and its corresponding perfusion map (D). As with the mice, a high flow can be seen at 
the location of the blood vessels, and a heterogeneous signal is apparent across the liver 
parenchyma. (E) Bland-Altman analysis comparing perfusion estimates shows no trend, a mean 




 was measured, suggestive of an over-estimation of the PC-
MRI.  
4.7.3.2 ASL and PC-MRI perfusion measurements of cirrhosis 
Experiments were performed in sham operated (n = 11) and BDL (n = 11) rats.  Four weeks 
post-surgery, mean BDL body weight (403 ± 14 g) was significantly lower than mean sham 
body weight (463 ± 7 g; p < 0.001).  Conversely, mean BDL wet liver mass (30 ± 2 g) was 
significantly higher than mean sham wet liver mass (14 ± 1 g; p < 0.0001). Problems with 
prospective inversion triggering resulted in poor quality ASL data for two BDL and one sham 
operated subject.  Final analysis was performed using data from ten sham operated and 
seven BDL rats. 
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The hepatic ASL technique did not measure any significant perfusion differences between 
sham (317 ± 84 ml 100g-1 min-1) and cirrhotic (302 ± 64 ml 100g-1 min-1) animals (p > 0.7, 
Mann Whitney-U), though the PC-MRI measured a significant decrease (p < 0.005, Mann 
Whitney-U) between sham (444 ± 119 ml 100g-1 min-1) and cirrhotic bulk perfusion (211 ± 
113 ml 100g-1 min-1) (Figure 4.45A). There was no significant change (Mann Whitney U, p > 
0.3) in the subtracted PC-MRI estimated arterial contributions: HPIsham 38 ± 6 %, HPIcirrhotic 41 
± 8 %. From the PC-MRI estimates of portal venous flow, a reduced portal bulk flow was 
observed in the BDL group (114 ± 51 ml 100g-1 min-1), compared to sham rats (273 ± 90 ml 
100g-1 min-1), indicative of portal hypertension.  
Baseline T1 measurements taken from the global inversion maps were compared in sham (n 
= 10) and BDL (n = 7) rats.  Baseline mean hepatic parenchymal T1 in BDL animals (1523 ± 43 
ms) was significantly higher (p < 0.001, Mann Whitney-U) than in  sham operated animals 
(1266 ± 17 ms) (Figure 4.45B). 
 
Figure 4.45: (A) Mean group-wise perfusion as estimated by ASL (grey) and PC-MRI (black); no 
significant differences were measured by ASL whereas PC-MRI measured a reduced perfusion in the 
cirrhotic animals. (B) Mean parenchymal T1 as measured using the FAIR technique showed a good 
sensitivity to the onset of cirrhosis.  
4.7.4 Discussion 
This research compared a novel measurement of bulk liver perfusion from phase contrast 
measurements and total liver perfusion using FAIR-LL ASL in rats. A significant 
overestimation was measured in the PC-MRI measurement relative to ASL in healthy livers 
relative to previous literature using invasive techniques which has shown rat liver perfusion 
to be between 190 – 240 ml 100g-1 min-1 (40-42). However, the PC-MRI estimation of 
hepatic arterial fraction showed good correlation with the microsphere validation (data not 
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shown), suggestive that this technique may be producing a systematic overestimation in 
total liver bulk flow. 
The PC-MRI method detected significantly lower TLBF in the cirrhotic animals; however, no 
such reduction was detected using ASL. This may be due to the large cirrhotic rats 
weighting limiting bandwidth of inversion pulse due to the coil loading. Thus the labelling 
efficiency may have been highly variably between animals, thus confounding accurate 
perfusion quantification using the ASL method. The typical inversion bandwidth used in this 
study was 4000 Hz. Whereas previous work on the same system showed that a bandwidth 
of >10,000 Hz was required for robust inversion at 9.4T (43). Furthermore, the resultant 
large inversion pulse and gradients often caused a pressure spike in the respiratory bellows, 
and would disrupt the gating. 
Where the TLBF subtractive technique has shown its sensitivity to reduced flow in this 
disease state, the advantage of ASL is its potential ability to spatially map localised areas of 
dysfunction. In addition, as a by-product of the T1 mapping in the FAIR sequence, the 
cirrhotic livers exhibited a significant increase in global longitudinal relaxation, due to raised 
tissue inflammation (44). Future work can include T2* measurements to detect iron 
accumulation as this MRI parameter has been shown to alter in cases of fibrosis (45). In 
addition, as the presence of iron can reduce T1, T2* measurements could account for 
reduced potential longitudinal changes. 
A large shortcoming of the FAIR-LL technique in rats was that the sequence parameters 
were not extensively optimised for the larger animal. The slice thickness was doubled to 
accommodate the larger anatomy and gain SNR in the readout, and the slice-selective 
inversion thickness was adjusted to 9 mm following some preliminary investigations (data 
not shown). In addition, alternative methods of perfusion quantification to the Belle model 
can be explored to improve on the values estimated here. 
The phase-contrast technique had been previously validated against an invasive transit 
ultrasound technique and found a good correlation between the portal flow 
measurements, suggestive that the subtraction method of estimating TLBF may require 
further investigation. In addition, microsphere data showed a slight increase in HPI for the 
cirrhotic group, in correspondence to the phase-contrast MRI. Microsphere analysis wasn’t 
extensively carried out to measure total liver blood flow, as such invasive experiments have 
many potential pitfalls for estimating perfusion such as aggregation leading to a poor 
mixing and distribution and complications of optical quantification (46).   
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Despite some disagreement with the PC-MRI and FAIR-LL in absolute blood flow, these two 
techniques could be used in the future to respectively estimate the contributions of the 
blood vessels in disease-state livers and regional maps of liver perfusion. The relation of 
vascular inputs in liver dysfunction can be further examined by altering the portal venous 
contribution by vasoconstrictors such as Terlipressin (47), and increased post-prandial flow; 
in the healthy liver, a reduced flow will be compensated by the hepatic arterial buffer 
response (HABR) (38, 48).  
4.8 Application of FAIR-LL to a Model of Stimulated Liver Growth 
4.8.1 Introduction 
Hepatic resection candidates require only 25% of their functional liver, however for 
patients with hepatic dysfunction or damage due to chemotherapy, the advised future liver 
remnant (FLR) is around 40% (7), which may be unachievable. Recently, the FLR was 
reported to increase by 10-46% within 6-8 weeks following a selective portal venous 
ligation and dissection procedure (8). The insult due to the reduced perfusion and 
subsequent atrophy causes neighbouring lobes to enlarge, and a dissection along the 
falciform ligament has been demonstrated to cause a rapid growth of the left lateral lobe. 
However, so far in this experimental procedure, little has been done to characterise the 
functionality of the enlarged liver lobes, asides from histological assessment from post-
surgery biopsies. Perfusion measurements may offer an assessment of liver functionality, 
and in addition, contribute to understanding the mechanism of the liver regeneration (9).  
In this pilot study, MRI was used to assess a rat model of stimulated liver growth following 
selective ligation of two portal venous branches. As lobes downstream to the selective 
ligation would have reduced portal flow, the neighbouring lobes may have a resultant 
raised perfusion (9) which has been theorised to drive the subsequent hyperplasia. High 
resolution MRI was used to monitor the volumetric changes to the liver lobes, and in 
addition, hepatic arterial spin labelling was used to assess lobular changes in hepatic 
function as determined by liver perfusion.  
4.8.2 Methods 
4.8.2.1 Rat Model 
A schematic of the surgery for the model can be seen in Figure 4.47A. Two male Sprague-
Dawley rats (300 – 400g) were anesthetised and the portal vein branches to the left lateral 
lobe (LLL, red), left median lobe (LM, white) and right lobes (R, yellow) were selectively 
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ligated following a mid-line incision. This model was designed so that the neighbouring right 
median (RM, green) and caudate lobes (C, blue) would enlarge to account for the insult to 
the liver.  
4.8.2.2 MRI Protocol 
Surgery was performed on day 1, rats were imaged at day 2, day 5 and day 7. A high 
resolution, respiration gated, multi-slice Fast Spin Echo (FSE) sequence was used to image 
the whole liver. Sequence parameters: slice thickness 0.75 mm, FOV 65 x 65 mm2, matrix 
size 192 x 192, effective TE = 19 ms, k0 = 3, ETL 4, TR = 200.  
For the superior slices nearer the heart, a separate FSE sequence which included cardiac 
gating was used. The improved effects of cardiac gating the superior slices can be seen in 
Figure 4.46; respiratory gating was insufficient to delineate the liver lobes and vessel 
structures (Figure 4.46A). Using a multi-slice, cardiac-triggered FSE, the motion artefacts are 
considerably reduced, though blurring was still visible using too long an echo train length 
(Figure 4.46B), an optimal imaging was found using an echo train length of 2, with an echo 
spacing of 7.5 ms, to maintain a similar contrast (Figure 4.46C).  
Following the anatomical imaging, the FAIR-LL sequence (parameters the same as for the 
cirrhotic rats) was planned on a slice which contained the RM, C, R and LLL. 
 
Figure 4.46: Effects of cardiac gating 2D FSE anatomical imaging of the superior liver. (A) 
Representative image with respiratory gating only, motion artefacts and signal loss are common due 
to cardiac motion. (B) Cardiac triggered image with an echo train length of 4 (echo spacing 7.5 ms); 
the image is more coherent but still presents some blurring. (C) Cardiac triggered FSE with an echo 
train length of 2 presents an optimal image clarity for delineating liver and blood vessel structures.  
4.8.2.3 Data Analysis 
Livers were segmented by two experienced pre-clinical liver MR imaging experts using 
Amira (FEI, Oregon, USA). Percentage volume changes of each lobe were calculated by 
normalising the segmented volumes to a weight-matched, control rat which underwent the 




It was observed while segmenting the FSE data that the ligated lobes exhibited a relatively 
hypo-intense signal to the non-ligated lobes (Figure 4.47B). This intrinsic contrast facilitated 
lobe delineation, and an example 3D visualisation of a segmented liver at day 2, 5 and 7 can 
be visualised in Figure 4.47C. The livers have been arranged in an axial orientation, from an 
inferior perspective. From visual inspections, a marked increase in right median (RM, green) 
and the caudate lobes (C, blue) can be observed alongside shrinkage of the left lateral lobe 
(LLL, red) and the right lobe (R, yellow). The portal vein ligation induced an expected 
atrophy in the LLL and R over the 7 days, while promoting hypertrophy in the RM and C 
(Figure 4.47D). A significant difference was measured between the ligated and non-ligated 
volume changes at day 7 (p < 0.05, Mann Whitney-U). Percentage volume changes relative 
to a weight-matched liver at day 7 were 95 ± 1 % (RM), -35% ± 16 % (LLL), 52 ± 4 % (C), -51 ± 
15 % (R).  
The corresponding perfusion map of the segmented lobes from Figure 4.47B can be seen at 
Figure 4.47E – a lower level of perfusion can be seen in the ligated lobes. No trend was 
shown in lobe perfusion (data not shown) over the week, however a significant (p  < 0.001, 
Mann Whitney-U) mean perfusion deficit was observed in ligated lobes (1.6 ± 0.6 mlg-1min-
1) relative to non-ligated lobes (2.8 ± 0.4 mlg-1min-1) averaged over the three time points 
(Figure 4.47F).  
4.8.4 Discussion 
In this pilot study, we have demonstrated FAIR-LL ASL applied to a model of selective portal 
ligation as means of determining viable liver tissue, as assessed by perfusion, in order to 
non-invasively improve on volumetric assessment of future liver remnant. We show in this 
model that the right median lobe almost doubled in volume 1 week post-surgery. This rapid 
regeneration will be greatly beneficial to resection patients by ensuring these patients have 
an adequate post-resection liver volume, in addition to reducing waiting time prior to 
hepatectomy.  
Typically, the portal vein supplies around 75% of the blood to the liver (49); however an 
approximate 40% difference in perfusion was measured in lobes with a ligated portal 
supply, relative to the un-ligated lobes – this may be due to the hepatic arterial buffer 
response, which can accommodate reduction in portal venous flow7. Though the ligated 
lobes perfusion may be higher than expected, these results demonstrate that the FAIR-LL 
technique is sensitive to perfusion changes in rats. The PC-MRI estimated an approximate 
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50% reduction in bulk flow in the cirrhotic livers but, this was not detected with the FAIR 
ASL, thus further work is needed to validate the perfusion measurements. Phase-contrast 
MRI wasn’t used in this study as the technique’s estimation of bulk perfusion would not 
offer regional information on the blood flow in each lobe. Future work may explore the 
suitability of the perfusion as a measure of tissue viability by comparison to hepatocyte-
targeting contrast agents which estimate liver function (50). 
Previous clearance measurements of rat livers have measured lobe perfusion at 2.41 mlg-
1min-1 (51): the hypertrophic lobes display a slight raised perfusion from this value and the 
atrophic lobes show an expected reduction of blood delivery. This may support the theory 
that an increased perfusion will drive the rapid hyperplasia (9), but further investigations 
will be needed to explore this. The level of perfusion within the atrophic lobes is potentially 
higher than expected following cessation of the portal supply. Previous ‘functional-MRI’ of 
rat livers following total portal ligation measured a 20% change in inferred arterial blood 
flow (52), though magnitude of change would not account for the 1.6 ± 0.6 mlg-1min-1 
measured in the atrophic lobes. The role of ASL has been highlighted in this study in 
application to post-operation patients, as perfusion measurements may inform surgical 





Figure 4.47: Stimulated growth and perfusion differences in a ligated liver: (A) Schematic of a rat liver 
shows the location of the selective ligation (red blocks) on the portal branches leading to the left 
lateral lobe (LLL, red) and the right lobe (R, yellow). This insult to the liver promotes growth in the 
right median (RM, green) and the caudate (C, blue) lobes. This colourscheme is maintained 
throughout this figure. (B) An example T2-weighted FSE image of the rat liver, post-ligation lobe 
segmentation (lobes have been outlined and labelled) was facilitated by a relative hypo-intensity of 
the ligated lobes. (C) Example 3D visualisation of the lobe growth and shrinkage over one week and 
correspondng bar graph (D) of each lobe’s respective volume changes. (E) Perfusion map 
corresponding to the FSE image; a reduced perfusion can be seen in the ligated lobes. (F) A 




In this chapter the FAIR-LL sequence optimised in the Chapter 3 has been applied to two 
animal models of hepatic disease and a pilot study of hepatic intervention. We have 
combined intrinsic susceptibility (IS) MRI and arterial spin labelling (ASL) to produce a novel 
multi-parametric measurement of blood flow changes in liver metastases following vascular 
disrupting agent therapy. We found that hepatic ASL provided an assessment of response 
to OXi4503 that is more directly associated with the mechanism of action compared to IS-
MRI, and showed a correlation in well-perfused tumours with pre-therapy perfusion and 
the subsequent change 90 minutes following administration of the drug. The hepatic ASL 
technique was then compared with a non-invasive estimate of bulk liver perfusion from 
blood velocity measurements from phase contrast MRI in application to a rat model of liver 
cirrhosis. Though the PC-MRI was suggestive of an overestimation of bulk perfusion, it was 
sensitive to a perfusion deficit in the cirrhotic animals, whereas the ASL was not. Finally, the 
FAIR-LL sequence was applied to a rat model of stimulated liver growth, and measured an 
expected perfusion difference between ligated and control lobes, whilst the anatomical 
MRI measured accelerated volume changes in the lobes.  
The PC-MRI technique used in the cirrhotic rat study offered an insight in to separately 
measuring the respective contributions of the portal vein and hepatic artery, albeit using a 
subtractive method. The next chapter will investigate improving this measure of relative 
bulk arterial and portal perfusion estimates, by implementing a vessel-selective pseudo-
continuous ASL sequence to the mouse liver. The advantage of such an ASL technique is 
that it offers a direct measure from each vessel and a voxel-wise map of the relative 
perfusion can be produced. As the hepatic vessels’ contributions vary in disease and 
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Feasibility of pre-clinical hepatic 
pseudo-Continuous ASL 
This chapter reports on the development undertaken to establish a method of pseudo-
continuous arterial spin labelling (pCASL) in the mouse liver. The potential advantage of 
such a technique would be the ability to selectively measure regional portal and arterial 
perfusion.  
A pCASL-EPI sequence was first tested in an agar and then a water flow phantom. This was 
followed by an experiment applying pCASL-EPI to a mouse kidney, which included an 
optimisation of the acquisition protocol. A series of experiments were then undertaken to 
optimise the pCASL sequence for application to the liver. First, phase contrast MRI 
measurements were taken within the portal vein and descending aorta in order to optimise 
the tagging efficiency in these vessels. The portal venous perfusion was first optimised, as a 
larger perfusion signal would be available. The B0 field within the portal vein was mapped 
through the respiration cycle in order to assess the possible reduction on the tagging 
efficiency due to inhalation. After these steps to optimise tag efficiency, the sequence was 
applied to the portal vein and descending aorta to successfully produce the first pre-clinical 
measurement of hepatic perfusion in mice using a pseudo-continuous ASL preparation. The 
pCASL-EPI estimates of hepatic arterial and portal venous perfusion were compared to the 
FAIR-ASL approach described in Chapter 3.  
The pCASL-EPI pulse sequence was developed by Dr James Meakin whilst at Oxford 
University. The initial experiments were performed with Dr Jack Wells and Magda Sokolska. 
Magda Sokolska developed the simulation of pCASL efficiency and advised on calculating 




In Chapter 4, estimates of total liver blood flow using a FAIR-ASL preparation were applied 
to disease models of liver metastases and cirrhosis. However, the insight that FAIR can 
provide about liver haemodynamics is restricted due to its non-selective labelling of in-
flowing blood. As has been previously demonstrated using invasive techniques, the ratio of 
portal venous and hepatic arterial contributions may alter as a result of liver dysfunction (1, 
2). A non-invasive MRI method, which doesn’t use contrast agents, to separate the portal 
venous and hepatic arterial perfusion would be a useful tool to study disease and 
theraputic progression in both animal models and clinical applications. Pseudo-continuous 
ASL (pCASL) tags blood flowing through a defined plane (3) and has been applied to 
separate out blood vessel contributions to brain tissue (4), and thus the feasibility of this 
technique in the mouse liver will be investigated in this chapter.  
The pCASL sequence was first tested in an agar and a flow phantom, to test the 
implementation of the sequence. The sequence was then applied to the kidneys in vivo, as 
pCASL has been implemented pre-clinically in this tissue (5), and informed on abdominal 
acquisition and gating strategies. As was mentioned in Chapter 2.4.3, the pCASL tag will be 
reduced in its efficacy due to B0 inhomogeneity and the velocity profile of the flowing spins. 
The effects of field inhomogeneity are likely to be more pronounced at high field strengths 
(6), in particular the liver has many air-tissue boundaries that can induce high susceptibility. 
Thus a method to characterise the efficiency of the portal venous tag was investigated, as 
this would produce the larger of the perfusion signals, by mapping field changes during the 
respiratory cycle and measuring the velocity of blood in the target tagging vessels. The 
efficiency is estimated using a pCASL tagging simulator for a range of sequence parameters. 
Finally, the sequence was tested in the liver, for both arterial and venous blood supplies, 
and the efficiency of the portal-venous labelling estimated.  
5.2 Phantom imaging 
5.2.1 Saturation experiments 
The pCASL-EPI experiment was initially tested for successful implementation using an agar 
phantom (described in Chapter 3.2). The pCASL sequence was tested using a five-shot, 
gradient-echo EPI: FOV 25 x 25 mm2, matrix size 64 x 64, slice thickness 1 mm, effective TE 
9.8 ms. The pCASL parameters: tag duration 1.4 s, post labelling delay 0.2 s, TR 1.8 s. In 
order to test the application of the tag in a stationary and unperfused object – the tag 
location was set to the readout slice – therefore in a multi-phase experiment (Chapter 
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2.4.3.2), the tag should impart a varied amount of saturation to the image, as 
demonstrated by Figure 5.48. Some ghosting artefacts can be seen within these images, 
potentially due to vibrations of the phantom within the coil. However, for the purposes of 
this experiment, varying saturation can still be visualised despite the ghosting. Future 
experiments testing different read-out strategies can use this set-up for quick ex vivo -
testing.  
 
Figure 5.48: Multi-phase experiment performed on the image read-out slice for an agar phantom. 
A varying level of signal saturation can be visually assessed, in correspondence to the expected 
behaviour. Such an experiment will be useful when developing the sequence and image readouts. 
5.2.2 Flow Phantom Experiment 
Having established the pulse sequence in a non-flowing phantom, it was then tested in a 
water flow-phantom in order to investigate flow-driven inversion.  A 50ml Falcon tube was 
loaded to a syringe driver, which pushed water through tubing (inner diameter of 1mm). 
The tubing was wound within the MRI bore in order to cover sufficient length for the 
inflowing water to align with B0 field (5*T1*v). The tubing then ran straight through the MRI 
scanner and in to a reservoir outside – the syringe driver could then be reversed to reload 
the water volume within the syringe after the experiment (Figure 5.49A). Two flow rates (3 
ml/min and 6 ml/min) were used to test the phase contrast flow estimate, and the 3ml/min 
flow rate was used for the pCASL testing to minimise flow artefacts. The corresponding 
velocity of the water to the applied flow rates can be seen in Table 5.3. These flow rates 
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were chosen from empirical testing which allowed for a long enough time for sequence 
acquisition (≈ 8 min).  
Flow velocities were estimated using the plug flow relation that the flow rate (Q) is 
determined by the product of the fluid velocity (v) and the pipe cross sectional area (A). The 
mean velocity can be estimated using a laminar flow approximation;  which accounts for 







  Equation 5.37 
The pCASL sequence was run with different values for Gmax, the gradient applied 
simultaneously with the discretised tagging pulse (Chapter 2.4.3), which will control the 
average gradient over the tagging duration. The tagging efficiency of different velocities will 
depend on the Gave parameter, and so the theoretical efficiency and measured efficiency 
will be tested for a single flow rate vs. Gave.  As Gmax controls the average gradient in our 
sequence, the remainder of this chapter will adjust this variable for optimisation; the values 
of the average gradient (Gave) corresponding to the maximum tagging gradient (Gmax) are 
shown in Table 5.3.  
 Gmax (G/cm) Gave (G/cm)  
 6.33 0.32  
 4.22 0.21  
 3.17 0.16  
 2.53 0.13  
Table 5.3: Gmax and the corresponding Gave values. 
5.2.3 pCASL Simulator 
A pCASL simulation (8) was run inputting the measured flow velocities over an 
implementable range of Gmax  (2-7 G/cm). The simulator was implemented in MATLAB 
which solved the Bloch equations for a moving magnetisation and the effective magnetic 
field experienced, inclusive of longitudinal and transverse relaxation.  
5.2.4 Flow Phantom Methods: Sequence Parameters 
5.2.4.1 Phase Contrast MRI 
Phase contrast MRI was introduced in the previous chapter as a method to non-invasively 
estimate the liver bulk perfusion. The flow measurement was used to validate the 
estimated flow from the apparatus, and thus ensure the scan planning for pCASL 
experiment was correct.  
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Phase contrast images were acquired using a gradient echo cine sequence; FOV 25 x 25 
mm2, matrix size 128 x 128, slice thickness 1 mm, TE/TR 1.8/5 ms. Velocity encoding 
gradients: Gpc 1.5 G/cm , τpc 2 ms; venc 11.1 cm/s. Phase contrast data were acquired for 
flow rates of 0, 3 and 6 ml/min. For the phantom experiment, no gating was used and 5 
frames were acquired for averaging – scan time was 23 seconds. 
5.2.4.2 pCASL EPI 
The pCASL sequence was tested using a single-shot, gradient-echo EPI: FOV 25 x 25 mm2, 
matrix size 64 x 64, slice thickness 2 mm, effective TE 5.3 ms. The pCASL parameters: tag 
duration 2.5 s, post labelling delay 0.3 s, TR 4 s, tag – readout distance = 1.5 cm at 3 ml/min.  
A multi-phase experiment was run with 8 phases with a 45° spacing, to optimise the 
tag/control phase, followed by ten repeat acquisitions of the selected tag and control pair. 
This experiment was repeated with Gmax set at 2.5, 3.2, 4.2 and 6.3 G/cm. This experiment 
was used to investigate signal saturation as an approximate measure of tag efficiency. The 
saturation was calculated as the mean percentage signal difference between the tag and 
control image from a ROI within the pipe. 
5.2.5 Flow Phantom Results 
Phase contrast MRI measurements of the mean velocity across the tubing corresponded 
well with predicted velocities (Table 5.4). A laminar flow profile can be observed across the 
pipe at both flow rates (Figure 5.49B), a reference, zero-flow image has been included. The 
underestimation of the speed at 6 ml/min compared to the theoretical velocity is a result of 
the venc parameter being set too low; without appropriate unwrapping post-processing, an 
erroneous value is measured at the centre of the pipe (star). In addition, an 
underestimation of flow may be induced due to the connectors between the syringe and 
tubing; however such ‘real-world’ effects do not seem to drastically affect the flow at 3 
ml/min. 
 
Using a velocity of 3 cm/s, the tag efficiency is predicted to increase with a larger Gmax 
(Figure 5.49C). Testing this out in the flow phantom, a larger degree of saturation can be 
Flow rate (ml/min) 0 3 6 
Theoretical velocity (cm/s) 0.0 3.2 6.4 
Mean velocity (cm/s) 0.1 3.1 5.9 
Table 5.4: Applied flow rates, predicted velocities (using Equation 5.37) and magnitude of the 
measured velocities using phase-contrast MRI. A good correspondence can be seen between 
the theoretical and measured velocities.  
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seen in at higher flow rates Figure 5.49D. As the tag efficiency is predicted to be around 0.5, 
this will produce an effective null of the water signal, thus estimating the efficiency from 
the difference in signal will approach a maximum. The increased saturation and plateau 
with Gmax and may be indicative of experimental factors that further reduce the simulated 
efficiency. This experiment proved a successful application of the pseudo-continuous flow 
driven inversion on the MRI scanner as well as a demonstration of the simulator.  
 
Figure 5.49: (A) Schematic of flow phantom set-up: a 50 ml phantom was loaded on a syringe 
driver which pushed water through tubing with a 1 mm inner diameter. The tubing was wound 
within the scanner bore to allow for the water to align with the static field, and passed through 
the coil to a reservoir outside of the MRI scanner. (B) Phase contrast MRI acquired velocity maps 
at flow rates of 0, 3 and 6 ml/min. The venc was set at 11.1 cm/s for all the scans, however at 6 
ml/min this was inadequate for some phase wrapped erroneous velocities have been calculated 
(star). (C) Tag efficiency simulations for a flow rates of 3 cm/s; a better inversion can be achieved 
by increasing Gmax. (D) Signal saturation differences from ten tag/control repeats within a flow 
phantom across four values of Gmax for a flow rate of 3 ml/min. Higher Gmax produced a larger 
expected amount of signal reduction, as a result of the water being tagged more effectively.  
5.2.6 Conclusions 
The series of phantom experiments has shown an effective implementation of the pCASL 
sequence on the system, and investigated systematic methods to optimise tagging. The 
sequence was then applied to wild-type mouse kidneys in order to establish in vivo 
methodology and quantification.  
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5.3 Implementation of Renal pCASL  
5.3.1 Renal pCASL 
In vivo murine renal pCASL was implemented as a methodological step between sequence 
validation using a phantom and eventual application in vivo to the liver. This was chosen 
because i) a previous study has reported murine renal perfusion using both FAIR-ASL and 
pCASL enabling a degree of comparison to earlier work performed under similar 
experimental conditions, ii) kidney perfusion is greater than liver perfusion and will yield 
increased SNR in the perfusion weighted measurements, iii) the extent of movement due to 
respiration is reduced in comparison to the liver, and gating approaches can be 
investigated.  
5.3.2 Pulse Sequence MRI parameters 
Five male C57/Black mice (approximate weight 25g) were anaesthetised and maintained at 
1.75% isoflurane in 1L oxygen/min. Mice were positioned so that the top of the kidneys 
were positioned at the iso-centre of the magnet, this allowed for both the imaging plane 
and the tag location to be proximal to the iso-centre in order to yield optimal quality EPI 
and labelling. The descending aorta was labelled, placing the centre of the tag location 
between 6 – 10 mm away from the imaging slice, typically in the middle of the liver, where 
the descending aorta runs straightest.  
The pCASL sequence parameters as described by Duhamel et al. (5) were used as a 
guideline for this section. A 3-shot spin-echo (SE) EPI readout (FOV 30 x 30 mm2, matrix size 
64 x 64, slice thickness 1 mm, k0 11, effective TE 14.9 ms) followed a balanced pCASL 
preparation (10 control-tag pairs, two averages per image, tag duration 3s, post-labelling 
delay 0.3s, Gmax/Gave = 2.53/0.13 G cm
-1, Hanning duration/spacing 0.6 ms/ 1.2 ms, effective 
velocity range 17–48 cm s-1, minimum tag gap 2mm). For kidney imaging, a three-shot EPI 
acquisition was chosen as a compromise between SNR time efficiency, echo time and image 
distortion.  
The scan protocol was as follows: a single average, multi-phase pCASL experiment (Chapter 
2.4.3.2) was performed to optimise tagging efficiency (8 phases at 45° steps, acquisition 
time 4 minutes); the biggest difference in signal intensity separated by a 180° phase was 
then chosen for the tag and control. Ten repeats of tag-control pairs were used for the 
perfusion imaging (acquisition time around 10 minutes). The FAIR-LL sequence was run for 
T1 mapping and as a reference perfusion scan, in a matched position to the EPI readout; the 
acquisition parameters and quantification were as described in the Chapter 3.6.  
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5.3.3 Perfusion Quantification 
Perfusion quantification was taken from the Duhamel et al. paper which used the general 
kinetic model (9) for when the image time (TI), (or post labelling delay) is greater than the 
arterial transit time δ (TI > δ). The paper was comparing a FAIR and pCASL preparation, and 
utilised the T1 maps generated in the FAIR acquisition to aid quantification.  
In the study, the arterial transit time was set to δ = 0.2 s, taken from brain perfusion data. 

























. Equation 5.38 
Where λ is the partition coefficient, set to 0.9 ml g-1, M0 is a reference equilibrium 
magnetisation image (i.e. no labelling), renal blood flow (RBF) in units of ml g-1 min-1, α is 
the inversion efficiency, T1,app is the apparent T1 as estimated from the slice-selective FAIR 
data, T1a is the arterial blood T1 and τ is the tag duration. The arterial blood relaxation time 
T1a was set to 1.9 s, taken from the previous measurements at 9.4T (10). The inversion 
efficiency α was set to 0.65 as reported by Duhamel et al., which was estimated from a 
ratio of the pCASL to FAIR perfusion values. The FAIR acquisitions will be quantified using 
the Belle model as an initial test, as with the previous chapter but using a partition 
coefficient of 0.9 ml g-1. 
5.3.4 Respiratory Synchronisation Simulation 
The pCASL images acquired by Duhamel et al. was synchronised with the respiratory cycle 
(Figure 5.50A) – given a range of breathing rates, the pCASL tag train (green block) would 
be respiratory triggered so that the image acquisition (blue block) would finish in a period 
without breathing. The group reported that they found an optimal breathing rate was 
around 90 breaths min-1, however from our own early in vivo experiments it was seen that 
small changes in high breathing rates could often lead to images being acquired during 
respiration.  
A brief simulation was thus established that tested for successful image acquisition for a 
fixed tag duration and post labelling delay, as used in the kidney pCASL experiment (3 
seconds and 0.3 seconds respectively), for a range of physiological breathing rates (30 – 100 
breaths min-1). An inhalation window was assumed to be 0.4 s, which has been empirically 
observed in mice. A successful image was defined as one acquired in between breaths, 
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assuming an instantaneous acquisition. The pCASL train started post-exhalation, as this 
would reflect the set-up in the triggering software.  
In Figure 5.50B, a successful image is equal to one and unsuccessful image equal to zero – it 
is apparent that lower rates of respiration have wider ‘windows’ of image success, thus 
there may be a benefit of imaging at slower breathing rates as some variation will inevitably 
occur. Applying this simulation for a range of tag durations from 1.5 – 3.5 s and for a fixed 
post labelling delay of 0.3 s (Figure 5.50C), it is then possible to select the tagging duration 
when planning pCASL experiments based on the animal’s breathing rates. In this plot, white 
and black squares respectively represent successful/unsuccessful image acquisition. 
Alternatively, if a series of experiments have started using a particular tagging duration, a 
delay can be placed within the gating software which will shift the beginning of the tagging 
pulses and avoid capturing respiration motion, and this simulation can aid in planning that.  
With a tag duration of 3 s and a post label delay of 0.3 s, the plot suggests a breathing rate 
around 55 breaths min-1 would be optimal. Duhamel et al. may have suggested higher 
breathing rates as they may have found that the most physiologically stable with their 
choice of animal strain (C57B1/6J  around 25g) and anaesthetic (isoflurane at 1.5% in .29 L 
min-1). A wide image-success window is available using a short tag duration with low 
respiration rates, however the potential of reduced labelled bolus at such tag durations will 





Figure 5.50: (A) Schematic demonstrating the concept of synchronised acquisition- the pCASL tag 
(green block) is triggered post-exhalation, and runs for its chosen duration. After the post labelling 
delay, the EPI image is acquired (blue block) – however there will be a unique set of respiration rates 
that the image can be successfully acquired at. [adapted from Duhamel et al. (5)] (B) Simulation of 
image success over a range of physiological respiration rates, with a tag duration of 3 s and a post 
labelling delay of 0.3 s. It is apparent that the ‘windows’ of image success are wider at slower 
breathing rates. (C) The image success simulation was run with a variety of tag durations for a fixed 
post labelling delay of 0.3 s. In this plot, an image success of one is a white square - it is possible to 
visualise the appropriate pCASL parameters a given breathing rate.  
5.3.5 Results 
A SE-EPI readout has been previously successfully applied to the kidneys, and an example 
EPI image at 9.4T can be seen in Figure 5.51B, compared to a high-resolution FSE image in 
Figure 5.51A. The EPI image does not suffer from gross deformations, though the fat-
saturation has not been completely successful, the kidneys do not seem to be obscured by 
any artefacts. The perfusion-weighted image (PWI) following the tag-control subtraction 
and averaged over the ten pairs can be seen in Figure 5.51C: A ring-shaped signal can be 
seen at the location of the renal cortex, showing successful pCASL tagging of the arterial 
blood. For quantification using Equation 5.38, the apparent T1 is taken from the slice-
selective FAIR experiment (Figure 5.51D); mean T1S, FAIR was measured at 1.39 ± 0.29 s within 
the cortex.  
158 
 
Visual assessment of the perfusion over the kidney as estimated by pCASL-EPI (Figure 
5.51E) and FAIR-LL (Figure 5.51F) shows good correspondence. The pCASL-EPI technique 
measured a mean renal cortex perfusion of 5.3 ± 0.3 ml g-1min-1 (mean ± standard error) 
and the FAIR-LL measured a mean perfusion 5.0 ± 0.2 ml g-1min-1. As expected, a reduced 
mean perfusion was estimated in the renal medulla: 1.1 ± 0.2 ml g-1min-1 measured with 
pCASL-EPI and 0.8 ± 0.1 ml g-1min-1 measured with FAIR-LL. The perfusion as estimated by 
both techniques across the five mice can be seen in Figure 5.51G, a significant difference 
was measured between the techniques (p < 0.05, paired t-test). This is indicative of a slight 
underestimation of the pCASL perfusion, though the FAIR parameters were not optimised 




Figure 5.51: Estimation of renal perfusion using ASL. (A) Axial high-resolution fast spin echo (FSE) 
reference image, showing excellent contrast between the kidneys, muscle, spleen, liver and 
intestines. (B) Corresponding spin-echo EPI image (M0 reference). (C) pCASL-generated perfusion 
weighted image (PWI), showing a bright ring-like signal at the location of the renal cortex. (D) Slice 
selective T1 map, as estimated from the FAIR acquisition, the renal cortex and medulla are clearly 
distinguishable. Perfusion maps as calculated by pCASL (E) and FAIR (F) ASL, in both maps a bright 
ring of perfusion can be seen in the renal cortex. (G) Comparison of pCASL (red) and FAIR-ASL (green) 
perfusion values (mean + ste) across the five animals, a significant difference was measured (p < 0.5, 
paired t-test).   
5.3.6 Discussion and Conclusion 
The perfusion values compare well with previous measurements of kidney perfusion 
measured with ASL; the mean cortex perfusion was measured in the range of 5.5 – 7.5 ml g-
1min-1 by Duhamel et al. in mice at 11.75T (5) and the mean medulla perfusion was 
measured in the range of 1.40 – 2.30 ml g-1min-1. Rajendran et al. (11) used a FAIR SE-EPI 
method at 7T in mice and measured a mean cortex perfusion of 3.97 ± 0.36 ml g-1min-1 
(mean ± standard deviation), and a mean medulla perfusion of medulla 1.66 ± 0.41 ml g-
1min-1. Though a significant difference was measured between the FAIR-LL and pCASL-EPI 
estimates of renal perfusion, the mean difference (0.4 ml g-1min-1) was not larger than the 
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variation over the group. The FAIR-LL quantification was not optimised for mice kidneys: 
the 6 mm slice-selective inversion in the FAIR experiment was larger than previous studies 
(4 mm (11)), and the Belle model was used for quantification as an initial look-see. The 
mean T1S, FAIR was measured at 1.39 ± 0.29 s within the renal cortex, this is in within 
reasonable agreement with previous reported values, though at different field strengths; 
1.48 ± 0.08 s at 11.75T (5) and 1.57 ± 0.16 s at 7T (11). For those two papers, the 
longitudinal relaxation time of blood was respectively 2.1 s and 2.2 s, though the latter 
measurement was taken ex vivo. 
Duhamel et al. compared readout schemes between an EPI and FSE acquisition. It was 
reported that the FSE acquisition was much more favourable in the coronal plane with their 
imaging system. However, implementation of a FSE readout resulted in poor perfusion 
signal for both phantom and in vivo experiments (data not shown). This can be further 
investigated as the FSE readout may prove favourable over EPI acquisition for liver imaging 
due to its reduced sensitivity to susceptibility-induced artefacts.  
This study used the optimised FAIR acquisition from Chapter 3, which meant that there was 
a resolution difference between the LL and EPI acquisition. Future work may include 
reducing the resolution of the LL sequence, though this will quicken the scan, aligning the 
images using the same resolution is not necessarily straight-forward as the EPI image is 
susceptible to image distortions. Conversely, increasing the EPI matrix size will decrease the 
already small phase encoding bandwidth, and thus image distortions may be exacerbated 
due to B0 imperfections.  
This study successfully implemented the pCASL sequence within the mouse abdomen. This 
study was carried out as pre-cursor to liver imaging, to gain experience with respiratory 
gating and quantification. The ring-like PWI signal seen in the renal cortex gives perfusion 
imaging of the kidney a distinct advantage as the tagging success can be quickly visually 
assessed. The liver may not have such a distinct perfusion pattern, but it is encouraging that 
with these pCASL settings it was possible to tag the blood in the descending aorta superior 
to the kidneys. The next section will investigate optimising the tagging of the portal vein, as 
this will present the largest perfusion signal within the liver.  
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5.4 Optimisation of hepatic pCASL 
5.4.1 Introduction 
Having established the pCASL sequence successfully in vivo within the mouse abdomen, 
using a ‘synchronised’ EPI readout, the method has potential to be applied to the liver. 
However, the liver has a unique dual blood supply, and the slow flow within the portal vein 
may have a poor tagging efficiency, which may be further reduced due to respiratory 
motion.  
This section investigated methods to optimise the pCASL pulse sequence for application to 
the liver. A phase contrast MRI sequence was used to measure the flow in the hepatic 
vessels, these values were then applied to the pCASL simulation to analyse the optimal 
tagging gradients. Following this the portal vein was imaged through the respiratory cycle 
to determine if there would be any resultant B0 shifts and examine if these would inhibit 
pCASL tagging. Finally, a gradient-echo Look-Locker and EPI readout were compared in the 
kidney to optimise the perfusion estimation. 
5.4.2 Velocity Measurements in the Hepatic Vasculature 
5.4.2.1 Selecting the Dual Supply of the Liver 
Separating the liver’s blood vessels for selective tagging is potentially difficult due to the 
proximal nature of the hepatic artery (HA) to the portal vein (PV) (Figure 5.52A). The 
hepatic artery branches from the descending aorta (DA) towards the inferior end of the 
liver from the celiac trunk. Though Wong et al. have shown a method of distinguishing the 
perfusion from closely positioned blood vessels using transverse gradients (12), we aim to 
separate out the perfusion contribution in a two-tag approach as can be seen in the 
schematic in Figure 5.52B (13). This two-tag approach will aim to separate venous and 
arterial perfusion by sequential tagging of the portal vein and the descending aorta. We aim 
to tag the portal vein at a location before the celiac trunk and thus only sensitise the 
perfusion weighting to the venous blood (PV tag). With the DA tag is placed at the top of 
the liver, some of the blood flowing down the descending aorta will then enter the liver via 
the HA. A cardiac-gated phase contrast MRI was applied to measure the blood velocity of 
the DA and PV In order to optimise tagging of these two vessels. From these measurements 
of blood velocities within the vessels, the pCASL simulator will estimate the potential 
tagging efficiency over a range of Gmax.  
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5.4.2.2 Methods: PC-MRI  
Three male C57/Black mice (mean weight 25g) were anesthetised under isoflurane and 
three ECG leads were used to monitor the cardiac pulse (SA Instruments). The phase 
contrast sequence was as described in Chapter 4.7.2.3. As the portal vein and descending 
aorta run fairly axially, the slices were placed thus and the velocity encoding gradient 
applied along the z-axis. Two positions of the slice was used, to match the proposed tagging 
regions: one at the region of the celiac trunk to measure the PV (and IVC) flow, and the 
second at the top of the liver to measure the DA flow. The MRI scan parameters are FOV 30 
x 30 mm2, matrix 128 x 128, TE/TR 1.16/5 ms, 20 frames within the cardiac cycle, VENC, PV 45 
cm/s, VENC, DA 82 cm/s (14). 
5.4.2.3 Results: Velocity Measurement of the Hepatic Vasculature  
An example phase-contrast MRI measurement with the portal vein (PV), inferior vena cava 
(IVC) and descending aorta (DA) ROI overlaid on a T2-weighted anatomical image is shown 
in Figure 5.52C. The DA flow can be seen to be opposite in direction to that of the PV and 
IVC.  An example velocity profile of the blood vessels through the cardiac cycle as estimated 
by the PC-MRI (Figure 5.52D) shows that the descending aorta, as expected, has a large 
velocity peak post-systole, whereas the IVC has a much more broader cardiac dynamic. The 
portal vein has a constant flow over the cardiac cycle, such behaviour is expected as this 
blood vessel is drawing the venous blood from the mesenteries (15, 16). The mean velocity 
measured in the portal vein was 8.1 ± 0.4 cm/s (mean ± standard error), and the mean DA 
speed 17.8 ± 0.5 cm/s. There is little literature reporting on the portal vein in mice, 
however a previous phase contrast MRI measurement reported a mean supra-renal aortic 
flow of 17.2 (14.8–19.5) cm/s in 18 wild-type C57BL/6J mice, which corresponds well with 




Figure 5.52: (A) High resolution, axial FSE image of the major hepatic vasculature, at a location 
superior to the celiac trunk. The vasculature appears hypo-intense relative to the dark liver tissue; 
the portal vein (PV), and much smaller hepatic artery (HA) perfuse the liver. The blood travels 
throught the liver sinusoids and eventually collects in to the inferior vena cava (IVC) which returns 
the blood to the heart. The descending aorta has its primary branch at the celiac trunk, from which 
the hepatic artery enters the liver. (B) The perfusing vessels can be visualised in this sagittal 
schematic. As the hepatic artery is small and proximal to the portal vein, a system of tagging the 
portal vein inferior to the celiac trunk (PV Tag) and the superior part of the descending aorta (DA 
Tag) may allow for the perfusion contributions to be separated. (C) Single frame within the PC-MRI 
overlaid on the magnitude data, as expected the PV and IVC are flowing in the opposite direction to 
the DA. (D) Plot of the blood velocity throughout the cardiac cycle – a large peak can be seen in the 
DA (blue) post-systole. The IVC (green) has a more spread peak over the cardiac cycle, and the PV 
(red) exhibits a steady flow. (E) Simulations of tag efficiency for the measured velocities within the 
portal vein (blue) and descending aorta (red) as determined by phase-contrast MRI. 
5.4.2.4 Simulations of Tagging Efficiency 
The optimal pCASL tagging parameters were determined by running the pCASL simulation 
with the measured velocities over a range of Gmax (Figure 5.52E). From these simulations, 
the slower flow in the portal vein (blue line) will benefit from a larger Gmax and the 
descending aorta (red line) should have an optimal tagging regime around 4 G/cm.  
5.4.3 B0 mapping of the Respiratory Cycle 
5.4.3.1 B0 mapping  
As described in Chapter 2.4.3, the pCASL sequence is particularly sensitive to B0 
inhomogeneity, which can lead to an inefficient inversion. It was then of interest to 
investigate what changes to the static field may occur during respiration, and to determine 
what effects that would have on the tag efficiency. This section focuses on estimating the 
effects of the tagging efficiency in the portal vein. 
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B0 mapping is a common sequence in static organs such as the brain (6, 17), the technique 
acquires gradient echo images at multiple echoes, and the phase increments are attributed 
to local changes to the static field. The technique of B0 mapping has been used for field 
corrections within the heart (18), as well as EPI image correction within the brain (19). B0 
differences between the tagging and imaging plane will also contribute to tagging 
inefficiency, the total B0 effects will then by the sum of the “static” field differences 
between the planes plus any shifts induced from respiration. 
5.4.3.2 Pulse Sequence & Methods 
In order to map through the respiratory cycle, a cine sequence was utilised to rapidly 
acquire an image throughout inhalation and exhalation (Figure 5.53). Cine sequences are 
used in cardiac imaging due to the rapid and regular motion of the heart. Generally, 
prospective gating is used to trigger a segmented acquisition of frames within the cardiac 
cycle, profiting from the regular motion of the heart to build up a ‘movie’ of the heart’s 
motion. This concept will be utilised to image the breathing cycle, assuming a regular 
respiratory motion – which can be expected for anesthetised mice with stable physiology.  
The trigger was set to the earliest point in the inspiration phase the physiology monitoring 
software could detect, this triggered the sampling pulse train, spaced at TRCINE to capture 
the breathing motion up to quiescence. Each sampling pulse was followed by a spoiled 
gradient-echo read out, with one line of k-space sampled at each point. The ‘resp-cine’ 
sequence assumes a regular respiration motion for the duration of the experiment, as well 
as the gating to be consistent. This assumption is usually valid for cardiac cine imaging as 
the heart exhibits regular motion and the ECG trigger generated from the QRS complex is 




Figure 5.53: Pulse sequence diagram of the segmented resp-cine: the frame train is triggered at the 
inspiration phase and then collects a single line and single echo for each excitation pulse. The 
number of frames is set in order to capture the breathing motion as well as the rest-phase.  
The resp-cine sequence was repeated at different TEs in order to calculate the B0 field. A 
requirement of the TE spacing is that the water-fat phase is kept constant; this increment 
can be determined using the Larmor equation (20):  
 
     
 
   
  Equation 5.39 
Where σ is the chemical shift, which for water-fat is approximately 3.5 ppm (1.36 kHz at 
9.4T (21)). For 9.4T, using a gyromagnetic ratio of 42.56 MHz T-1, the echo spacing ΔTE is 
equal to 0.71 ms.  
B0 mapping was performed in 3 male C57/Black mice (mean weight 25g), FOV 30 x 30 mm
2, 
matrix 128 x 128, number of frames 20, and TRCINE 15 ms. A series of axial and sagittal 
images were acquired to plan a single imaging slice which captured the majority of the 
portal vein. Such an orientation would be optimal for observing field changes along and 
within the portal vein and liver tissue with respect to the respiratory cycle. The respiration-
cine was run for three echoes TE = 1.2, 1.91 and 2.62 ms; each acquisition took 
approximately 5 minutes. 
5.4.3.3 Quantification 
Using a multi-echo approach, the ΔB0 value can be estimated from a linear fit of the phase 
relationship with the echo (6):  
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     γ       Equation 5.40 
The fitting function was written in MATLAB, which adopted a built-in, one-dimensional 
unwrap function to temporally correct aliased phases to estimate the ΔB0.  
5.4.3.4 Results: Simulations of Tagging Efficiency 
An example resp-cine at one TE (Figure 5.54A) shows the respiration and rest phases of the 
breathing cycle. The images are acquired in an oblique plane, approximately coronally in 
order to capture the portal vein within the slice. The lungs appear hypo-intense towards 
the top of the frame (the head of the animal is towards the top of the frame in this 
orientation) and it is possible to observe them expanding and contracting. The portal vein in 
these images appears hyper-intense relative to the liver tissue, and has been segmented 
out on one frame in red. From this dataset it is possible to visually assess that the breathing 
has been steady throughout the duration of the acquisition: there are no obvious artefacts 
present within the images. Combining this dataset with the other two TE resp-cines, it is 
possible to calculate the B0 map through the respiratory cycle (Figure 5.54B). This is the first 
measurement of a field map in the mouse liver during respiration; the portal vein has a 
unique offset frequency from the liver. A large B0 change is present in the top-left hand of 
the liver adjacent to the lung as a result of the inspiration, though no large changes are 
seen across the remaining of the liver.  
The mean maximal shift was calculated by taking a ROI within the portal vein - drawn for 
each frame to ensure no liver tissue was being included, an example of which can be seen 
in Figure 5.54C. The shift was calculated from the baseline frequency of each mouse 
measured during the respiratory quiescence phase at the end of the cine. A peak in the 
static field shift can be seen at the point of maximal inhalation, followed by a plateau 
period during the rest phase (star). The mean maximal shift this was measured at 152 ± 25 
Hz (mean ± standard error) within the portal vein and 114 ± 7 Hz for a liver region.  
From a line profile covering 40 pixels (approximately 9 mm) within the liver, the mean 
maximal difference between tagging and imaging plane was measured to be 327 ± 311 Hz. 
This result is heavily skewed by one liver with a particularly bad shim; excluding this 
dataset, the mean maximal difference reduces to 147 ± 1 Hz.  
In order to assess how this shift may affect the tagging efficiency, the pCASL simulation was 
run with a series of B0 offsets (from 0 - 250 Hz in 10 Hz increments) and a range of Gmax 
(Figure 5.54D). The simulation demonstrates the technique’s sensitivity to a B0 offset, an 
oscillatory pattern is produced as the control and tag magnetisation invert relative to each 
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other. The B0 offset acts as a phase increment similar to section 5.2.4. Visual assessment 
determined the mean width of the B0 shift during the respiratory cycle to be 155 ± 9 ms. An 
time-efficiency vector was then created for a tagging train with duration of 3 s and a 
breathing rate of 55 bpm; this would result in three breaths occurring during labelling. The 
time-efficiency vector was set to the idealised efficiency estimated by the simulator for the 
portal vein, except for the periods of respiration, which were adjusted for the estimated 
efficiency change due the frequency shift. The time-efficiency vector was averaged to 
produce a respiration-corrected efficiency (Table 5.5).  
Gmax (G/cm) 2.5 3.2 4.2 6.3 
Simulated Efficiency 0.66 0.71 0.76 0.83 
Respiration Efficiency 0.57 0.61 0.65 0.71 
Table 5.5: Simulated and respiration induced B0 shift-corrected efficiency calculated 
for a portal vein tagging regime with pCASL over a range of Gmax.  
The respiration-corrected efficiencies are expectedly lower than the ideal simulated 
efficiencies, on average by 86% for the assumed respiration rate and shape. This gives a 
good indication of the effects of the respiration on the tag efficiency, and additionally 
suggests that methods to minimise the number of breaths occurring during labelling (i.e. a 
slower breathing rate or shorter tagging duration) would produce favourable tagging 
efficiencies. Selecting Gmax at 6.3 G/cm, the resultant estimated tagging efficiency is 0.71, 
which should be sufficient to produce a successful tag - previous measurements of pCASL 
efficiency around this number: Duhamel et al. reported a tagging efficiency of 0.61 and 0.65 
in mice kidneys. Furthermore, this paper measured a ΔM/M0 (indicative of the perfusion 
signal) between 8 – 20%, as kidney perfusion is expected to be approximately double that 





Figure 5.54: (A) Magnitude images of the respiration-cine. The images are acquired in an oblique 
angle, the head towards the top of the image, in order to capture the portal vein which appears 
hyper-intense compared to the liver (red ROI). The lungs can be seen as two areas of hypo-intensity 
at the top of the image, these can be seen expanding and contracting over the first ten frames. (B) 
Corresponding B0 maps, with a zoom on the portal vein inserted. A relatively small amount of 
changes can be seen across the liver during the respiration – the regions adjacent to the lungs can be 
seen to have a large amount of static field shift, as may be expected. (C) Example frequency shift 
profile of the portal vein during the breathing cycle. The region of respiratory quiscence has been 
marked with a star, and the mean maximal shift was measured around 150Hz. (D) Simulations of 
efficiency for increasing increments of B0 shift, the efficiency modulates as a result of the tagging 
phase differences between the tag and control magnetisation.  
5.4.4 Comparison of pCASL Readout Strategies 
5.4.4.1 Readout Strategies 
The EPI readout is popular for techniques such as ASL due to its high SNR efficiency. The 
FAIR acquisition was combined with the Look-Locker (LL) readout in Chapter 3 due to the 
known difficulties of EPI imaging within the liver at high field strengths. Recent work has 
shown the advantages of LL imaging within the liver for better efficiency of multi-TI 
perfusion quantification (13, 22). The advantage of the Look-Locker readout following 
pCASL preparation is that the increased TIs improve perfusion quantification, as well as its 




Three different perfusion-sensitive sequences were compared: pCASL preparation with an 
EPI readout in one mouse, pCASL preparation with a Look-Locker readout and a FAIR 
preparation with a Look-Locker readout. For pCASL preparation, the parameters as used in 
section 5.3 were used (10 control-tag pairs, two averages per image, tag duration 3s, post-
labelling delay 0.3s, Gmax/Gave = 2.53/0.13 G cm
-1). Single-shot gradient echo pCASL-EPI 
sequence parameters were: FOV 30 x 30 mm2, matrix size 64 x 64, slice thickness 1 mm, k0 
7, effective TE 7 ms. The Look Locker readout following the pCASL tag had the following 
parameters: FOV 30 x 30 mm2, matrix size 64 x 64, slice thickness 1 mm, TR 4 s, TE = 2.3 ms; 
TRLook-Locker 3.1 ms, 8 segments per TI, TILook-Locker 75 ms, 50 TIs – acquisition time 3 minutes. A 
FAIR acquisition was additionally included as a reference (scan parameters: FOV 30 x 30 
mm2, matrix size 128 x 128, slice thickness 1 mm, TR 4 s, TE = 2.3 ms; TRLook-Locker 3.1 ms, 8 
segments per TI, TILook-Locker 25 ms, 100 TIs). The SNR of the perfusion weighted images was 
estimated from a ROI drawn in the kidneys and noise regions, and was calculated as SNR = 
0.66 * mean(signal)/std(noise); the 0.66 is a product of a Rician noise correction (20). 
Perfusion of both pCASL-EPI and pCASL-LL data was quantified using Equation 5.38, and the 
FAIR-LL data was quantified using the Belle model.  
5.4.4.3 Results 
Figure 5.55 shows the differences between the EPI and the LL readouts (Image row); visual 
assessment shows that, as before, EPI imaging has not suffered from any gross distortions 
in the kidneys. The perfusion weighted signal-to-noise (PWI row) is much higher in the 
single PLD EPI acquisition (from the 2 averages built in to the acquisition mode) than in 
both the Look-Locker readouts. The Look-Locker PWIs was taken from the image 
subtraction at a TI around 0.3 s in order to match the pCASL-EPI acquisition.  A comparison 
of the PWI SNR can be seen in Table 5.6. The LL readout exhibits a reduced SNR partly due 
to the low flip angle used in the acquisition. The FAIR-LL acquisition measured a larger PWI 
SNR than the pCASL-LL, which is unexpected for a pulsed ASL technique and a higher 
resolution.  
 
pCASL-EPI pCASL-LL FAIR-LL 
Perfusion (ml g-1min-1) 6.7 5.2 6.8 
PWI SNR 5.9 1.3 2.9 
Table 5.6: Perfusion estimated from pCASL preparation with both an EPI and Look-Locker (LL) 
readout. A reference FAIR-LL acquisition was taken, and the perfusion value agrees well with that 
estimated by pCASL-EPI. An SNR calculation of the perfusion weighted images using. The EPI readout, 
has the optimal SNR in the PWI, followed by the FAIR-LL. 
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The perfusion model as described in Equation 5.38 was used to initially estimate the 
perfusion using the Look-Locker readout following a pCASL preparation, the resultant 
perfusion maps can be seen in Figure 5.55 (Perfusion row). All three perfusion maps display 
the expected ring of renal cortex perfusion and reduced perfusion within the medulla. The 
signal within a renal cortex voxel is suitably described by this model post PENIR correction, 
(Figure 5.55B) despite no correction for the magnetisation saturation as generated by the 
Look-Locker read-out (23), however this simplified model may account for the apparent 




Figure 5.55: (A) A comparison of the pCASL preparation with an EPI readout and a Look-Locker 
readout, anda further comparison with a FAIR Look-Locker acquisition (n = 1). A single-shot gradient 
echo EPI image was used; however this acquisition does take two averages, as a reference image. 
The Look-Locker images were acquired with a 64 x 64 matrix for the pCASL preparation, and a 128 x 
128 matrix for the FAIR Look-Locker acquisition. Below are the perfusion weighted images (PWI) for 
the three acquisitions, it is observable that the EPI image has a favourable PWI SNR, but a bright 
ring-like signal can be seen in all images. Finally, the perfusion maps as generated from each 
perfusion-weighting and readout; a similar level of perfusion can be observed between all 
techniques. (B) A simple model (using Equation 5.38) fitting for the Look-Locker acquisition. Using 
the PENIR algorithm, it was possible to remove the sginal acquired during respiration (red) and 






5.4.5 Optimisation of Hepatic pCASL: Discussion and Conclusions 
5.4.5.1 Phase Contrast MRI 
Blood velocity measurements, obtained using a non-invasive phase-contrast MRI technique, 
measured the flow within the portal vein and descending aorta, so the pCASL sequence can 
be designed to optimally label these vessels. These measurements were particularly useful 
as the portal vein velocity measurements are not widely reported in mice. The estimations 
of flow in the descending aorta (17.8 ± 0.5 cm/s) showed a good correspondence with 
previously reported phase contrast MRI data in mice in the same location. For tagging the 
portal vein blood, the simulations suggest that the Gmax parameter should be maximised in 
order to achieve the best inversion efficiency. The renal pCASL experiment showed a good 
perfusion signal using an aortic tag with a Gmax of 2.5 G/cm, however the simulation from 
the descending aorta measurements suggest a Gmax around 4 G/cm will further improve 
this. This relative inefficiency could account for the reduced kidney perfusion signal 
measured by pCASL compared to FAIR in the section above. The PC-MRI sequence may be 
further used as a comparative estimator of liver perfusion from bulk flow calculations taken 
from the portal vein. The subtractive measure of total and hepatic arterial flow (Chapter 
4.7.2.3) could additionally be measured (24),  though the subtraction introduces larger 
errors and two-position IVC flow measurements will require cardiac triggering and lengthen 
the experiment, whereas the portal venous flow is constant (Figure 5.52D) and will only 
require respiration gating.  
5.4.5.2 B0 Mapping of the Portal Vein 
As far as the author is aware, this was the first application of a B0 mapping technique 
applied to a mouse liver, and the first example of mapping the field changes over the 
respiratory cycle. The quantification assumed that the resp-cines, with the TEs acquired 
sequentially, aligned due to a regular breathing motion and prospective triggering. 
Generally for abdominal imaging, respiratory gating is set to acquire in the quiescent phase 
between breaths, thus there is some flexibility in where the trigger starts within these static 
periods. However, in order to capture a consistent trigger point, the resp-cine is dependent 
on a regular breathing rate and motion to aid the physiology software to detect the ‘falling-
edge’ at inhalation.  The data did not present any obvious image artefacts to indicate the 
potential effects of breathing irregularities, thus the sequential imaging and prospective 
gating method has been successful. This could be further improved by increasing the 
segmentation of the resp-cine to quicken the acquisition time and reduce the possibility of 
any variation in the animal’s physiology. Future B0 mapping in the liver will not necessarily 
173 
 
investigate the respiratory influence, so a standard gated, multi-slice, multi-echo GE 
acquisition will speed up the imaging time.  
The measured frequency shift across the breathing cycle (150 Hz) is of larger magnitude to 
previous clinical literature: Robinson et al. (6) measured an approximate 80 Hz shift across 
the brain at 4T. Hernando et al. (25) applied a B0 mapping technique to estimate iron 
content in the liver and measured frequency variations at 3T in the range of -20 to 80Hz. In 
these images, it was also possible to see intrinsic B0 differences in the portal vein to the 
liver parenchyma. Bolan et al. (26) measured a maximum difference of 70 Hz in the breast 
at 4T between images acquired at max inspiration/expiration. Shah et al. (27) used a 2-echo 
cine combined with parallel imaging to measure changes within the range of 20 – 60 Hz 
across cardiac cycle at 1.5T in the heart. This difference in magnitude is likely to be due to 
the liver’s compression within the respiratory cycle, and in addition, may be due to the 
higher magnetic field used in the pre-clinical system, and also potentially due to the manual 
shimming routine which does not flatten the field in a regional manner. 
The resp-cine pulse sequence, which maps motion due to breathing, could be applied to a 
number of pre-clinical techniques to assess the effects of respiratory motion in different 
anatomical positions. A series of resp-cines could allow a 4D map of the liver’s motion 
during respiration – which could help retrospective analysis as well as modelling image 
artefacts (28).  
The simulation of tag efficiency which accounted for periods of poor inversion due to 
respiration-induced B0 shifts showed that while the tag duration is much greater than the 
total period of respiration, an effective tag should be possible. The period of respiratory 
quiescence was assumed to not contribute to any B0 shift, as verified by a minimal 
frequency change in the period 200-300 ms in 9C. A method of real-time shimming (17) 
based on the respiratory bellows signal could be a method to account for respiratory 
effects to maximise tag efficiency, however this will require complex hardware 
adjustments, which were found to be incompatible with Agilent’s sequence programming 
design. 
5.4.5.3 Readout Strategies 
Recent improvement in the Agilent software and EPI sequences has improved the quality of 
abdominal EPI imaging. As seen in the kidney data in Section 5.4, both the PWI and 
perfusion map have a good SNR for a single post labelling delay. This study showed that, 
though the Look-Locker readout allows for an accurate pixel-wise modelling of the 
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perfusion, the intrinsic low signal-to-noise from using a small flip angle proves prohibitive in 
this application. The Look-Locker acquisition will include a number of breaths, and though 
the corrupted images can be discarded using the PENIR algorithm, the sequence is still very 
reliant on steady breathing. Any variations in breathing over the segmented acquisition 
make it difficult to distinguish the low perfusion signal. Future work can apply this 
investigation to more animals and the Look-Locker readout may find utility in the liver 
pCASL measurement, as the readout is not reliant on specific respiration rates for image 
‘synchronisation’. The Look-Locker technique may provide an efficient method of 
investigating the post labelling kinetics, however with the reduced PWI SNR, it may be very 
difficult to detect perfusion signal as liver: total hepatic perfusion is approximately half of 
that of the kidney (29), and less perfusion signal will be available after separately labelling 
the blood vessels. Thus, the EPI readout was chosen as the optimal readout for application 
of pCASL to the liver, though this technique may be difficult to implement in the anatomy 
due to possible increases in B0 inhomogeneities.  
5.5 Initial Measurements of Hepatic pCASL 
5.5.1 Portal Vein pCASL Methods 
The preceding experiments have considered optimisation and feasibility of application of a 
pCASL technique to measure the portal venous perfusion in a mouse liver. From these 
experiments, the following parameters were used to test the PV-pCASL in vivo.  
Eight C57/Black mice (approximate weight 25g) were positioned so that the imaging plane 
and the tag location were both proximal to the magnet iso-centre. Two modes of EPI were 
tested; a single shot gradient-echo (GE-EPI) and a three-shot spin-echo (SE-EPI). Imaging 
parameters were FOV 30 x 30mm2, matrix size 64 x 64, TEGE/TESE = 6/12 ms. The GE-EPI was 
tested initially in each mouse, as this would provide the quickest acquisition. However, if 
the imaging quality appeared poor, the SE-EPI readout was used instead for pCASL 
experiments.  
The pCASL sequence parameters: the tag duration was switched between 2.5 and 3 s 
dependent on respiration rates, post-labelling delay 0.3s, Gmax/Gave = 2.53/0.13 G cm
-1, 
Hanning duration/ spacing 0.6 ms/ 1.2 ms, TR 4 s.  
As before in the kidney experiments, a multi-phase experiment was performed to optimise 
tagging efficiency10, followed by ten tag-control pairs (acquisition time for the single-shot 
GE-EPI was 3 minutes, while 10 minutes for the three-shot SE-EPI). With the reduced 
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acquisition time, the single-shot GE-EPI additionally has the advantage of a potentially more 
stable physiology which should aid the synchronisation of imaging with respiration. 
No retrospective gating was applied to the initial pCASL images. A liver ROI was drawn in 
the EPI image guided by a down-sampled T1,selective map, from which mean perfusion values 
were taken. Perfusion maps were calculated using the kidney pCASL quantification in 
Chapter 5.3.  
5.5.2 Results: Comparison of EPI Readouts for PV pCASL  
A comparison of GE and SE-EPI of the liver can be observed in Figure 5.56 (Anatomical row); 
a reference image of a T2-weighted FSE acquisition has been included. For all 8 animals, the 
single-shot GE-EPI acquisition was used, and in two animals a SE-EPI acquisition was taken 
for comparison. A good visual correspondence can be seen between the FSE and the SE-EPI 
image, though some chemical-shift artefacts are apparent. The single-shot gradient echo 
image does not present any large deformations, though there is some visible signal dropout 
towards the top of the image, possibly due to cardiac motion. These images reflect the 
improvement in EPI software and hardware that have aided pre-clinical imaging. EPI in the 
liver is still quite challenging, particularly as shimming is performed over the imaging plane 
as well as the tagging vessel, which covers a large area of high susceptibility within the 
abdomen.  
Both readouts produce coherent signal within the liver parenchyma in the perfusion 
weighted images (PWI row), a region of hypo-intense signal can be seen at the location of 
the gall bladder (appearing hyper-intense on the T2-weighted anatomical image), 
particularly on the SE-EPI image. The perfusion maps (Perfusion Map row) visually 
correspond and match the perfusion map as estimated using the FAIR-LL sequence. Despite 
the drop-out in signal of the raw GE-EPI images, the perfusion map in this region is not 
affected. No significant difference in the liver perfusion estimate was observed between SE- 
and GE-EPI acquisition (3.1 ± 0.6 ml g-1min-1 (mean ± std) and 3.1 ± 0.2 ml g-1min-1 
respectively, n = 2). The GE-EPI readout was chosen for further liver imaging, though the 
image quality is reduced, the speed of the acquisition will allow for quicker feedback when 
optimising tagging and the reduced scan time will benefit from a reduced likelihood of 




Figure 5.56: Estimation of portal venous perfusion using pCASL. A reference anatomical, axial FSE 
image (liver outlined in red) is shown next to example gradient echo and spin echo EPI readouts (top 
row, Anatomical). Perfusion weighted image (PWI), within the liver for both readouts (middle row, 
PWI). Perfusion maps (bottom row) as calculated by a reference LL-FAIR, and a single PLD pCASL 
using both spin echo and gradient echo EPI. A good visual agreement can be seen between both 
pCASL readouts, and the perfusion levels are similar to the reference FAIR acquisition.  
5.5.3 Application of PENIR to pCASL data 
The above data (Figure 5.56) demonstrated an acquisition where the physiology remained 
sufficiently stable so that the synchronised methodology (Chapter 5.3.4) was successful. 
However, in most cases there may be small variations in respiratory rate during the imaging 
period, so the PENIR algorithm (Chapter 3.4.2) was adapted for these datasets in order to 
remove motion-affected images.  
The PENIR system had considerably less images to generate a threshold with compared to 
the LL images to which it was previously applied, so a dual-condition was implemented 
which required both an increase in the phase-encoded, extra-corporeal space as well as a 
decrease in signal within the body ROI, with respect to the average signal over tag and 
control images. This dual-condition system ensured that images weren’t rejected too 
sensitively. Following rejection, the tag and control images were separately averaged, and 
then subtracted from each other to form the PWI. 
The implementation of the PENIR system to the data can be seen in an example dataset in 
Figure 5.57. The individual tag and control images are displayed on the left hand side; three 
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of these images have been acquired during a respiration. These exhibit poor image quality 
and a reduced signal, an example corrupted image is highlighted with an arrow. These 
images erroneously influence subtraction by propagating the magnitude image in to PWI 
signal. In Figure 5.57A, a large area of signal dropout is visible (long arrow) within the liver 
parenchyma and also a bright signal can be seen in the back muscle (short arrow). The 
PENIR corrected dataset successfully removed the respiration-corrupted images, and the 
resulting PWI displays a more coherent signal within the liver parenchyma and the 
erroneous back muscle perfusion signal has been removed. The portal vein perfusion maps 
as calculated following no correction and PENIR correction can be seen in Figure 5.57B – 
the ROI in these perfusion maps does not include the muscle tissue around the liver. The 
uncorrected PWI results in a large area of perfusion dropout and an overestimation of the 
perfusion signal when compared to the FAIR-LL perfusion map. The PENIR corrected 
perfusion map visually corresponds well with that as estimated by FAIR-LL. The PENIR 





Figure 5.57: Application of the PENIR system to pCASL data. (A) Ten repeats of tag-control pairs, 
three images were acquired during respiration (arrow). These corrupted images will resultantly 
influence the perfusion weighted signal when the data is subtracted, the arrows in the uncorrected 
PWI show a region of hypoitensity due to respiration artefacts, and an erroneous bright perfusion 
weighed signal in the back muscle due to image subtraction. In the PENIR corrected datasets, these 
three images have been successfully removed and this yields an improved PWI – no perfusion signal 
is seen in the muscle. (B) Perfusion maps calculated without correction, following PENIR and a 
reference PENIR corrected LL-FAIR perfusion map. The uncorrected perfusion map shows an raised 
level of perfusion as well as a large drop out in perfusion signal. The corrected perfusion map 
matches the reference FAIR data very well.  
5.5.4 Results: Portal Venous Perfusion using pCASL-EPI 
The perfusion measured across 8 animals showed a mean pCASL perfusion 3.0 ± 0.3 ml g-
1min-1 (mean ± standard error), and mean FAIR perfusion 3.4 ± 0.7 ml g-1min-1. An ex-vivo 
experiment was additionally carried out in two animals, which measured a perfusion 
decrease from 3.9 ± 1.4 ml g-1min-1 (mean ± std) to 0.3 ± 0.1 ml g-1min-1.  
The perfusion estimated by the pCASL was expected to be approximately 75% of that of the 
FAIR-ASL’s estimate of total liver blood flow, whereas the ratio was measured at 93%. This 
over-estimation in the perfusion may be as a result of the kidney-based quantification 
equation used earlier (Equation 5.38), which sets the inversion efficiency factor α = 0.65. 
This ‘real-world’ value was used rather than the simulated inversion efficiency calculated in 
Chapter 5.4.3.4 as there may be factors which affect the overall efficiency. The simulation 
was carried out to assess the theoretical efficiency of the pCASL sequence in the mouse 
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liver; the next section investigates measuring the in vivo tagging efficiency of the portal 
vein. 
5.5.5 In vivo Tagging Efficiency Estimation 
The tagging efficiency of a pCASL experiment may depend on a number of factors such the 
B0 field, scanner hardware (30), resonance offset, and the RF pulse flip angle (31).  The 
theoretical method to calculated efficiency α is by the difference in control (  
 ) and tag 
(  




    
 
   
  Equation 5.41 
The difference is normalised by the equilibrium magnetisation M0. However as MRI signal is 
measures only the magnitude of the magnetisation, this equation was then adapted, 
assuming that the magnetisation of tagged spins passed through the null point (i.e. 
efficiency > 0.5). From the earlier efficiency simulations of the sequence, this assumption of 
the inversion seems valid: 
 
  
     
   
  Equation 5.42 
This approximate inversion efficiency β, is calculated from a very short post labelling delay 
and measures the blood vessel signal in the control (SC) and tagged (ST) images, as well as 
the reference S0.  
The PV-pCASL sequence was applied to three mice, and the Gmax parameter was increased 
whilst maintaining the tag location plane relative to the iso-centre. A post labelling delay of 
10 ms was used for this experiment, with ten repeated tag-control pairs following a multi-
phase experiment. A reference M0 EPI image was acquired in order to calculate the 
efficiency according to Equation 5.42. 
Gmax 2.5 3.2 4.2 6.2 
Sim. Resp. Efficiency 0.57 0.62 0.65 0.71 
In vivo Efficiency 0.67 ± 0.15 0.67 ± 0.15 0.72 ± 0.15 0.73 ± 0.15 
Table 5.7: In vivo measurements of portal vein pCASL tag efficiency as a function of the 
tag-gradient parameter Gmax (mean ± std, n = 3). The simulated efficiencies, corrected for 
respiration B0 shifts have been also included for comparison.  
The calculated efficiencies are significantly higher than the respiration-corrected simulated 
efficiencies (p < 0.05, paired t-test). This indicates that the effects of respiration on labelling 
efficiency may be overestimated in the earlier simulation. As predicted, the measured in 
vivo efficiency shows an improved tag at the higher values of Gmax. Including this measured 
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efficiency into the perfusion quantification may introduce an approximate 12% reduction to 
the portal venous blood flow estimate, however the resultant perfusion will still be 
overestimated compared to the FAIR perfusion.  
5.5.6 Methods: Initial Measurements of Hepatic Arterial pCASL  
There had been some difficulty in producing successful perfusion images tagging the 
descending aorta. This has been due to challenging EPI imaging and shimming over the 
descending aorta and imaging plane, as well as unstable physiology on the experiment 
days. The perfusion signal expected from the arterial supply is a third of that of the portal 
vein, and the small signal changes is often difficult to spot when running the multi-phase 
calibration experiment, and may require a number of averages to be more apparent. 
However, five data sets have proved very promising, using the pCASL GE-EPI methods used 
above, with Gmax = 4.2 and a tag gap of 3 mm.  
5.5.7 Results: Hepatic Arterial Perfusion using pCASL-EPI 
The results of the DA tag placed at the top of the liver as can be seen in Figure 5.58. A 
reference FSE image (Figure 5.58A) delineates the liver parenchyma and blood vessels from 
the bowels and stomach. The single-shot GE-EPI (Figure 5.58B) presents a deformation on 
the right-hand side of the image. The perfusion weighted image (Figure 5.58C), post-PENIR 
correction to the pCASL data, shows a relatively homogenous signal within the liver 
parenchyma, with a bright region within the intestines. The T1app values for the 
quantification are taken from the slice-selective T1 mapping experiment within the FAIR 
method (Figure 5.58D). A relatively homogenous T1 is measured across the liver 
parenchyma; the gut and the major blood vessel stand out with a reduced longitudinal 
relaxation. The resultant perfusion map following tagging of the descending aorta (Figure 
5.58E) shows a markedly reduced perfusion compared to the total blood flow as measured 
by FAIR (Figure 5.58F); a potentially spurious high perfusion signal can be seen at the 
location of some intestines within the slice.  
The perfusion measured across 5 animals showed a mean pCASL estimate of arterial 
perfusion 1.0 ± 0.5 ml g-1min-1 (mean ± standard error), and mean FAIR perfusion 2.2 ± 0.5 
ml g-1min-1. The hepatic artery’s perfusion estimated by the pCASL was overestimated (44%) 





Figure 5.58: Estimation of hepatic arterial perfusion using pCASL from a single mouse. (A) Axial high-
resolution fast spin echo (FSE) reference image. (B) Corresponding spin-echo EPI image (M0 
reference). (C) Perfusion weighted image (PWI), showing a bright signal at the location of the blood 
vessels. (D) Slice selective T1 map, as estimated from the FAIR acquisition. Perfusion maps as 
calculated by DA-pCASL (E) and FAIR (F) – the FAIR perfusion data is higher, as expected, as it reflects 
the total liver blood flow.  
The ratio of the pCASL mean estimated hepatic arterial to the sum of arterial and portal 
venous perfusion was 25 ± 49%, which is in agreement with previous literature, and 
indicates that the pCASL technique may be successful. However, further investigations in to 
its quantification are necessary so it can be compared to FAIR-LL.  
5.5.8 Discussion: Initial Measurements of Hepatic pCASL 
This section reports on the first successful application of pCASL techniques to separate the 
portal venous and hepatic arterial perfusion in the mouse liver. Though the PV and DA 
pCASL-EPI perfusion were overestimated compared to the FAIR-LL measurements, the 
mean HA to the PV perfusion was found to be around 25%, though this value was not 
estimated from relative contributions of the same liver. This agrees well with the known 
relative bulk flow to the liver from these feeding vessels (15) and provides encouragement 
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that this technique was able to accurately distinguish PV and HA flow contributions for the 
first time. 
The PENIR algorithm was adapted for the tag-control pair pCASL-EPI data, and successfully 
performed data-driven retrospective gating. A data-logger based rejection mode could be 
easily implemented to the EPI data, which is likely to perform retrospective gating on 
single-shot data more reliably. However, this will require acquiring the physiology and pulse 
timing data for each experiment, and so the PENIR system provides a data-efficient method 
of retrospective gating. A prospective system had been tested which used a ‘flag’ system 
within the sequence to check on the respiration status at the time of acquisition – and then 
repeat that tag and acquisition if necessary. However, it was more time-efficient to use a 
‘brute-force’ approach which entails prospectively triggering the start of the pCASL pulse 
train. The start-point of the trigger could be adjusted manually so that the EPI acquisition 
will occur between breaths, and when physiological variations occurred, PENIR analysis was 
applied to remove erroneous images. 
One of most difficult aspects of this work is rapid imaging using the EPI sequence. Though 
the single-shot imaging produces a time and SNR efficient acquisition, the sequence is 
sensitive to many factors in vivo, and the liver is particularly challenging with its many air-
tissue boundaries and motion which can produce distortions and image artefacts. A robust 
shim is essential over the imaging plane, though for efficient tagging, a homogenous field 
over the tagging vessel is also vital. This will potentially be made even more difficult if an 
experiment tagging the PV and DA in the same liver, as this will cover a large volume within 
the magnet. A dual-shim approach was tested, which switched the shim settings for tag and 
imaging phase, however, the VNMRJ software could only operate with one shim setting for 
a scan.  
In addition, measuring the arterial perfusion from the descending aorta labelling was 
challenging. The multi-phase experiment produced very small changes in tissue signal, due 
to small perfusion signal available from the arterial perfusion. More recently, we proposed 
a method which tested the success of labelling the descending aorta with the pCASL 
sequence within a slice including a kidney, as the perfusion differences are much more 
apparent and can be quickly assessed in real-time. 
From experimental experience, a thick shim voxel (around 5-6 times the slice thickness) was 
selected, and shimming was focussed on this region. From analysis of a separate test 
volume placed within the blood vessel, this shimming method would often produce a 
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robust shim within the imaging plane and labelling vessel. The thick shim voxel will also 
benefit a multi-slice readout, which can be easily implemented in to this sequence and 
facilitate whole liver coverage. However, EPI over the whole liver may exhibit image 
distortions due to high-susceptibility regions around the liver, in addition to signal loss due 
to cardiac motion. 
A limitation of the pCASL investigation is that the PV-tag and the DA-tag were not applied in 
the same liver. With the current approach this will require repositioning of the animal in 
order to minimise the imaging and tagging distance to the iso-centre (5), this is sub-optimal 
as the animal will have to be re-shimmed, and the imaging slice may be difficult to align. A 
future investigation can be carried out with the imaging slice placed at the iso-centre, 
testing the tag efficacy of a separate DA and PV tag. In order to minimise the imaging and 
labelling regions, a vessel-encoded pCASL approach (4) may be able to separate the hepatic 
artery from the portal vein. Such a tagging scheme would aid whole-liver coverage, as the 
positioning of descending aorta tag currently saturates the superior liver tissue, though a 
located around the celiac trunk will produce a similar saturation of the inferior liver. In any 
case, such a technique will not be trivial to implement, as the hepatic artery does not have 
an extensive straight run from the celiac trunk to the liver.  
Particularly in the PV perfusion maps, there is a large PWI signal within the blood vessels at 
a post-labelling delay of 0.3 s. This is indicative of an insufficient post-labelling delay, and 
which may cause an underestimation of the perfusion. Further work should apply multiple 
post-label delays to observe the perfusion kinetics, and in addition, potentially include a 
micro-vascular component to the perfusion model for the highly vascularised liver tissue, as 
the blood volume may dominate the perfusion signal (32).  
One potential issue is that during the long pCASL tag duration (> 2.5 s), the blood will have 
time to circulate through the body and thus the PV and DA tagging may detect mixture of 
liver perfusion signals. It was assumed that the transit time for circulating blood will be 
sufficiently long that labelled water will have relaxed back to equilibrium. From in-house 
DCE-MRI experiments in rats, the contrast bolus was observed to arrive 1-2 seconds in the 
portal vein after the aorta, and this is likely to be shorter in the mouse. However, as the PDA-
pCASL/PPV-pCASL was calculated to be similar to the expected 25% ratio (15), this suggests re-
circulating blood may not be influential on the perfusion signal. Re-circulation may be 
avoided in the clinical situation, as from DCE experiments the portal venous arrival time is 
approximately 15 seconds after the peak arterial phase (33).  
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The quantification may require a more liver-specific model of the complex hepatic kinetics, 
as is often employed in the DCE-estimated liver perfusion. One obvious limitation of this 
current quantification is the arterial transit time value of 0.2 s, taken from the kidney 
perfusion quantification by Duhamel et al. - though this was borrowed from brain 
measurements. This value is likely to be different for the liver, as the pCASL tagging has 
proved successful in both the portal vein and descending aorta, a Look-Locker readout may 
offer an efficient method to better observe the perfusion kinetics. A further advantage of 
the gradient-echo Look-Locker readout is that the images will better match the T1,app map 
generated as part of the FAIR-LL experiment used for the perfusion quantification. 
Currently, some image distortions produced by the EPI image may induce some errors in 
the perfusion quantification. The possible inadequacy of the model used for liver blood flow 
quantification may account for the slight discrepancy between perfusion estimates using 
FAIR and pCASL labelling schemes that was observed in this work. 
5.6 Conclusions and Further Work 
This chapter reported on the methodological development, theoretical and implemented 
optimisation of a novel measurement of pCASL in the mouse liver.  This work demonstrated 
a successful implementation to separate both the portal vein and the hepatic artery’s 
contribution to hepatic perfusion. The arterial and venous perfusion estimates were over-
estimated, though within reasonable agreement with the FAIR-LL sequence that was 
optimised and assessed in the chapter 3.   
Future tests of the pCASL sequence can modulate the contributions of the portal vein; 
hypercapnia can induce dilation of the portal vein (34) though the change in blood 
deoxyhaemoglobin content can induce susceptibility changes, which may affect the EPI 
readout. The hepatic contributions can be further investigated using pCASL tagging with 
induced portal blood flow changes post-prandium (13, 22), vasoconstriction (35) or invasive 
vessel ligation.  
The sequential PV and DA-tag pCASL method can be further applied to hepatic diseases; the 
hepatic perfusion index (HPI) has been shown to increase in cancerous and cirrhotic tissue 
(1, 2). Though the perfusion in pathological states may be expected to be lower, as the 
arterial PWI showed a reasonable SNR, this work suggests that the pCASL technique has 
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6.1 Summary and Future Work 
The primary aim of this thesis was to investigate into the feasibility of utilising arterial spin 
labelling (ASL) MRI techniques in application to the liver, which was a limited field at the 
beginning of this research (1, 2), which has since grown moderately (3-6). This work 
demonstrated the development and first application of two arterial spin labelling methods 
to mice and rat livers. The techniques were applied to a number of hepatic disease and 
therapy models, and will continue to be applied in future liver work within the laboratory.  
In Chapter 3, a ‘pulsed’, FAIR-ASL technique used in combination with a Look-Locker 
readout was optimised to investigate a measure of total liver blood flow in mice. The initial 
focus was to remove the influence of respiratory motion-induced artefacts that may reduce 
the image quality and perfusion signal. An algorithm which exploited the many images 
acquired with the Look-Locker readout was used to retrospectively condition the data for 
improved T1 fitting. This ‘PENIR’ system proved to be more suitable for the image analysis 
than a previously established data-logger method (7), though both methods are reliant on a 
steady breathing regime when the data is acquired. Both these methods reduced the T1 
uncertainties compared to a non-corrected fitting.  
After initial measurements of liver perfusion within mice, a repeatability study was carried 
out to estimate the technique’s sensitivity to variations in liver perfusion; the within-
session repeatability of the technique comparable to previous myocardial measurements 
(7). However, relatively large variations were measured between sessions, and this may be 
partly due the single slice acquisition used for the repeatability study. The mice were not 
controlled for diet variation as they were left to eat ad libitum, however, no trends were 
observed across the cohort to suggest that imaging time in the day was influential. 
The Belle model (8) was used to quantify the perfusion maps, though there is scope for 
further investigations in to estimating liver blood flow. Preliminary work in to the blood-
pool correction based quantification (9), based on a multi-slice correction for myocardial 
perfusion estimates, resulted in non-physiologically high estimations of perfusion.  A 
general kinetic model (10) produced low estimates of liver perfusion in comparison with the 
literature. However, the body of clinical research in to liver ASL uses the general perfusion 
model (3, 5), rather than the Belle model, thus optimising the model for the pre-clinical 
liver can be further investigated. In addition, the complex blood flow of the liver has been 
extensively modelled from dynamic contrast measurements taken with MRI and CT (11, 
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12), and these kinetic models potentially can be appropriated to quantifying the ASL 
tagging.  
Having established an ASL method of liver perfusion, the technique was applied to a model 
of liver metastases to test its ability to detect localised deficits within tumours. Perfusion 
differences were measured between normal liver and two cell lines exhibiting different 
vascular structures. The FAIR ASL sequence was sensitive to acute (90 minutes) changes in 
well-perfused tumours following the application of a vascular disrupting agent. However, 
further work is necessary to characterise the repeatability of the HASL technique in a 
tumour environment, particularly for longitudinal observations of therapy, as tumours have 
been characterised to re-develop after VDA treatment (13).  
The FAIR ASL method was then applied to two rat models. First, it was applied to a rat 
model of cirrhosis, and compared to a subtractive method to estimate total liver blood flow 
using phase-contrast MRI, as an alternative, non-invasive and contrast-free technique. The 
FAIR estimates of perfusion agreed well with previous invasive measurements of the rat 
liver (14-16), however a significant difference was observed between FAIR and PC-MRI 
estimates of perfusion. However, PC-MRI was sensitive to the expected blood flow 
reduction in the cirrhotic livers (17), though the FAIR ASL was not. The FAIR sequence 
additionally measured a T1 increase corresponding to an increase in fibrosis (18), 
demonstrating the model success. The PC-MRI indirectly measured an increase in the 
hepatic arterial fraction in the cirrhotic livers, corresponding to microsphere experiments, 
though a microsphere measure of total blood flow wasn’t taken. The measured bias 
between the perfusion estimates of PC-MRI and FAIR ASL may be further investigated by 
applying both sequences to mouse models.  
Secondly, the FAIR method was used to investigate liver functionality by assessment of its 
perfusion in a rat model of stimulated liver growth following selective portal ligation. High-
resolution fast spin echo images were acquired to assess the volumetric changes between 
the liver lobes, showing successful model development. A perfusion deficit was measured 
between ligated and control liver lobes, indicative that the FAIR-LL sequence was sensitive 
to perfusion changes in rats, though a ligation model will drastically reduce the perfusion 
compared to liver dysfunction.  
Finally, inspired by the estimates of the relative arterial and venous contributions by the 
phase contrast MRI, the feasibility of pseudo-continuous ASL (pCASL) in the mouse liver was 
investigated. A simulation of the pCASL tagging was run which used blood flow 
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measurements within the portal vein and descending aorta. The simulation was also 
adapted to estimate the effects of changes in the B0 field due to respiratory motion, and 
found that the predicted tagging efficiency was comparable to previously measured renal 
perfusion in mice (19). The vessel selective, pCASL-EPI sequence was then successfully 
applied to separately tag the portal vein and hepatic artery via the descending aorta. This 
result requires further validation of the relative tagging efficiencies, though the pulsatile 
flow within the descending aorta will complicate such a measurement. The relative mean 
portal venous and hepatic arterial perfusion were consistent with the literature (20), 
though the combined total perfusion was greater than the FAIR measurement. The ability 
to separate the two blood supplies to the liver will aid diagnosis, as the relationship of the 
contributions alters in most hepatic diseases. A direct measure of relative perfusions using 
pCASL may improve on dynamic modelling post-administration of contrast agents, which is 
reliant on characterising the arterial input function (11), and thus will have application to 
the disease models explored in this thesis as well as in the clinic (5).  Furthermore, the 
pCASL sequence has been used within the laboratory by Eoin Finnerty to measure the 
changes in portal venous blood flow to aid understanding of the susceptibility changes 
within the liver and vasculature in response to different inhaled gases.  
6.2 Final Conclusions 
The aim of this thesis was to investigate in to the feasibility of hepatic ASL in mice for 
eventual assessment of liver disease models. The techniques optimised here offer a novel 
use of non-invasive MRI techniques to spatially assess liver perfusion in-vivo, which can 
inform on disease onset and therapy efficacy in a number of clinically-relevant animal 
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